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8ABSTRACT
Src homology 3 (SH3) domains are small modular protein structures that recognize and
bind to short proline-rich sequence motifs in their ligand proteins. Viral proteins may
also harbor such binding motifs and thereby serve as SH3 ligands in order to regulate
the host cell signaling to support virus growth and replication, and to modulate
virulence. The aim of this study was to examine if influenza A virus (IAV) might also use
this strategy to take control of its host cells, and to characterize possible SH3 domain-
containing host cell binding partners of IAV to establish their role in the cell biology of
IAV infection.
IAVs cause seasonal epidemics and occasional pandemics that pose a major threat to
human health. The nonstructural protein 1 (NS1) is an important virulence factor of IAV.
It is a multifunctional protein that suppresses the host interferon response via multiple
mechanisms. Another function of NS1 is to activate phosphatidylinositol-3 kinase (PI3K)
signaling in the host cell through direct binding to the p85β regulatory subunit of PI3K.
The NS1-induced activation of PI3K is required for efficient replication of many IAV
strains.
We  found  that  NS1  proteins  from  some  IAV  strains  contain  an  SH3  binding  site  that
mediates  strong  and  selective  binding  to  the  N-terminal  SH3  (nSH3)  domain  of  Crk-
family proteins, an important class of adaptor proteins involved in the coordination of
cellular signal transduction. This Crk SH3 binding motif was present in the NS1 of
infamous 1918 Spanish Flu pandemic virus as well as in many contemporary avian IAV
strains. In contrast, it is not found in most NS1 proteins of seasonal human IAV strains.
We found that the capacity of avian and Spanish Flu NS1 proteins to interact with Crk
SH3 domains provided them with a greatly enhanced capacity to activate PI3K signaling.
The molecular mechanism underlying this potentiation was found to be due to a
reorganization of the natural PI3K-Crk complex by the SH3-binding competent NS1
protein. Of note, Crk proteins were found to indirectly (via p85β binding) contribute also
to  PI3K  regulation  by  NS1  proteins  of  common  human  IAV  strains  that  lack  an  SH3
binding motif and a capacity for direct Crk recruitment.
Moreover, we found that the role of the NS1/Crk interaction is not limited to PI3K
regulation. We observed that binding of NS1 to the Crk SH3 domain induced a robust
nuclear accumulation of the predominantly cytoplasmic Crk proteins. This nuclear
translocation of Crk proteins was shown to lead to a change in tyrosine phosphorylation
pattern of nuclear proteins.
In summary, our studies establish Crk adaptor proteins as important cellular co-factors
exploited by the IAV virulence factor NS1 to manipulate host cell signaling. These results
increase our understanding of the role of NS1 in IAV cell biology, and reveal possible
new  targets  for  future  antiviral  drug  development  aimed  against  critical  host  cell
interactions rather than highly mutable viral proteins.
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1 REVIEW OF LITERATURE
1.1   Influenza A virus
Influenza A virus (IAV) belongs to the family Orthomyxoviridae,  which  is  a  family  of
enveloped viruses with segmented single-stranded RNA genome (Lamb and Krug, 2001).
At the present, the family includes five other virus genera: Influenzavirus B,
Influenzavirus C, Thogotovirus, Quaranjavirus, and Isavirus (ICTV, 2014). IAVs are further
divided into different subtypes based on the antigenic variation of the surface
glycoproteins, the hemagglutin (HA) and the neuraminidase (NA). Currently, there are
18 known subtybes for HA (H1-18), and 11 for NA (N1-11) (Fouchier et al., 2005; Lamb
and  Krug,  2001;  Tong  et  al.,  2012;  Tong  et  al.,  2013).  The  HA  subtypes  1-16  and  NA
subtypes 1-9 have been isolated from the aquatic wild birds (CDC, 2015). In contrast,
only a limited number of IAV subtypes have been isolated from humans. In addition to
aquatic birds and humans, IAVs also infect a variety of animal species, including other
birds, pigs, horses, seals, cats, and dogs (Wright and Webster, 2001). Recently, two new
subtypes, H17N10, and H18N11 have been isolated form bats (Tong et al., 2012; Tong
et al., 2013).
The aquatic birds of the orders Anseriformes (ducks,  geese,  swan,  etc.)  and
Charadriiformes (gulls, terns, waders, etc.) are the major natural reservoir species for
IAVs (Webster et al., 1992). In wild aquatic birds, the IAVs infect predominantly the
epithelial cells of the lower intestinal tract. The transmission from bird to bird occurs via
a fecal-oral route and the virus is maintained mainly as asymptomatic infections in the
population. In contrast, domesticated birds of the order Galliformes (turkeys, chickens,
quails, etc.) are susceptible for IAV infection after viral adaptation but they are not a
reservoir host for the virus. The first mammalian IAV infection was clinically detected in
swine during the Spanish Flu pandemic in 1918 (Taubenberger et al., 2001). Since that,
IAVs have been isolated from numerous other mammalian host species as well, including
humans, horses, dogs, and marine mammals. Swine are considered as a prime
intermediate host for generation of novel IAVs which may have pandemic potential to
humans, since they  are susceptible for infections with both avian and human IAV strains
(Webster et al., 1992).
The IAV genome is comprised of eight RNA segments. Depending on the virus strain, the
eight segments encode up to 10-13 proteins (see Table 1) (Lamb and Krug, 2001). Two
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and Webster, 2001). IAV causes seasonal epidemics among humans, which are
estimated to result in about 3-5 million cases of severe illness, and about 250 000 - 500
000 deaths every year (WHO, 2014). Occasionally, when a novel subtype of IAV emerges,
typically from an animal origin, global pandemics occur. In the 20th century, there have
been four such pandemics. The most severe pandemic known of all time occurred in
1918-1919. The famous “Spanish Flu” has been estimated to have clinically affected
approximately 500 million people, and caused the death of over 40 million people (Wang
and Palese, 2013). Pandemics in 1957 (“Asian Flu”) and 1968 (“Hongkong Flu”) were less
severe,  yet  having  significant  mortality  rates.  The  most  recent  pandemic  occurred  in
2009, when an antigenically novel H1N1 virus emerged in swine and started to circulate
in humans (Wang and Palese, 2013). This pandemic virus, called the “Swine Flu”, is still
circulating among humans.
Table 1. Influenza A virus genome segments, polypeptides and their functions. Adapted from Krug and
Fodor, 2013.
1.1.2   Structure of the virion
IAV virions can display different shapes, the most common one being close to spherical
with a diameter of 80-120 nm (Fujiyoshi et al., 1994). The virions possess three subviral
components:  the  envelope,  the  matrix  layer,  and  the  RNP  core  (see  Figure  1  for
schematic representation of the IAV virion). The viral envelope is a lipid bilayer derived
from the host cell plasma membrane, containing both cholesterol-enriched lipid rafts
and non-raft lipids (Lamb and Krug, 2001). Two transmembrane viral proteins, HA and
NA, stick out from the lipid bilayer. The third transmembrane protein, the viral integral
membrane protein (M2) is located within the lipid bilayer and serves as an ion channel.
The viral matrix protein (M1) lies underneath the lipid bilayer, making up the matrix
layer  and  linking  the  viral  envelope  to  the  viral  RNP  core.  M1  interacts  with  the
Segment Gene Protein Amino acids* Protein mass (kDa)* Protein function
1 PB2 PB2 759 84-87 Polymerase subunit, cap-binding
2 PB1 PB1 757 87-96 Polymerase subunit, nucleotide addition
N40 718 Unknown
PB1-F2 87 Apoptosis  regulator/virulence factor
3 PA PA 716 83-85 Polymerase subunit, endonuclease
PA-X 252 Modulates host response/degrades
host cel polymerase II transcripts
4 HA HA 566 63 Surface glycoprotein, receptor binding
5 NP NP 498 50-60 RNP component, viral replication
6 NA NA 454 48-63 Surface glycoprotein
7 M M1 252 25-28 Matrix protein
M2 97 11-15 Ion channel
8 NS NS1 230 25-27 Nonstructural protein, multifunctional
NS2/NEP 121 12-14 Nuclear export protein
* approximation; there is variation between the strains
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cytoplasmic tails of HA, NA, and M2 on the outer side and the vRNA and NP on the inner
side (Nayak et al., 2009; Rossman and Lamb, 2011). The IAV genome is segmented into
eight negative-sense RNA strands, located inside the matrix shell. Each RNA strand is
packed into ribonucleoprotein (RNP) complexes that consists of nucleoproteins (NP) and
viral RNA polymerases (PA, PB1 and PB2).
Figure 1. Schematic diagram of the structure of influenza A virus particle. Adapted from Lamb and Krug,
2001.
1.2   Influenza A virus life cycle
The IAV life cycle can be divided into five stages: 1) virus entry into the host cell; 2) entry
of viral RNPs (vRNPs) into the nucleus; 3) transcription and replication of the viral
genome; 4) export of the vRNPs from the nucleus; and 5) assembly and budding at the
host cell membrane. In the following, the steps are discussed in more detail (see Figure
2 for schematic representation of IAV life cycle).
1.2.1   Entry
The HA of IAV is a homotrimer that binds to sialic acid containing cell surface receptors
(Lamb and Krug, 2001). The specificity of the HA molecules in binding cell surface sialic
acid receptors depends on the linkage between sialic acids and the carbohydrates they
are bound. There are two of these linkages α(2,3) and α(2,6). IAVs isolated from humans
recognize preferentially the α(2,6) linkage, whereas those from birds recognize the
α(2,3) linkage. Pig trachea contain sialic acids linked to carbohydrates with both linkages
and the swine has therefore been considered as a prime mixing vessel for the generation
of IAV of pandemic potential to humans (Webster et al., 1992).
Upon binding to cell surface receptors, virus particles are endocytosed into early
endosomes.  About two thirds of the endocytosed IAV particles have been found to
associate with clathrin-coated pits, and one third of the viruses are internalized via
clathrin-independent pathway (Rust et al., 2004). Following the internalization, IAVs are
transported to late endosomes where the acidic environment induces the fusion of the
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viral and endosomal membrane, following the dissociation and degradation of M1 from
RNPs and the release of viral genome.
1.2.2   Nuclear import of the viral genome
Unlike most other negative sense RNA viruses, the transcription and replication of IAV
genome occurs in the nucleus of the infected cell (Herz et al., 1981, Jackson et al., 1982).
Thus, in order for IAV to replicate, the vRNPs must enter the nucleus. Since they are too
large for passive diffusion through nuclear pore complexes (NPCs), an active nuclear
transport mechanism is required. The cytoplasmic vRNPs travel into the nucleus by using
the importin-α - importin-β1 -dependent nuclear import pathway (Eisfeld et al., 2015).
The transportation involves the recognition of nuclear localization signals (NLSs). All four
vRNP associated proteins are reported to contain an NLS, but the NLS in NP seems to be
sufficient for vRNP nuclear import (Cros et al., 2005).
Figure 2. Schematic representation of influenza A virus life cycle. See the text for description. Adapted
from (Shi et al., 2014).
1.2.3   Transcription and replication of the viral genome
After  the  nuclear  import  of  vRNPs,  they  are  transcribed  to  positive-sense  RNA  to
produce viral mRNA. This is known as primary transcription. As the mature cellular RNAs,
the viral mRNAs have poly(A) tails, and 5’ caps. The 5’caps originate from cellular mRNA
by process called “cap-snatching” (Bouloy et al., 1978; Plotch et al., 1979; Plotch et al.,
1981).  The  viral  polymerase  PB2,  which  has  endonuclease  activity,  binds  to  the  5’
methylated caps of cellular mRNAs and steals them to be used as primer for primary
transcription of vRNPs. The mechanism of viral mRNA polyadenylation is different from
cellular mRNA polyadenylation. While cellular mRNAs are polyadenylated through
cleavage at the polyadenylation signal by cleavage and polyadenylation specificity factor
(CPSF) and subsequent addition of a poly(A) tail at the 3’end, the polyadenylation of viral
mRNA  is  a  result  of  the  polymerase  moving  back  and  forth  over  a  stretch  of
approximately 17 uridine residues located in the 5’ end of the viral segment (Eisfeld et
al., 2015). Only two of the  eight viral mRNAs require splicing; segments 7 and 8 (Lamb
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and Krug, 2001). The cellular splicing machinery is responsible for the splicing of the
segments. The viral proteins are then translated in the cytoplasm by host cell ribosomes.
The replication of genomic vRNA happens in two steps: the initial synthesis of cRNA (the
positive-sense RNA strand) that is complementary to the full-length vRNA; and the
copying of cRNA into new negative-sense vRNAs (Lamb and Krug, 2001). The newly
synthesized viral mRNA cannot act as a template for new vRNAs as it has a 5’ cap derived
from  host  and  it  is  truncated  relative  to  the  full-length  genomic  segments.  The  viral
polymerase initiates the cRNA synthesis in a cap-independent manner, and must be able
to proceed through the polyadenylation site at the 5' end of vRNA. It is not well known,
how the synthesis from viral mRNA is switched to the synthesis of cRNA. Soluble NP is
required to prevent termination of the synthesis and polyadenylation at the poly(A) site
(Beaton and Krug, 1984). Some host proteins have also been suggested to have a role in
the process. For example, the direct interaction of viral polymerase with the large
subunit of host cell Pol II enzyme (Engelhardt et al., 2005) has been proposed to improve
the availability of capped RNA primers for viral transcription (Martinez-Alonso et al.,
2016). In addition, all three viral polymerase subunits (PA, PB1 and PB2) are required for
efficient  synthesis  of  cRNA  (Nakagawa  et  al.,  1996).  Finally,  the  cRNAs  are  used  as  a
template to synthesize the negative-strand vRNAs. Soluble NP and polymerase subunits
are added to the newly formed vRNAs to form vRNP complexes.
1.2.4   Export of the viral genome from the nucleus
IAV uses the cellular CRM1-dependent nuclear export pathway to actively mediate the
transport of the newly synthesized vRNPs from the nucleus to the cytoplasm. There are
two  viral  proteins  essential  for  the  vRNP  nuclear  export:  M1  and  NEP  (Eisfeld  et  al.,
2015). The M1 that is bound to the vRNP interacts with NEP which in turn interacts with
the CRM1 via two NES (nuclear export signal) sequences, and contributes to the nuclear
exit of vRNPs. Recent data implies that in addition to the interactions of NEP with M1
and CRM1, NEP also interacts with vRNP associated PB1 subunit of the polymerase
complex  (Brunotte  et  al.,  2014)  but  further  work  is  needed  to  clarify  this  process.  In
addition, the NP and some cellular protein kinases have been proposed to be involved
in the nuclear export of vRNPs (Eisfeld et al., 2015).
Furthermore, there is growing evidence for apoptosis playing a critical role in the nuclear
export of vRNPs. Wurzer et al. reported that inhibition of caspases resulted in reduced
production of infectious virus progeny due to nuclear retention of vRNP complexes
(Wurzer  et  al.,  2003).  This  was  specifically  seen  at  a  later  stage  of  infection  and  was
shown to be caspase 3-dependent. Recently, a study by Mühlbauer et al. showed that
the induction of caspases during IAV infection increases the diffusion limit of nuclear
pores allowing the vRNPs to passively diffuse out of the nucleus (Muhlbauer et al., 2015).
These results suggest a model in which the vRNPs may exit the nucleus by two different
methods depending on the time point of infection. In the intermediate steps of the virus
life cycle, the vRNPs are exported by an active export mechanism which involves CRM1.
At a later stage of infection, the caspase activity increases leading to the widening of
nuclear pores, which allows the passive diffusion of vRNPs from the nucleus.
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1.2.5   Virion assembly and budding
The newly synthesized viral proteins and vRNPs are transported to the lipid raft domains
on the apical side of the cell plasma membrane where the virus assembly and budding
occurs (Lamb and Krug,  2001).  The transmembrane viral  glycoproteins HA and NA as
well as the ion channel M2 span the plasma membrane. On the cytoplasmic face of the
membrane,  M1  interacts  with  the  cytoplasmic  tails  of  HA,  NA,  and  M2,  and  in  turn
interacts with the vRNPs.
Initiation of the virion budding is not well known. It has been suggested that the arrival
of the vRNPs to the cell surface or their interaction with M1 promotes the budding
(Lamb and Krug, 2001; Rossman and Lamb, 2011). Host cell protein UBR4, an ubiquitin
ligase, has been shown to play an important role in the process (Tripathi et al., 2015).
Binding of UBR4 with viral M2 ion channel promotes transport of viral proteins to the
cell surface. The exact mechanism of virus budding is also unknown. NA has an
important role in viral budding, by cleaving the sialic acid residues from the
glycoproteins and from the surface of infected cells. This facilitates the efficient release
of viral particles from the plasma membrane, and prevents self-aggregation of progeny
virions. Other viral proteins, like HA, M1, and M2, have also been postulated to have
different roles in viral budding but their contribution to the process is not clear.
1.3   Influenza A virus NS1 protein
NS1 is relatively small protein and it is the main viral antagonist of the innate immune
response during IAV infection (Ayllon and Garcia-Sastre, 2015; Hale et al., 2008c).
Despite its small size, NS1 has an outstanding number of described functions and
interaction partners in the host cell. As the name “nonstuctural” implies, the NS1 protein
is not a structural component of the IAV virion, instead it is expressed at very high levels
in infected cells (Krug and Etkind, 1973).
1.3.1   Stucture of NS1
The shortest vRNA segment (segment 8) is transcribed into two mRNAs, which encode
the nonstructural protein 1 (NS1) and nuclear export protein (NEP) (Inglis et al., 1979;
Lamb and Choppin, 1979; Lamb and Krug, 2001). NS1 and NEP share 9 N-terminal amino
acid residues, as the NS1 protein is translated from the unspliced primary mRNA
transcript, whereas NEP is translated from a spliced transcript (Lamb and Lai, 1980). The
splicing procedure is regulated, and only ~10-15 % of the segment 8 is spliced to encode
NEP (Robb et al., 2010).
NS1 is a small, approximately 26 kDa, protein that has a strain specific length of 230-237
amino acids (see Figure 3 for schematic representation of NS1 protein)  (Lamb and Krug,
2001). NS1 consists of two distinct globular domains: an aminoterminal (N-terminal)
RNA-binding domain (RBD, amino acids 1-73), and a carboxyterminal (C-terminal)
effector domain (ED, amino acids 85-230/7) separated by a short linker region (Ayllon
and Garcia-Sastre, 2015). The two domains are well conserved within strains but the
flexible linker region and disordered C-terminal tail display significant sequence
variability. The strain specific length of the NS1 depends on amino acid deletions and
insertions in these regions. For example, the linker region of highly pathogenic avian
H5N1 IAV strains isolated after 2000 carry a deletion of five amino acids in the linker
region and the NS1 of human IAVs isolated between 1950 and 1989 has a seven amino
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effector domain (ED, amino acids 85-230/7) separated by a short linker region (Ayllon
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variability. The strain specific length of the NS1 depends on amino acid deletions and
insertions in these regions. For example, the linker region of highly pathogenic avian
H5N1 IAV strains isolated after 2000 carry a deletion of five amino acids in the linker
region and the NS1 of human IAVs isolated between 1950 and 1989 has a seven amino
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acid extension in the C-terminal tail (Dundon and Capua, 2009; Melen et al., 2007). Two
RBD associates to form homodimers with a six-helix antiparallel bundle (Cheng et al.,
2009; Liu et al., 1997). Dimerization is essential for its binding to double-stranded RNA
(dsRNA) (Chien et al., 1997; Qian et al., 1995; Wang et al., 1999). The arginine residue at
position 38 is absolutely required (Wang et al., 1999) but other adjacent amino acids
also participate in dsRNA binding (Cheng et al., 2009). The ED, which is formed by seven
β-strands and three α-helices, also dimerizes (Aramini et al., 2011; Hale et al., 2008a).
The interaction between EDs takes place through the highly conserved tryptophan
residues at position 187 (Kerry et al., 2011). ED binds to numerous cellular proteins and
mediates many NS1 functions (see Figure 3) (Ayllon and Garcia-Sastre, 2015; Hale et al.,
2008c).
Figure 3. Schematic representation of the primary structure of NS1 protein, together with its known
interaction partners. See the text for description and abbreviations. Adapted from Ayllon and Garcia-
Sastre, 2015.
1.3.2   Intracellular localization of NS1
NS1 protein has distinct roles in the nucleus and the cytoplasm. For example, CPSF30
binding takes place in the nucleus, while regulation of RIG-I pathway happens in
cytoplasm. Thus, the regulation of NS1 localization is important. Soon after virus
infection, newly synthesized NS1 accumulates in the nucleus, but is transported to the
cytoplasm at late time points of infection. The localization of NS1 is mediated by one or
two nuclear localization signals (NLS) as well as by one nuclear export signal (NES)
(Forbes et al., 2013; Han et al., 2010; Melen et al., 2007). NLS1 is found between amino
acids 35 and 41, overlapping with the dsRNA binding sequence in RBD (Greenspan et al.,
1988; Melen et al., 2007). It is well-conserved among IAV strains, while C-terminally
located NLS2 is virus strain-specific (Greenspan et al., 1988; Melen et al., 2007; Melen
et al., 2012). In addition, a virus strain specific nucleolar localization signal (NoLS) has
been identified. NoLs overlaps with NLS2, and it requires additional basic residues at
positions 224 and 229 (Melen et al., 2007; Melen et al., 2012). The nuclear export of NS1
is regulated by NES, which is located between amino acids 138-147, leucine residues 144
and 146 being critical for its function (Li et al., 1998).
1.3.3   Post-translational modifications of NS1
NS1 has been found to be modified in three ways: phosphorylation, ISG15 (interferon-
stimulated gene 15) modification, and SUMO (small ubiquitin-like modifier)
modification. These modifications have been reported to affect the function of NS1 and
viral replication.
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NS1 is phosphorylated at residues S42, S48, T49, and T215 (Hale et al., 2009; Hsiang et
al.,  2012;  Kathum  et  al.,  2015).  The  substitution  of  T215  to  alanine  in  A/Udorn  NS1
resulted in attenuation of viral replication (Hale et al., 2009). This was shown later not
to be because of phosphorylation of this site, but because of a deleterious structural
change  of  NS1  due  to  the  mutation  (Hsiang  et  al.,  2012).  Out  of  the  other
phosphorylated residues, only the phosphorylation of S42 and T49 was shown to have a
relevant role (Hsiang et al., 2012; Kathum et al., 2015). The substitution of residue 42 in
A/Udorn strain affected dsRNA binding and consequently replication, while the
phosphorylation of T49 was shown to inhibit the association of NS1 with dsRNA, RIG-I
and TRIM25.
NS1 has been shown to be conjugated to two ubiquitin-like proteins ISG15, an interferon
stimulated ubiquitin homologue (Tang et al., 2010; Zhao et al., 2010) and SUMO (Pal et
al., 2010). Lysine residue 41 (K41) in NS1 RBD was reported to be the main target for
ISGylation by ISG15, and this modification resulted in disruption of interaction with
importin α, but had no effect on the RNA binding activity, which is also mediated by K41
residue (Zhao et al.,  2010). Two lysine residues in the C-terminal region of NS1, K219
and K221, have been identified as the sites for sumoylation (Xu et al., 2011). The
sumoylation of these sites seems to enhance the stability of the NS1 protein, and
substitution of K to E in these sites in A/WSN strain resulted in slower replication of the
virus.
1.3.4    Inhibition of interferon production by NS1
Innate interferon (IFN) response is one of the first barriers a virus faces when infecting
a  host  cell.  It  serves  as  a  potent  antiviral  mechanism  that  limits  the  replication  and
spread of viruses (Randall and Goodbourn, 2008). Interferons are soluble cytokines and
the expression of IFN-α, IFN-β, IFN-λ, and IFN-γ is induced upon viral infection. They act
in both autocrine and paracrine manner to upregulate interferon stimulated genes
(ISGs). ISGs are involved in development of an antiviral state in host cell and in alerting
neighboring cells of the incoming thread. Some ISGs may also be induced directly by a
viral infection. The innate IFN response also activates the specific adaptive immune
response. Pathogens have developed a number of different strategies to overcome,
limit, or hide from the IFN system and establish successful infection.
One of the most important functions of IAV NS1 protein is its role in the inhibition of IFN
production. Studies with recombinant IAVs that do not express NS1 or that express
truncated forms of NS1, have revealed the essential role for NS1 to counteract the host
IFN response (Egorov et  al.,  1998;  Fernandez-Sesma et  al.,  2006;  Garcia-Sastre et  al.,
1998). The IAV strain A/PR8/8/34 (A/PR8) with NS1 deletion replicated to titres ~1000-
fold lower than wt A/PR8 virus in  IFN-competent cells  (Garcia-Sastre et  al.,  1998).  By
contrast, in IFN-deficient cells, Vero cells, virus lacking the NS1 replicated almost as
effective as the wt virus. Egorov et al. generated IAVs with truncated forms of NS1 with
varying lengths (Egorov et al., 1998). They reported that while the replication of a virus
with NS1 coding the first 124 amino acids was only slightly affected, the production of
viruses with shorter forms of NS1 were markedly lowered in IFN-competent systems.
Mutations of arginine 38 and lysine 41 greatly impaired the ability of NS1 to block
interferon production (Pichlmair et al., 2006). The length of NS1 did not influence virus
replication in IFN-incompetent cells. In addition, cells infected with IAV lacking the NS1
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produce more IFN-α and IFN-β than wt virus (Fernandez-Sesma et al., 2006). Together,
these studies indicated, and further studies have proved, that NS1 is an important factor
limiting the host innate IFN response during IAV infection. NS1 has been shown to inhibit
host cell interferon production both pre- and post-transcriptionally and different IAV
strains have evolved diverse strategies to counteract host innate IFN-mediated antiviral
response with NS1 protein (Hayman et al., 2007; Kuo et al., 2010).
1.3.4.1   Inhibition of the RIG-I pathway
RIG-I (retinoic acid-inducible gene 1) is a cytoplasmic RNA helicase that detects viral
genomic single-stranded RNA (ssRNA) bearing 5’ phosphates upon IAV infection, which
leads to the activation of RIG-I pathway resulting in the induction of the synthesis of
type  I  IFNs  (Schlee  and  Hartmann,  2010).  The  binding  of  vRNA  to  RIG-I  triggers  a
conformational change, exposing two N-terminal caspase recruiting domains (CARDs)
(Myong et al., 2009). The second CARD of RIG-I is then ubiquitinated by the E3 ligases
TRIM25  and  RIPLET  (Gack  et  al.,  2009;  Oshiumi  et  al.,  2009).  The  activation  of  RIG-I
pathway leads to the phosphorylation and nuclear translocation of transcription factors,
such as IRF3 (interferon response factor 3), AP-1 (activator protein 1) and NFκB (nuclear
factor κB), which drive the transcription of the type I IFN genes (McWhirter et al., 2005).
The NS1 protein of IAV has been shown to inhibit the activation of IRF3 (Talon et al.,
2000), NFκB (Wang et al.,  2000) and AP-1 (Ludwig et al.,  2002). Recently, it has been
found that this inhibition takes place at the RIG-I pathway and NS1 has different ways
to limit the activation to repress the IFN expression. NS1 may inhibit RIG-I signaling by
forming  a  complex  with  RIG-I  itself  (Jureka  et  al.,  2015;  Pichlmair  et  al.,  2006)  or  by
interacting with the ubiquitin ligases TRIM25 (Gack et al., 2009) and RIPLET (Rajsbaum
et al., 2012) that are responsible for activation of the RIG-I pathway. Interaction of NS1
with TRIM25 blocks the E3 ligase activity on the CARD domains of RIG-I, and mutations
in TRIM25 interaction site in NS1 cause viral attenuation and higher IFN induction (Gack
et al.,  2009). The association of NS1 with RIPLET also prevents the activation of RIG-I
(Rajsbaum et al., 2012). The interaction site responsible for TRIM25 and RIPLET
interaction seems to be different, and the interaction properties to these proteins by
NS1 are virus strain specific (Rajsbaum et al., 2012). In addition, the direct interaction
between NS1 and RIG-I has so far been reported only for Spanish Flu NS1, whereas the
NS1 from IAV strain A/Udorn/73 (A/Udorn)  was unable to interact  directly  with RIG-I
(Jureka  et  al.,  2015).  Thus,  the  mechanism  of  RIG-I  inhibition  seems  to  have  evolved
individually in NS1 proteins of different IAV strains.
The RNA-binding property of NS1 has also been postulated to be one mechanism for
NS1 to limit  the activation of  RIG-I  pathway by sequestering vRNAs away from RIG-I.
However, the affinity of NS1 to RNA is much lower than that of RIG-I (Chien et al., 2004).
On the other hand, mutations of the important residues for NS1 RNA binding site
(arginine R38 and lysine K41) greatly impair the ability of NS1 to block interferon
production (Pichlmair et al., 2006). In addition, mutations at these residues also
abrogate  the  interactions  of  NS1  with  RIG-I,  TRIM25  and  RIPLET  (Gack  et  al.,  2009;
Pichlmair  et  al.,  2006;  Rajsbaum  et  al.,  2012).  Recently,  another  amino  acid  in  close
proximity to the RNA-binding site on NS1 has been added to the RIG-I story: threonine
49 (T49) (Kathum et al., 2015). This residue was shown to impair the interaction of NS1
with dsRNA, RIG-I and TRIM25 when phosphorylated. The phosphorylation of T49
19
produce more IFN-α and IFN-β than wt virus (Fernandez-Sesma et al., 2006). Together,
these studies indicated, and further studies have proved, that NS1 is an important factor
limiting the host innate IFN response during IAV infection. NS1 has been shown to inhibit
host cell interferon production both pre- and post-transcriptionally and different IAV
strains have evolved diverse strategies to counteract host innate IFN-mediated antiviral
response with NS1 protein (Hayman et al., 2007; Kuo et al., 2010).
1.3.4.1   Inhibition of the RIG-I pathway
RIG-I (retinoic acid-inducible gene 1) is a cytoplasmic RNA helicase that detects viral
genomic single-stranded RNA (ssRNA) bearing 5’ phosphates upon IAV infection, which
leads to the activation of RIG-I pathway resulting in the induction of the synthesis of
type  I  IFNs  (Schlee  and  Hartmann,  2010).  The  binding  of  vRNA  to  RIG-I  triggers  a
conformational change, exposing two N-terminal caspase recruiting domains (CARDs)
(Myong et al., 2009). The second CARD of RIG-I is then ubiquitinated by the E3 ligases
TRIM25  and  RIPLET  (Gack  et  al.,  2009;  Oshiumi  et  al.,  2009).  The  activation  of  RIG-I
pathway leads to the phosphorylation and nuclear translocation of transcription factors,
such as IRF3 (interferon response factor 3), AP-1 (activator protein 1) and NFκB (nuclear
factor κB), which drive the transcription of the type I IFN genes (McWhirter et al., 2005).
The NS1 protein of IAV has been shown to inhibit the activation of IRF3 (Talon et al.,
2000), NFκB (Wang et al.,  2000) and AP-1 (Ludwig et al.,  2002). Recently, it has been
found that this inhibition takes place at the RIG-I pathway and NS1 has different ways
to limit the activation to repress the IFN expression. NS1 may inhibit RIG-I signaling by
forming  a  complex  with  RIG-I  itself  (Jureka  et  al.,  2015;  Pichlmair  et  al.,  2006)  or  by
interacting with the ubiquitin ligases TRIM25 (Gack et al., 2009) and RIPLET (Rajsbaum
et al., 2012) that are responsible for activation of the RIG-I pathway. Interaction of NS1
with TRIM25 blocks the E3 ligase activity on the CARD domains of RIG-I, and mutations
in TRIM25 interaction site in NS1 cause viral attenuation and higher IFN induction (Gack
et al.,  2009). The association of NS1 with RIPLET also prevents the activation of RIG-I
(Rajsbaum et al., 2012). The interaction site responsible for TRIM25 and RIPLET
interaction seems to be different, and the interaction properties to these proteins by
NS1 are virus strain specific (Rajsbaum et al., 2012). In addition, the direct interaction
between NS1 and RIG-I has so far been reported only for Spanish Flu NS1, whereas the
NS1 from IAV strain A/Udorn/73 (A/Udorn)  was unable to interact  directly  with RIG-I
(Jureka  et  al.,  2015).  Thus,  the  mechanism  of  RIG-I  inhibition  seems  to  have  evolved
individually in NS1 proteins of different IAV strains.
The RNA-binding property of NS1 has also been postulated to be one mechanism for
NS1 to limit  the activation of  RIG-I  pathway by sequestering vRNAs away from RIG-I.
However, the affinity of NS1 to RNA is much lower than that of RIG-I (Chien et al., 2004).
On the other hand, mutations of the important residues for NS1 RNA binding site
(arginine R38 and lysine K41) greatly impair the ability of NS1 to block interferon
production (Pichlmair et al., 2006). In addition, mutations at these residues also
abrogate  the  interactions  of  NS1  with  RIG-I,  TRIM25  and  RIPLET  (Gack  et  al.,  2009;
Pichlmair  et  al.,  2006;  Rajsbaum  et  al.,  2012).  Recently,  another  amino  acid  in  close
proximity to the RNA-binding site on NS1 has been added to the RIG-I story: threonine
49 (T49) (Kathum et al., 2015). This residue was shown to impair the interaction of NS1
with dsRNA, RIG-I and TRIM25 when phosphorylated. The phosphorylation of T49
20
happens at late time points of infection, and was suggested to act as a spatial-temporal
regulator of NS1 to direct its function from the inhibition of innate immunity to its other
functions to facilitate IAV infection (Kathum et al., 2015).
1.3.4.2   Inhibition of host gene expression
The IAV NS1 protein inhibits the production of IFNs and other antiviral proteins also by
suppressing the host gene expression. The CPSF (Cleavage and Polyadenylation
Specificity Factor) catalyzes the addition of poly(A) tails to cellular pre-mRNAs (Colgan
and Manley, 1997; Wahle and Keller, 1996). NS1 binds to CPSF30, the 30 kDa subunit of
the CPSF complex, and inhibits the 3’ end processing of cellular pre-mRNAs (Nemeroff
et al., 1998). The unprocessed pre-mRNAs accumulate in the nucleus, and cellular mRNA
processing in the cytoplasm is inhibited (Das et al., 2008). Thus, the translation of IFNs
and other antiviral genes is blocked. Since the polyadenylation of viral mRNAs is
catalyzed by the viral polymerase, the viral transcripts are not affected by the repression
of CPSF (Robertson et al., 1981). The sequestered pre-mRNAs in the nucleus have also
been suggested to provide a steady pool of capped 5’ ends for cap snatching by the viral
polymerase (Nemeroff et al., 1998).
There are several NS1 residues that have been reported to be relevant for the CPSF30
interaction. The interaction is mediated by the conserved hydrophobic residues 184-
188, of which the W187 residue is also involved in NS1 ED dimerization (Das et al., 2008).
Indeed, the dimerization of NS1 is important for the CPSF30 interaction. The interaction
is further stabilized by two NS1 amino acids, phenylalanine F103 and methionine M106
(Kainov et al., 2011; Kochs et al., 2007; Twu et al., 2006). Mutation of these two amino
acids does not abrogate the interaction, only reduces the binding of NS1 to CPSF30. The
capacity to bind CPSF30 and to suppress gene expression varies between different IAV
strains. Most of the avian and all human isolate IAV strains reported from 1998 onward
share a strong binding capacity to CPSF30 (Ayllon and Garcia-Sastre, 2015). In contrast,
the A/PR8 strain that is widely used in laboratories, and the highly pathogenic H5N1
avian IAV strain involved in the 1997 human outbreak in Hong Kong lack this property
due to amino acid residue substitution at positions 103 and 106 (Kochs et al., 2007; Twu
et al., 2006). NS1 of 2009 pandemic (The Swine Flu) IAV is also defective in binding to
CPSF30  due  to  amino  acid  substitutions  at  positions  108,  125,  and  189  (Hale  et  al.,
2010c).
In contrast to CPSF30-inhibition, which un-specifically blocks the expression of all host
genes, some IAV strains have another, specific mechanism for the inhibition of host gene
expression. NS1 proteins of H3N2 IAVs isolated since 1989 have a 7 amino acid extension
in their C-terminus (being 237 amino acids long) (Ayllon and Garcia-Sastre, 2015). The
C-terminus of these NS1 proteins contains a sequence, ARSKV, which is very similar to
the motif ARTKQ found on histone H3. The tail of NS1 acts as a mimic for H3 and binds
to  PAF1  transcription-elongation  complex  which  regulates  genes  involved  in  the  IFN
response (Marazzi et al., 2012). Consequently, the elongation of host gene transcription
is blocked.
1.3.4.3   JNK pathway
IAV infection has been reported to trigger the phosphorylation and activation of c-jun
N-terminal kinase (JNK) pathway (Ludwig et al., 2001). JNK phosphorylation leads to
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response (Marazzi et al., 2012). Consequently, the elongation of host gene transcription
is blocked.
1.3.4.3   JNK pathway
IAV infection has been reported to trigger the phosphorylation and activation of c-jun
N-terminal kinase (JNK) pathway (Ludwig et al., 2001). JNK phosphorylation leads to
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activation of AP-1 transcription factors ATF-2 and c-Jun, which are required for the
induction of  IFN-β production.  IAV has been reported to activate JNK by two means:
directly by NS1 protein or through vRNA recognition by RIG-I (Nacken et al., 2014). The
activation of JNK seems to have a virus-supportive function, since the chemical inhibition
of JNK resulted in decreased virus replication (Nacken et al., 2012). The ability of NS1 to
activate JNK depends on subtype specific sequence variation at amino acid 103 (Nacken
et al., 2014). Phenylalanine at this position, the same amino acid involved in stabilization
of CPSF30 interaction, was shown to be important for JNK activation. On the other hand,
NS1 protein of some IAV strains have been reported to inhibit JNK activation (see below)
(Hrincius et al., 2010; Ludwig et al., 2002). Partly it may be indirect, due to the ability of
NS1 to inhibit RIG-I.
1.3.4.4   Inhibition of the activity of antiviral proteins PKR and OAS
NS1 limits also interferon response at the post-transcriptional level by inhibiting two ISG
products, PKR (protein kinase R) and OAS (2’-5’-oligo A synthetase). The transcription of
PKR and OAS is upregulated upon virus infection, they play a key role in host cell antiviral
response and they are activated by binding to dsRNA (Ayllon and Garcia-Sastre, 2015;
Krug, 2015). For PKR, studies with influenza B virus have shown that cytoplasmic vRNP
can function as an activator (Dauber et al., 2009) which is also believed to be true in IAV
infected cells (Dauber and Wolff, 2009). The recognition of dsRNA or vRNPs leads to
autophosphorylation and activation of PKR. The activated PKR then binds and
phosphorylates its best studied target, the eukaryotic translation initiation factor 2
(eIF2α), ultimately leading to inhibition of translation initiation. The PKR mediated block
of translation impairs viral spread, since the replication of viruses critically depends on
the cellular translation machinery.
OAS catalyzes the formation of 2’-5’-poly(A) chains from ATP to activate the otherwise
latent RNase L, which repress viral infection by degrading single-stranded RNA
(Silverman, 2007). OAS/RNaseL may also enhance the activation of IFN transcription,
since the degradation products may bind to and activate RIG-I. Also, the PKR has been
reported to play an additional role in IFN-induction and the host apoptotic responses
(Garcia et al., 2006; Silverman, 2007).
For long time, it was believed that NS1 inhibits PKR activation by competing for binding
to dsRNA (Hatada et al., 1999; Lu et al., 1995). However, the activity of PKR is efficiently
limited  also  by  RNA-binding  defective  NS1  (Li  et  al.,  2006;  Min  and  Krug,  2006).  In
addition,  the  affinity  of  NS1  to  dsRNA  is  much  lower  compared  to  PKR,  so  the
competition is out ruled  (Li et al., 2006).  Instead, it has been shown that NS1 prevents
the activation of PKR by direct interaction, and the amino acids 123-127 in NS1 have
been reported to be important (Min et al., 2007). A recent study by Li et al. has provided
a new insight to the regulation of PKR by NS1 protein (Li et al., 2015). NS1 triggers the
upregulation of vtRNAs (vaultRNA), which are part of a large ribonucleoprotein particles
located in the cytoplasm. This results in inhibition of PKR activity. In contrast, the dsRNA
binding affinity of OAS is low enough for NS1 to outcompete it (Min and Krug, 2006).
Thus, the mechanism for NS1 to inhibit OAS/RNaseL may be by sequestering the dsRNA
away from OAS. Recently, RNA helicase MDA5 (melanoma differentiation-associated
gene 5), a relative of RIG-I, was shown to be involved in the enhancement of the antiviral
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response through the recognition of the OAS/RNaseL system (Benitez et al., 2015) and
PKR (Pham et al., 2016).
1.3.5   NS1 in apoptotic pathways
Apoptosis is considered to be a cellular antiviral mechanism to limit viral replication. As
such, IAVs have developed various means by which to regulate this host defense
strategy and NS1 is reported to have both pro- and anti-apoptotic functions (Hale et al.,
2008c). The anti-apoptotic functions of NS1 can be linked to its ability to suppress IFN
production (Zhirnov et al., 2002). While A/PR8 IAV with deleted NS1 induced higher
levels  of  apoptosis  than  wt  A/PR8  virus  in  IFN-competent  system,  similar  levels  of
apoptosis was observed in IFN-incompetent system with both viruses. This was
speculated to indicate that the anti-apoptotic function of NS1 is IFN-dependent.
As  PKR  and  OAS/RNase  L  have  also  been  reported  to  play  a  role  in  apoptosis,  the
inhibition of these proteins by NS1 may lead to suppression of cell death (Min and Krug,
2006; Takizawa et al., 1996). NS1 also inhibits the JNK-pathway, pathway that is linked
to  activation  of  apoptosis  (Hrincius  et  al.,  2010;  Ludwig  et  al.,  2002).  As  well,  the
association of NS1 to Scribble through PDZ-domain binding has been reported to be anti-
apoptotic (see below) (Liu et al., 2010). In addition, activation of the host cell PI3-kinase
(PI3K) pathway (see below) has been described as an additional, IFN-independent
method by which NS1 may limit the induction of apoptosis (Ehrhardt et al., 2007; Shin
et al., 2007b; Zhirnov and Klenk, 2007). However, NS1 has also been reported to have
pro-apoptotic functions. Transient expression of NS1 from several human, swine and
avian IAV isolates have been reported to induce apoptosis in cultured cells (Han et al.,
2012; Lam et al., 2008; Lam et al., 2011; Schultz-Cherry et al., 2001; Zhang et al., 2011).
The mechanism how NS1 induces apoptosis is not known. Zhang et al. (2011) proposed,
that NS1 interacts with Hsp90 (heat shock protein 90), which would promote the
activation of caspase cascade (Zhang et al., 2011).
It may be that controversial apoptosis mechanisms reported by NS1 are caused by the
differences in virus strain NS1 proteins, as well as the host systems used in the studies.
It  may also be that  the differential  apoptosis  control  is  temporally  regulated,  so that
apoptosis is inhibited early during infection (promotes the replication of the genome),
whilst enhanced at late time points of infection (increases the release of progeny
virions).
1.3.6   Interactions of NS1 with other host cell factors
1.3.6.1   PDZ domain mediated interactions
The PDZ domains bind to a specific PDZ binding motif (PBM) that is typically found at the
extreme C-terminus of a target protein, although in some cases the binding motif can
have an internal location (Javier and Rice, 2011). The IAV NS1 protein displays PBM at
the  very  C-terminus  of  the  NS1  sequence  (Obenauer  et  al.,  2006).  In  avian  IAV  NS1
protein the consensus sequence for PBM is either ESEV or EPEV, whereas in human IAV
isolates the consensus sequence is RSKV. Only the NS1 proteins from avian IAV isolates
have so far been reported to bind to PDZ domain containing proteins, which have anti-
apoptotic or cell polarity regulatory functions (Javier and Rice, 2011). The interaction of
NS1 PBM with two PDZ domains of Scribble protein protected the IAV infected cells from
apoptosis (Liu et al.,  2010). Furthermore, the interaction of NS1 with PDZ domains of
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Scribble and Dlg-1 was reported to disrupt cellular tight junctions to increase the
permeability  of  infected  cells  (Golebiewski  et  al.,  2011).  NS1  PBM  also  mediates  the
binding and inactivation of MAG-1, which leads to higher IFN-β production (Kumar et al.,
2012). This rather unexpected function for NS1 seems to be masked by other IAV anti-
IFN functions and the relevance of this interaction to IAV infection remains to be solved.
The ESEV-sequence was found to increase the replication and virulence of human
A/WSN (A/WSN/33) IAV strain (Jackson et  al.,  2008)  and H3N2 IAV strains (Liu et  al.,
2010) when introduced to the NS1 sequence of these viruses. In addition the avian H7N1
strain was shown to benefit from the ESEV-sequence since the mutation of the motif
resulted in lower replication of the virus (Soubies et al., 2010). In contrast, when the
ESEV-sequence was introduced into highly pathogenic H5N1 virus it did not affect
virulence in a mouse model (Zielecki et al., 2010). Similarly, the deletion of PBM from
NS1 in low-pathogenic avian H7N1 virus strains had no effect on replication (Soubies et
al., 2013). Likewise, the restoration of PBM in the NS1 of the 2009 H1N1 pandemic virus
did not have an effect on the viral growth in cultured cells (Hale et al., 2010b) but had a
positive effect on viral transmission in a guinea pig model (Kim et al., 2014). Thus, the
requirement of PBM for viral replication is strictly virus strain specific.
1.3.6.2   SH3 domain mediated interactions
The Src homology 3 (SH3) domains bind to proline-rich sequences to transmit various
signals (see below). As first reported in study I of this thesis, the Spanish Flu and many
avian IAV NS1 proteins contain a functional SH3 domain binding motif close to their C-
terminus. This motif mediates the binding of NS1 to the SH3 domains of Crk adaptor
proteins.  The  NS1  proteins  of  human  IAVs  do  not  possess  this  motif.  Hrincius  et  al.
showed that downregulation of Crk proteins resulted in impaired propagation of IAVs
that contain SH3 binding competent NS1 protein due to the inhibition of IAV-mediated
activation of c-jun N-terminal kinase (JNK) signaling pathway (Hrincius et al., 2010).
Especially, CrkI was shown to be important for the inhibition of JNK-pathway and
subsequent inhibition of apoptosis. In another study by the same group, NS1 was
demonstrated to reduce the activity of tyrosine kinase c-Abl (Hrincius et al., 2014). The
inhibition was shown to be mediated by the Crk-binding capacity of NS1 but also by a
direct interaction of NS1 with c-Abl. The reduced activity of c-Abl led to lower basal
levels of Crk phosphorylation and severe cytopathic effects of infected cells. Chemical
inhibition of c-Abl impaired propagation and pathogenicity of avian IAV. The NS1-
mediated inhibition of c-Abl was further shown to result in severe lung injury and to
facilitate secondary bacterial infections in mice when functional SH3 binding motif was
introduced into the NS1 protein of human IAV strain A/PR8 (Hrincius et al., 2015).
1.3.7   Regulation of viral RNA and protein synthesis by NS1
The gene expression of IAV can be divided into an early and late phase. NS and NP vRNAs
are replicated and transcribed in the early phase, while in the late phase all 8 vRNAs are
replicated and transcribed (Shapiro et al., 1987; Skehel, 1973). Several studies have
provided evidence that NS1 is involved in the regulation of vRNA synthesis. Mutation in
the NS1 sequence at residues 123 and 124 resulted in deregulation of the normal time
course  of  vRNA  synthesis,  with  both  early  and  late  vRNAs  being  replicated  and
transcribed at high levels already at very early times after infection (Min et al., 2007),
while deletion of whole ED impaired the transcription of late genes (Maamary et al.,
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2012). The mechanism how NS1 regulates temporally vRNA synthesis is not known. It
has been suggested that the interaction of NS1 with virus polymerase complex plays a
role  in  the  process  (Kuo  and  Krug,  2009).  In  addition,  a  recent  study  by  Chen  et  al.
suggested that the inhibition of DDX21, a helicase able to block the viral polymerase
complex, by NS1 may be the key factor for this regulation (Chen et al., 2014).
In IAV infected cells, the translation of host cell mRNAs is strongly inhibited, so the viral
proteins may be translated efficiently (Garfinkel and Katze, 1993). NS1 has also shown
to  stimulate  the  synthesis  of  viral  proteins  (de  la  Luna  et  al.,  1995).  Amino  acids  at
positions 25/26, 48, and 67 in the RBD of NS1 have been reported to be essential for the
stimulation of translation (Kainov et al., 2011). The NS1 binds to 5’ untranslated region
of  viral  mRNA  (Park  and  Katze,  1995)  and  to  several  proteins  involved  in  eukaryotic
translation, such as eIF4GI (elongation and initiation factor 4GI) (Aragon et al., 2000) and
PABP1 (Burgui et al., 2003), as well as hStaufen (Falcon et al., 1999), a dsRNA binding
protein involved in the transport of mRNA to activate translation sites. The proposed
model is that NS1 recruits these translation factors to the 5’ ends of viral mRNAs to favor
the translation of viral proteins.
1.4   PI3K/Akt pathway
1.4.1   An overview of the PI3K/Akt pathway
The phosphatidylinositol-3-kinases (PI3Ks) are members of a conserved family of
intracellular kinases that exhibit both protein kinase and lipid kinase activity. They are
classified in three main classes (I-III) according to their substrate specificity and
sequence homology. Class I PI3Ks are further divided into two subclasses: IA and IB. Class
IA PI3Ks are heterodimers that consist of a regulatory subunit and a catalytic subunit. In
mammalians there are three class IA catalytic (p110 α, β and δ) and five regulatory
(p85α, p85β, p55γ, p55α, and p50α) subunits known (Engelman et al., 2006). Cellular
responses that involve PI3K signaling include survival, proliferation, trafficking, and
regulation of immune function. Basal activity of PI3K/Akt signaling ensures cell survival,
while inactivation of the pathway results in apoptosis.
The activation of PI3K is tightly controlled (see Figure 4 for schematic representation of
activation of PI3K/Akt signaling). The PI3K pathway is activated upon ligand binding on
cell surface receptor tyrosine kinases (RTKs) which leads to dimerization and
autophosphorylation of RTKs. The regulatory subunit p85 contains an SH2 (Src-
homology 2) domain which binds to tyrosine phosphorylated YXXM motifs on the RTKs.
This triggers the activation of p110 catalytic subunit leading to conversion of
phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). PIP3 serves as a second messenger interacting with PH (pleckstrin
homology) domain-containing proteins. PI3K has several downstream signaling
mediators. One important mediator is Akt (also known as PKB; protein kinase B) that
binds to PIP3, allowing PDK-1 (phosphoinositide-dependent kinase-1) to phosphorylate
threonine at the position 308 (T308) on Akt. The full activation of Akt requires another
phosphorylation of serine at position 473 (S473). The kinase responsible for S473
phosphorylation is either mTORC2 (mammalian target of rapamycin complex 2)
(Sarbassov et al., 2005) or DNA-PK (DNA-dependent protein kinase) (Feng et al., 2004)
depending on the initial stimulus.
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Akt is a serine/threonine kinase which upon full activation phosphorylates many target
proteins (Engelman et al., 2006). Regulation of apoptosis is an important function
ascribed to PI3K/Akt -signaling. Akt promotes cell survival by phosphorylating and
inactivating pro-apoptotic proteins, such as FasL (Fas-ligand), BAD (Bcl2-antagonist of
cell death) and caspase-9. Active Akt is also involved in other cellular functions, including
angiogenesis, metabolism, growth, protein synthesis, proliferation, and survival.
PI3K/Akt signaling is negatively regulated by different phosphatases. Dephosphorylation
of Akt is mediated by phosphatases PP2A (protein phosphatase 2A) (Millward et al.,
1999), and PHLPP (PH domain and leucine-rich repeat protein phosphatase) (Gao et al.,
2005). The most important negative regulator of PI3K signaling is the PTEN (phosphatase
of tensin homologue deleted on chromosome 10) which dephosphorylates PIP3 back to
PIP2 (Lam et al., 2008; Lam et al., 2011; Stambolic et al., 1998).
Figure 4. Schematic representation of PI3K/Akt pathway activation. See the text for description. After
Engelman et al., 2006; Hemmings and Restuccia, 2015.
1.4.2   Targeting of the PI3K/Akt pathway by viruses
Since the host cell PI3K/Akt signaling pathway has a critical regulatory role in many
cellular processes, including survival, proliferation, RNA processing, translation, and
regulation of immune function, viruses have evolved widely varying ways to target it
(Diehl and Schaal, 2013; Engelman et al., 2006). Many enveloped viruses activate the
PI3K/Akt pathway to facilitate the endocytic uptake of virions. For example, the
activation of PI3K during endocytic uptake of Ebola viruses is required since the
inhibition of the pathway leads to suppression of virus infection at an early step (Saeed
et  al.,  2008).  Vaccinia  virus,  herpes  simplex  virus  type-1  and  IAV  also  requires  PI3K
activation for host cell uptake (Diehl and Schaal, 2013; Ehrhardt et al., 2006).
In addition to entry, many viruses manipulate PI3K/Akt signaling to control apoptosis
during the viral infection (Diehl and Schaal, 2013). The viral protein LMP1 (latent
membrane  protein  1)  of  Epstein-Barr  (EBV)  virus  activates  the  PI3K/Akt  pathway  by
direct interaction with the p85 subunit, resulting in cell survival (Dawson et al., 2003).
Rotavirus NSP1 and hepatitis C virus (HCV) NS5A (nonstructural protein 5A) also interact
with p85 to induce PI3K/Akt pathway (Bagchi et al., 2010; Street et al., 2004). NS5A binds
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to p85 and the interaction is mediated by the SH3 domain of p85. In addition, herpes
simplex virus-1, respiratory syncytial virus, coxsackie virus B3, rubella virus, HIV-1, and
IAV prevents apoptosis by inducing the PI3K/Akt pathway during infection (Diehl and
Schaal, 2013). Some viruses utilize the PI3K/Akt pathway to regulate the translation of
viral proteins by activating mTOR (mammalian target of rapamycin), a downstream
target  of  Akt.  EBV  LMP2A,  adenovirus  E4-ORF1,  and  E6  and  E7  proteins  of  human
papilloma virus are examples of viral proteins which have been reported to activate
mTOR during infection (Diehl and Schaal, 2013).
1.4.3   Induction of the PI3K/Akt pathway by NS1 protein
The  PI3K  signaling  is  activated  twice  in  IAV  infected  cells  (Ehrhardt  et  al.,  2006).  The
attachment and entry of the virus cause the first, a transient PI3K activation, which is
related to the uptake of virus by endocytosis. The second wave of activation, sustained
activation, appears 4-6 hours post-infection (Ehrhardt et al., 2006; Hale et al., 2006). The
latter activation was abolished when an IAV lacking NS1 (delNS1) was used (Ehrhardt et
al.,  2006).  In  addition,  stable  expression  of  NS1  alone  was  able  to  induce  the
phosphorylation of Akt at S473, which was sensitive to general PI3K inhibitor (Hale et
al., 2006). Thus, the second activation of PI3K in IAV infected cells is mediated by NS1.
The structural and mechanistic basis for PI3K activation by NS1 has been well studied. It
is mediated by the interaction of NS1 with the p85 regulatory subunit of PI3K. The
interaction is isoform specific, since NS1 interacts only with the β isoform of p85 (Hale
et al., 2006; Shin et al., 2007a). The interaction preface between NS1 and p85β has been
established by mutational analyses as well as by resolving the crystal structure of the
interaction (Hale et al., 2008b; Hale et al., 2006; Hale et al., 2010a; Li et al., 2008).
p85β contains five domains: an SH3-domain, a GTPase activating protein domain, two
SH2-domains, and an inter SH2 (iSH2) domain which separates the two SH2 domains
(Okkenhaug and Vanhaesebroeck, 2001). The p85 subunit binds to p110 through the
iSH2 domain (Dhand et al., 1994; Klippel et al., 1993) where NS1 also binds (Hale et al.,
2008b). Tyrosine residue at the position of 89 (Y89) has been reported to be crucial for
the interaction  and substitution of tyrosine at this position to phenylalanine (Y89F)
abrogates the NS1-p85β binding and PI3K/Akt activation (Hale et al., 2006). The crystal
structure of the interaction confirmed that the residue Y89 and a proline at 164 (P164)
are located at the binding interface with p85β (Hale et al., 2010b). Glutamine residue
142 in NS1 seems to also contribute for the interaction (Hale et al., 2010b; Li et al., 2008).
In p85β the crucial amino acid for the interaction is valine at position 573 (Li et al., 2008).
Mutation of the corresponding residue on p85α (methionine 582) to valine enables NS1
to interact also with p85α (Li et al., 2008). Crystal structure of the interaction reveals
that methionine instead of valine at this position in p85β would be sterically precluded,
explaining the strict isoform specificity of NS1-p85 binding (Hale et al., 2010a). The
association of NS1 with p85β removes the inhibitory contacts between the p85β and
p110 leading to the activation of PI3K (Hale et al., 2008b; Hale et al., 2010a). In addition,
NS1 possibly directly stimulates the activity of p110 (Hale et al., 2010b). Mutations in a
small, acidic α-helix in NS1 (residues 95-100) that lies adjacent to the activation loop of
p110, generated a virus that was unable to produce PIP3 during the infection, and
consequently failed to induce S473 phosphorylation of Akt.
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The biological relevance of NS1-mediated PI3K activation for IAV infection is still not
clear. As the PI3K signaling is known to mediate cell survival via activation of Akt (Cooray,
2004), the NS1-mediated PI3K activation has been proposed to stimulate cell survival.
By using chemical PI3K-inhibitors during virus infection, NS1-mediated PI3K activation
was reported to be involved in inhibition of apoptosis in a human A/PR8 and an avian
A/FPV/Bratislava/79 IAV strains (Ehrhardt et al., 2007; Zhirnov and Klenk, 2007).
Likewise, Shin et al. reported a more proapoptotic phenotype of A/PR8 IAV with an NS1
mutated at residue P164, which is important for p85-binding (Shin et al., 2007a). Several
studies have also reported the importance of NS1-mediated PI3K activation for viral
replication and virulence. Ehrhardt and colleagues used a chemical PI3K-inhibitor during
the infection of cultured cells with A/PR8 and A/FPV IAV strains (Ehrhardt et al., 2006).
The inhibition of PI3K resulted in impaired viral propagation. Likewise, by mutating the
NS1 residue Y89 in human A/PR8 virus, it was shown that activation of PI3K signaling
enhances viral replication in tissue culture and the virulence in a mouse model (Ayllon
et al., 2012b; Hrincius et al., 2012). However, the requirement for PI3K activation seems
to be viral strain specific, since the Y89F mutation in another human IAV strain, A/WSN,
did not have any effect on viral replication or virulence (Ayllon et al., 2012b).
Furthermore,  mutation  in  A/Udorn  NS1  to  block  the  interaction  with  p85β and
subsequent loss of PI3K activation had no effect on IAV infected cell viability (Jackson et
al., 2010).
1.5   SH3 domains
The SH3 domains are short, approximately 50-70 residues long, and they are
characterized by their ability to bind to proline-rich peptide modules. They were
discovered in 1988 when two groups identified independent regions of sequence
similarity between divergent signaling proteins of the Src family of non-receptor
tyrosine kinases, the Crk oncogene, and phospholipase C-γ (PLCγ) (Mayer et al., 1988;
Stahl et al., 1988). The fact that the domain was found in many different proteins and
did not appear to have any enzymatic activity, implied that the domain was modular and
possessed independent functions in protein complexes.
SH3 domains are one of the most common modular protein domains found in eukaryotic
genomes (Mayer and Saksela, 2004). The human genome has been estimated to contain
296 different SH3 domains (Kärkkäinen et al., 2006). Since one protein may contain up
to six SH3 domains, the number for SH3 domain containing proteins is somewhat
smaller. SH3 domains are present in many different cellular proteins, including scaffold
proteins, adapter proteins and enzymes. They mediate specific protein-protein
interactions and they are involved in many important cellular functions, such as
regulation of signal transduction, cytoskeletal organization and membrane trafficking
(Mayer and Saksela, 2004). Binding of an SH3 domain to its specific ligand recruits
proteins to various subcellular locations, assembles multi-protein signaling complexes,
and regulates enzyme activities. Many SH3 domain containing proteins also possess
other protein-protein interaction domains, such as SH2 (Src homology 2) domains,
emphasizing the importance of these proteins in multi-protein complex formation and
signal transduction in cells. SH2 domains bind to short phosphotyrosine containing
motifs within their target proteins to mediate similar functions as SH3 domains.
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1.5.1   SH3 domain structure
Crystallography and NMR studies have revealed the highly conserved three dimensional
structure of SH3 domains (Musacchio et al., 1992; Yu et al., 1992). They consist of five
β-strands (β1- β5) that are arranged to two tightly packed anti-parallel β-sheets. The first
β-sheet is composed of β1, half of the β2 and the β5, while the second is formed of the
second half of the β2, β3 and β4 -strands. The β-strands are connected by three variable
loops, denoted as RT, n-Src, and distal loops as well as by a short 310 –helix. The first two
strands (β1- β2) are separated by the RT, the β2- β3 by the n-Src, the β3- β4 by the distal
loops, and the last two (β4- β5) by the 310 –helix.
The ligand binding site of SH3 domain has a relatively shallow binding surface. It is
formed by the conserved hydrophobic residues in β3- and β4-strands, N-Src loop and the
tip of the RT loop (Musacchio et al., 1992; Yu et al., 1992). The binding surface can be
divided into three binding pockets: two hydrophobic pockets, lined mainly by aromatic
residues and a specificity pocket, formed by residues from RT and n-Src loops.
1.5.2   SH3 domain ligand binding motifs
1.5.2.1   Typical ligand binding motifs
Early studies identified that the SH3 domains bind to proline-rich peptides (Ren et al.,
1993). It was further noticed that SH3 domains bind specifically to two consensus
peptides containing ɸP moieties, where ɸ is usually a hydrophobic residue (Kay et al.,
2000). SH3 ligand peptide adopts a polyproline-2 (PPII) structure, a left handed helix,
which has three residues per turn and is roughly triangular in cross-section (Musacchio,
2002).  The  base  of  this  triangle  sits  on  the  surface  of  the  SH3  domain  and  the  two
hydrophobic pockets of the SH3 binding site recognize ɸP dipeptides of the PPII helix,
whereas the third, “specificity” pocket binds to a positively charged residue, which
flanks the ɸPxɸP core binding motif (see Figure 5). The positively charged residue is
typically either lysine (K) or more commonly arginine (R).
The structural studies on SH3-peptide complexes have identified that PPII helix can bind
in two orientations with respect to the SH3 domain (Feng et al., 1994; Lim et al., 1994).
The peptides that can bind in N to C orientation relative to SH3 domain have been
classified as class I ligands, whereas the C to N binding peptides are called class II ligands.
The orientation of the peptide depends on the location of a positively charged residue.
The consensus sequence for class I ligands is +xɸPxɸP, and for class II ligands ɸPxɸPx+
(where P is proline, + is R or K, ɸ is a hydrophobic residue, and x is any amino acid). Some
SH3 domains bind to the ligand peptide only in one orientation, whereas some can bind
ligands in both orientations.
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Figure 5. Binding of class I and class II consensus ligands to SH3 domains. After Zarrinpar et al., 2003.
1.5.2.2   Atypical ligand binding motifs
In addition to class I and class II SH3 binding sites, a number of alternative motifs have
been identified that lack the core PxxP element (Li, 2005; Mayer and Saksela, 2004). For
example, the SH3 domains of Eps8 family members and the N-terminal SH3 domain of
Nck1 bind to ligands that do not contain canonical PxxP-motifs. Instead, they have a
unique binding preference for PxxDY motif (Kesti et al., 2007; Mongiovi et al., 1999). The
first hydrophobic pocket of Eps8L1 SH3 domain is not optimal for binding the
conventional PxxP peptides since it is smaller than usually (Aitio et al., 2008). Some SH3
binding motifs even totally lack the proline residues, like the SH3 domains of Fyn and
Fyb, which bind selectively to RKxxYxxY consensus in SKAP55 (Src kinase-associated
protein of 55 kDa) adaptor protein (Kang et al., 2000). Also, SH3 domains of Fyn and Lck
that bind to class I binding motifs, could interact with this motif. Hence, the recognition
of  RKxxYxxY  seems  to  be  similar  to  the  class  I  consensus  recognition  sequence.
Moreover, several SH3 ligand proteins have been found to contain an R/KxxK/R
consensus binding site. For example, the C-terminal SH3 domains of Grb2 and Gads
adaptor proteins interact with proteins that has the R/KxxK/R consensus (Berry et al.,
2002; Lewitzky et al., 2001; Liu et al., 2003). The R/KxxK/R consensus is sometimes
referred as the class III binding motif, since it is found in numerous SH3 ligand proteins
(Li, 2005). Many more unconventional binding site sequences have been identified,
including the RxxPxxxxP consensus found in the calcium activated potassium channel
which mediates binding to the SH3 domain of cortactin (Tian et al., 2006).
1.5.3   Affinity and specificity of SH3 domains
The affinity and specificity of SH3 domains to their ligands is relatively low and the
dissociation constant (Kd) normally varies in the 1-200 μM range (Mayer and Saksela,
2004). Since only five residues of the core binding motif have direct contact with the SH3
domain, additional contacts between the variable loops of the SH3 domain and residues
outside the core PxxP motif in the ligand play a critical role in determining the specificity
and affinity of an SH3 domain. For example, the unusually high affinity (Kd 24 nM) of the
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SH3 domain of p67phox phox (phagocyte oxidase) protein with p47phox requires 20
additional residues immediately C-terminal to the PxxP motif in p47phox (Kami et al.,
2002). When the additional residues were removed, the affinity of the interaction was
turned into a very modest one (Kd 20 μM). Also the avid and highly selective binding of
PEP (proline enriched phosphatase) to the SH3 domain of Csk requires additional
residues outside the binding motif. Two hydrophobic amino acids, isoleucine and valine,
located six residues after the consensus class II PxxP motif in PEP are placed into the
specificity pocket of Csk SH3 domain (Ghose et al., 2001). In addition, 310 helix structure
positioned after the PxxP motif in PEP helps to orientate the residues into the specificity
pocket.
The binding of HIV-1 Nef protein with SH3 domain of Src family kinase Hck provides an
example of an SH3 domain interaction where the affinity and specificity both require
additional residues outside the PxxP motif in Nef in the ligand and sequence variation in
the RT-loop of an SH3 domain. The affinity of Hck SH3 domain to Nef is very high (K d 0.25
μM), whereas another Src family member, Fyn, has a very modest binding affinity (Kd <
20 μM) for Nef. It was found that a single amino acid at the tip of the RT loop of the Hck
SH3 domain compared to Fyn was important for  this  high affinity  binding (Lee et  al.,
1995).  When  the  corresponding  amino  acid  in  the  RT-loop  of  Fyn  (arginine)  was
substituted for isoleucine as in Hck, the affinity of Fyn for Nef was almost as good as that
of Hck. In addition, the core PxxP site in Nef was not sufficient for the tight binding as a
12-residue long peptide overlapping the PxxP-site of Nef had only modest binding
affinity and specificity towards Hck SH3, suggesting that additional regions in Nef are
important for the interaction. The crystal structure of Nef-SH3 interaction revealed that
regions distal to the PxxP motif in Nef are important for the binding (Lee et al., 1996).
The PxxP motif of Nef is followed by two α-helices forming a hydrophobic pocket that
engages the specificity-determining isoleucine residue of the SH3 domain.
1.5.4   Viral proteins as SH3 domain ligands
As SH3 domains are involved in regulation of numerous cellular events, they serve as a
potential target for virus to regulate host cell signaling to optimize their replication
during the infection. Indeed, several viral proteins have been reported to interact with
host cell proteins through their SH3 domains. The first characterized viral SH3 domain
ligand protein was the Nef protein of HIV-1 (Saksela et al., 1995). Nef is essential for HIV-
1 replication and plays an important role as a pathogenesis factor of HIV-1 infection. The
best known cellular activities of Nef in host cell are dependent on its highly conserved
SH3 binding motif, which has a consensus PxxPxR (Saksela, 2011). Disruption of the
polyproline motif in Nef results in impaired replication. In addition to previously
mentioned Nef association with SH3 domains of Src-family kinases Hck and Fyn (Saksela
et al., 1995), Nef has also been reported to interact with other family members, namely
c-Src, Lck and Lyn. The binding of Nef to Hck is one of the strongest reported interactions
between an SH3 domain and its ligand (Lee et al., 1995), whereas the binding of Nef to
other SFKs has a modest affinity. The interaction of Nef with Hck results in the activation
of the kinase by disrupting the intramolecular interaction between the SH2-kinase linker
and the SH3 domain (Moarefi et al., 1997). The intramolecular SH3-ligand interaction is
a key mechanism in Src-family kinases. Trible et al. showed that among the Src-family
kinases,  Lyn  and  c-Src  were  also  activated  by  the  association  of  Nef  with  their  SH3
domains (Trible et al., 2006). In contrast, they noticed that Fyn, Lck, Fgr and Yes were
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not activated by the interaction. As a matter of fact, the association of Nef with Lck and
Fyn has been reported to lead to suppression of the kinase activity (Briggs et al., 2000;
Greenway et al., 1996).
The NS5A protein of hepatitis C virus (HCV) is essential for both viral replication and
virion assembly (Ross-Thriepland and Harris, 2015). It contains one N-terminal and two
C-terminal polyproline motifs and is known to have several host cell interaction partners
(Macdonald  et  al.,  2004;  Macdonald  et  al.,  2005;  Tan  et  al.,  1999).  No  interaction
partners for the N-terminal class I PxxP motif has been found so far. Instead, the two
closely spaced class II polyproline motifs near the C-terminus of NS5A have been
identified as a binding site for SH3 domains of numerous host cell proteins. The first C-
terminal PxxP binds to the SH3 domain of Src-family kinase Lyn, whereas the second C-
terminal PxxP has been reported to associate with the SH3 domains of other Src kinases,
namely Hck, Lck and Fyn (Macdonald et al., 2004) as well as with the adaptor protein
Grb2 (growth factor receptor-bouns protein 2) (Tan et al., 1999). The interaction of NS5A
with the SH3 domains of the Src-family kinases results in differential regulation of the
kinase activity. While the activity of Hck, Lck and Lyn is suppressed by the interaction,
the activity of Fyn is stimulated (Macdonald et al., 2004). The stimulation of Fyn by NS5A
binding to its SH3 domain was linked to tyrosine phosphorylation of transcription factor
Stat3. Since the constitutive phosphorylation of Stat3 is associated with many tumours,
the Fyn mediated phosphorylation of Stat3 was hypothesized to be involved in the
development of hepatocellular carcinoma in HCV-infection. The interaction of NS5A
with the SH3 domain of Grb2 was reported to disturb vaccinia virus induced
phosphorylation of ERK1/2 (extracellular signal-regulated kinases 1 and 2) (Tan et al.,
1999). The second C-terminal SH3 binding motif also mediates the association of NS5A
with the SH3 domains of  amphiphysin II  (Masumi et  al.,  2005),  MLK3 (Mixed Lineage
Kinase 3) (Amako et al., 2013) and an adaptor protein CMS (Cas ligand with multiple SH3
domains) (Igloi et al.,  2015; Mankouri et al.,  2009). Interaction with amphiphysin was
shown to decrease the phosphorylation of NS5A enabling efficient viral replication, since
hyperphosphorylation of NS5A inhibits virus replication (Masumi et al., 2005). HCV
establishes a persistent infection, thus it is important for the virus to control apoptosis.
Indeed, the interaction of NS5A with the SH3 domain of MLK3, a serine threonine
protein  kinase  that  is  a  member  of  MAP3K  (mitogen  activated  protein  kinase  kinase
kinase) family, has been linked to inhibition of apoptosis. MLK3 activates p38MAPK
which leads to up-regulation of K+ channel (Kv2.1) and apoptosis (Amako et al., 2013;
Mankouri et al., 2009). The interaction between the SH3 domain of MLK3 and the
second C-terminal polyproline motif of NS5A was demonstrated to prevent this
activation of Kv2.1 and oxidative-stress induced apoptosis by disturbing
MLK3/p38MAPK signaling (Amako et al., 2013). Finally, association of NS5A with the SH3
domain of CMS disrupts the EGFR (epidermal growth factor receptor) trafficking and
ubiquitination (Igloi et al., 2015). EGFR is a key factor for HCV entry and replication (Diao
et al., 2012).
1.6   Crk adaptor proteins
The history of Crk proteins starts in 1988 when Mayer et al. isolated the v-crk (or gag-
crk)  oncogene  from  chicken  tumor  virus  number  10  (CT10)  retrovirus  (Mayer  et  al.,
1988). It was named CT10 regulator of kinase (Crk) for its proposed function, since it was
able to increase cellular tyrosine phosphorylation and transform primary chicken
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embryo fibroblasts but was lacking any catalytic domain. v-crk is a fusion gene of the
viral gag gene and a cellular gene which encodes two separate domains (see figure 6).
Couple of years after the finding of v-Crk, Reichman et al. isolated the cellular homolog
of chicken Crk which had a similar structural organization to v-Crk but contained a ~50
aa proline rich linker and an additional C-terminal domain (Reichman et al., 1992).
Following the sequencing of cellular Crk in chickens, two isoforms of Crk (CrkI and CrkII)
and Crk-like (CrkL) were isolated (Matsuda et al., 1992), and the family of Crk adaptor
proteins are considered to comprise these three members: CrkI, CrkII and CrkL. CrkI and
Crk II are alternatively spliced products from one gene (Matsuda et al., 1992), whereas
CrkL is encoded by a distinct gene and shares high sequence homology with CrkII
(Galletta et al., 1999; ten Hoeve et al., 1993).
1.6.1   Stucture and binding specificities of Crk proteins
The Crk proteins are relatively small adaptor proteins lacking any enzymatic activity
(Feller,  2001).  The predicted molecular  masses for  Crk family  proteins are 28 kDa for
CrkI,  40 kDa for  CrkII,  and 36 kDa for  CrkL.  They possess one N-terminal  SH2 domain
followed by one (in CrkI) or two (in CrkII and CrkL) SH3 domains (see Figure 6). The SH3
domains are called the N-terminal (nSH3) and C-terminal (cSH3) according whether they
are more N- or C-terminally located. The nSH3 and cSH3 domains are separated by an
approximately 50 residue long linker region. Compared to CrkL SH2, CrkI and CrkII SH2
domain possess an extra stretch of 17 aas that contain a proline-rich region (Anafi et al.,
1996). The overall sequence identity of CrkII and CrkL is 56 %, and in the structural
domain regions 72 % (Kobashigawa and Inagaki, 2012).
Figure 6. Schematic representation of the domain structure of the Crk adaptor proteins. Sequence
identities are shown for CrkII and CrkL. After Birge et al., 2009 and Kobashiwaga and Inagaki, 2012.
The ligand binding specificities of the SH2 and nSH3 domains of CrkII and CrkL are similar.
For the SH2, the preferred binding motif is pYxxP (where pY means phosphorylated
tyrosine residue) (Songyang et al., 1993). Multiple pYxxP motifs are found in Crk SH2
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binding proteins like paxillin (Birge et al., 1993), p130Cas (Sakai et al., 1994), and c-Cbl
(Ribon et al., 1996). CrkII SH2 domain has also been reported to bind a pYxxL motif in
the cell cycle regulator Wee1 (Smith et al., 2000). In general, the nSH3 of Crk proteins
bind to class II polyproline motifs, and the consensus binding motif is PxxPxK (Knudsen
et  al.,  1994;  Tanaka  et  al.,  1994).  The  lysine  (K)  residue  as  a  positive  residue  in  the
consensus was found to be critical for high affinity binding of C3G to the nSH3 domain
of Crk proteins (Knudsen et al., 1995). Changing the lysine to arginine, which normally is
the preferred positive residue in SH3 binding motifs, strongly reduced the affinity of
C3G-derived peptide for the nSH3 domain. The remarkable affinity and selectivity
created by the lysine residue over arginine was explained by the unique structure of the
nSH3 domain specificity-pocket, where three acidic residues is involved in forming
hydrogen bonds with lysine (Wu et al., 1995). In contrast, the arginine side chain is not
well ordered and does not adopt an optimal conformation for hydrogen bonds. The cSH3
domain is an atypical SH3 domain, since the conserved residues in the hydrophobic
polyproline binding pockets are replaced by polar residues, and so far no polyproline
containing binding partners have been identified for the cSH3 (Muralidharan et al.,
2006). Instead, cSH3 is involved in regulation and nuclear export of the Crk proteins (see
below).
1.6.2   Regulation of Crk proteins
The linker region between nSH3 and cSH3 domains of CrkII and CrkL contains a tyrosine
residue (Y221 in CrkII and Y207 in CrkL; Figure 6) that is important for the regulation of
these proteins. When phosphorylated by tyrosine kinase c-Abl, the tyrosine in the linker
region of  CrkII  and CrkL binds to its  own SH2 domain to form a closed structure that
prevents the SH2 domain from binding to its tyrosine phosphorylated ligand proteins
(de Jong et al., 1997; Feller et al., 1994; Kobashigawa et al., 2007; Rosen et al., 1995). In
addition, the closed structure prevents the binding of nSH3 domain of CrkII ligands, but
in CrkL the nSH3 domain is fully accessible (Jankowski et al., 2012).
NMR studies with chicken CrkII revealed another auto-inhibition regulation method by
a cis-trans isomerization at a glycine-proline (G237-P238) peptide bond located at the
cSH3  boundary  (see  figure  7)  (Sarkar  et  al.,  2007;  Sarkar  et  al.,  2011).  In  the cis
conformer, nSH3 and cSH3 are able to interact with each other when three residues of
cSH3 (P238, F239 and I270) occupy the PPII binding site on nSH3 in a manner similar to
a PPII peptide. This prevents the binding of nSH3 domain to its natural ligands. In
contrast, the trans conformer adopts an open state where the PPII binding site on nSH3
is able to bind PPII ligands. In human CrkII, residues 224-237 (called the inter SH3 core;
ISC) within the cSH3 form contact the SH2 and both SH3 domains (Kobashigawa et al.,
2007). These contacts arrange the three domains into a compact structure and represses
the interaction of nSH3 domain with its ligands.
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Figure 7. Schematic representation of cis-trans isomerization in Crk II. After Sarkar et al., 2007.
The solution NMR structure of CrkL revealed that the overall domain organization in CrkL
is very different from CrkII (Jankowski et al.,  2012). The binding site of SH2 domain is
partially masked in CrkL, while in CrkII it is fully accessible. In addition, the cSH3 of CrkL
does not seem to have similar auto-inhibition activity as in CrkII. In CrkL the cSH3 domain
is mobile and does not interact with any of the other domains. Thus, the binding site of
nSH3 domain is fully accessible in CrkL, while in CrkII it is masked by the ISC.
Finally, the cSH3 domain has been shown to possess a positive regulatory role as well.
In contrast to conventional SH3 domains, cSH3 has a conserved PNAY-motif in the RT-
loop  (Reichman  et  al.,  2005).  The  tyrosine  residue,  Y251,  within  the  PNAY-motif  was
shown  to  be  phosphorylated  by  c-Abl  (Reichman  et  al.,  2005;  Sriram  et  al.,  2011).
Phosphorylation at Y251 enables the association of the c-Abl SH2 domain with this site,
which enhances the activation of Abl. In contrast, Jankowski et al. reported that in CrkL
only one tyrosine residue is phosphorylated by c-Abl in vitro (Jankowski et al., 2012).
1.6.3   Nuclear import and export of Crk proteins
Crk proteins are predominantly found in the cytoplasm, but they also are able to enter
the nucleus, although they do not seem to have an NLS. Therefore, they are thought to
be imported to the nucleus through their interaction with other proteins that contain
an NLS (Kar et al., 2007). The interaction of nSH3 with Wee1, DOCK180 and c-Abl has
been  reported  to  mediate  the  nuclear  translocation  of  CrkII  (Kar  et  al.,  2007).  For
example,  in  CrkII-Wee1  complex,  the  NES  of  CrkII  is  masked,  retaining  CrkII  in  the
nucleus. On the contrary, the nuclear export of Crk proteins is an active process, which
is mediated by the interaction of NES, located in cSH3 domain, with a nuclear export
receptor Crm1/exportin (chromosome maintenance region-1) (Smith et al., 2002).
Harkiolaki et al. reported that CrkL cSH3 can exist in monomeric or dimeric conformation
(Harkiolaki et al., 2006). The crystal structure of the cSH3 revealed that the NES is mostly
buried under the domain surface in both conformations. However, upon
dimer/monomer transition, partial unfolding of the cSH3 exposes the NES and the
complex with Crm1/exportin can form.
1.6.4   Biological function of Crk proteins
The members of the Crk family are involved in several signal transduction pathways
downstream of a wide range of receptors (Birge et al.,  2009; Feller, 2001). Like other
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only one tyrosine residue is phosphorylated by c-Abl in vitro (Jankowski et al., 2012).
1.6.3   Nuclear import and export of Crk proteins
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be imported to the nucleus through their interaction with other proteins that contain
an NLS (Kar et al., 2007). The interaction of nSH3 with Wee1, DOCK180 and c-Abl has
been  reported  to  mediate  the  nuclear  translocation  of  CrkII  (Kar  et  al.,  2007).  For
example,  in  CrkII-Wee1  complex,  the  NES  of  CrkII  is  masked,  retaining  CrkII  in  the
nucleus. On the contrary, the nuclear export of Crk proteins is an active process, which
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(Harkiolaki et al., 2006). The crystal structure of the cSH3 revealed that the NES is mostly
buried under the domain surface in both conformations. However, upon
dimer/monomer transition, partial unfolding of the cSH3 exposes the NES and the
complex with Crm1/exportin can form.
1.6.4   Biological function of Crk proteins
The members of the Crk family are involved in several signal transduction pathways
downstream of a wide range of receptors (Birge et al.,  2009; Feller, 2001). Like other
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adaptor proteins, they physically bridge tyrosine phosphorylated proteins to various
intracellular signaling pathways. The SH2 domain serves as an input pathway by binding
to activated receptors and the signal is then transmitted through the interaction
partners of nSH3 domain. Crk proteins have been reported to associate with numerous
cellular proteins through their SH2 and SH3 domains and they have important regulatory
roles in numerous cellular signaling processes, including cell adhesion, growth,
differentiation, proliferation, transformation, and apoptosis.
Although Crk proteins are ubiquitously expressed, and their SH2 and SH3 domains are
highly homologous with similar binding preferences, they seem to have distinct, non-
overlapping roles during embryonic development. Knockout of CrkI/II or CrkL leads to
different developmental defects and the mice die perinatally (Guris et al., 2001; Park et
al., 2006). Mice lacking the CrkI and CrkII die perinatally due to defects in cardiovascular
and  craniofacial  development  (Park  et  al.,  2006),  whereas  the  CrkL  null  mice  have
defects in neural crest and cardiac development (Guris et al., 2001). Furthermore, in
mouse embryonic fibroblasts (MEFs) where CrkII or CrkL has been depleted the other
protein does not compensate the loss of the other by overexpression, again suggesting
that each of the two genes has essential biological functions that cannot be replaced by
the other gene. Mice that lack CrkII but still expresses CrkI develop normally, suggesting
that CrkI can compensate the loss of CrkII in development, but they die within a few days
after birth by unknown mechanisms (Imaizumi et al., 1999).
However, Crk proteins have been shown to have essential overlapping roles as well.
Tissue-specific contribution of Crk proteins has been studied by generating floxed alleles
of Crk and CrkL. The lack of both CrkI/II and CrkL in skeletal muscle led to severe defects
in the neuromuscular synapse, whereas mice lacking only one of the proteins did not
show any defects (Hallock et al., 2010). A recent study demonstrated that Crk proteins
play overlapping roles in maintaining cell structure and motility in MEF cells (Park and
Curran, 2014). The lack of both genes resulted in smaller cell size, while the lack of only
Crk or CrkL did not have any effect on cell morphology.
1.6.4.1   Crk in PI3K signaling
Crk proteins have been reported to participate in the regulation of PI3K signaling. The
viral oncoprotein v-Crk activate PI3K/Akt pathway in CEF (chicken embryonic fibroblast)
cells (Akagi et al.,  2000). Both SH2 and SH3 domains are important for the activation,
since SH2- or SH3-mutant forms of v-Crk were not able to activate the pathway. The v-
Crk SH2 domain was demonstrated to be involved in PI3K activation by mediating the
activation of Src family kinases which in turn phosphorylate focal adhesion kinase (FAK)
(Akagi et al., 2002). Tyrosine phosphorylated FAK then associates with the SH2 domain
of p85 regulatory subunit of PI3K, which was shown to be essential for the pathway
activation. The v-Crk SH3 domain was demonstrated to participate in the induction of
the pathway by activating H-Ras, a member of Ras family of small G proteins, which in
turn binds to the p110 catalytic subunit of PI3K and may activate it. The activation of H-
Ras  was  shown  to  be  mediated  by  binding  of  SOS  (son  of  sevenless),  a  guanine
nucleotide exchange factor, to the SH3 domain of v-Crk.
In addition, Crk proteins have been reported to directly interact with the p85 regulatory
subunit of PI3K through the Crk nSH3 domain and a proline-rich motif in p85 (Gelkop et
al.,  2001;  Sattler  et  al.,  1997).  The  interaction  was  shown  to  be  involved  in  PI3K
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regulation upon immune cell activation, where a trimeric complex of Cbl, a ubiquitin
ligase, CrkII and p85 is formed (Gelkop et al., 2001). The Crk-p85-Cbl complex has also
been shown to be involved in oncogenic signaling in chronic myeloid leukemia (Sattler
et  al.,  1996).  Binding  of  CrkL  SH3  domain  to  Bcr-Abl  fusion  protein  resulted  in
phosphorylation of CrkL and subsequent binding to the SH2 domain of Cbl. Cbl is then
phosphorylated which leads to its association with p85.
1.6.4.2   Crk in apoptotic pathways
CrkII was shown to be required for apoptosis in Xenopus egg extract by activating
caspases (Evans et al., 1997). Depletion of CrkII from egg extracts prevented apoptosis,
and further studies indicated that the cell cycle regulatory protein Wee1 interacts with
CrkII SH2 domain (Smith et al., 2000). The involvement of CrkII-Wee1 interaction in
apoptosis was further studied in mammalian cells (Smith et al., 2002). This study
demonstrated an NES sequence found in the cSH3 domain of CrkII. It was found to
mediate the binding of CrkII to Crm1 and subsequent nuclear export of CrkII. Mutation
of this sequence enhanced the association of CrkII with Wee1. Furthermore, the
proapoptotic activity of CrkII was increased when the NES was impaired, further
implying that the proapoptotic function of CrkII depends on nuclear localization. Indeed,
specific targeting of CrkII by adding an NLS was shown to spontaneously activate
apoptosis (Kar et al., 2007).
CrkI and CrkII have also been shown to be required for ER (endoplasmic reticulum)
stress-induced apoptosis, which is mediated by the mitochondrial apoptotic pathway
(Austgen et al., 2012). CrkI/CrkII KO MEFs were resistant to ER stress-induced apoptosis.
In addition, ER stress was found to induce proteolytic cleavage of CrkI/II by a cysteine
protease. This about 14 kDa N-terminal fragment was further shown to have enhanced
apoptotic activity when transiently expressed. The proapoptotic function of the
fragment was found to be due to CrkI/II binding to an antiapoptotic Bcl-2 family protein,
Bcl-XL, upon ER stress induction. The interaction of CrkI/II with Bcl-XL is mediated by a
BH3 (Bcl2 homology 3) death domain found in the 14 kDa N-terminal fragment.
Approximately 9-12 amino acid long BH3 domain is involved in activation or inhibition
of proapoptotic or antiapoptotic proteins, respectively (Lomonosova and Chinnadurai,
2008).
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2 AIMS OF THE STUDY
The aim of this doctoral thesis was to study influenza A virus NS1 protein and its host
cell SH3 domain interactions. More specifically the aims were:
1. to characterize a putative SH3 binding motif in IAV NS1 protein, its host cell SH3-
domain interaction partners, and the functional role of these interactions.
2. to  study  the  role  and  molecular  mechanism  of  Crk-NS1  interaction  for  the
enhanced PI3K activation by NS1 protein.
3. to study the subcellular localization of the Crk-NS1 complex and its role in the
host cell.
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3 MATERIALS AND METHODS
3.1   Cell culture and transfections (I-III)
Human embryonic kidney fibroblast (293T) cell line (I,II)  was  purchased  from  ATCC,
human hepatocellular carcinoma (Huh7) cell line (I-III) was obtained from Mark Harris
(University of Leeds, England) , and human lung adenocarcinoma epithelial (A549) cell
line (I,III) was received from Ilkka Julkunen (THL, Helsinki, Finland). The cells were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich) supplemented
with 4500 mg/L of glucose, 10% fetal bovine serum (FBS) (Gibco), 0.05 mg/ml penicillin,
0.05 mg/ml streptomycin (Sigma Aldrich), and 1 mM L-glutamine (Sigma Aldrich) and
were maintained in a humidified atmosphere in the presence of 5% CO2 at 37 °C.
Transient transfection of 293T cells was performed by the calcium phosphate
precipitation method. Briefly: 10-20 μg of plasmid DNA was mixed with 250 μl of water,
and 250 μl of 2.5 M CaCl2 was added and mixed. The plasmid mix was added dropwise
in 500 μl of 2xHeBS (274 mM NaCl, 10 mM KCl, 1,4 mM Na2HPO4, 15 mM glucose, 42
mM  Hepes,  pH  7.05)  while  vortexing.  The  transfection  mix  was  kept  in  RT  for  20-30
minutes and added dropwise on top of the cells in 10 cm culture plate and the medium
was  changed  after  12  hours.  Huh7  and  A549  cells  were  transfected  with
Lipofectamine2000 (Invitrogen) according to the manufacturer’s instructions.
3.2   Plasmid constructs
3.2.1   Eukaryotic expression vectors (I-III)
The cDNA fragment for A/Mallard NS1 protein was cloned from the total cellular RNA of
cells infected with A/mallard/Netherlands/12/2000 (H7N3) IAV strain by standard
methods. Synthetic cDNA encoding A/Brevig Mission/1/18 (H1N1) IAV strain, so called
the Spanish Flu, NS1 protein (A/Brevig) was purchased from GENEART. The cDNAs for
NS1 proteins of A/WSN/33 (H1N1) (A/WSN) and A/Udorn/72 (H3N2) (A/Udorn) IAVs
were  obtained  from  Ilkka  Julkunen  (THL,  Helsinki,  Finland).  The  cDNAs  for  all  NS1
proteins were cloned into the pEBB vector (Tanaka et al., 1995) containing an N-terminal
myc epitope tag. Codon changes in NS1 gene were generated by standard overlap PCR
mutagenesis. In NS1-Cyto, the NLS1 was mutated (R38A, K41A) and a NES from MAPKK1
(LQKKLEELEL) was inserted before the NS1 coding sequence. The cDNA for CrkI, CrkII and
CrkL was cloned into the pEBB vector with a C-terminal biotin acceptor domain (PP-
domain) from PinPoint-Xa1 T-vector (Promega). The full-length cDNA for p85β was
purchased from the Genome Biology Unit (MGC-collection, University of Helsinki) and
cloned in to the pEBB vector with an N-terminal HA epitope tag or PP-domain. The codon
changes to p85β sequence were done by overlap PCR mutagenesis. The NS1 and p85β
mutations used in this study are summarized in Table 2.
Fluorescent fusion proteins were generated by fusing a red fluorescent protein,
mCherry,  to  the  N-terminus  of  A/Mallard  NS1  and  A/Mallard  NS1-Cyto,  and  a  green
fluorescent protein, eGFP, to the N-terminus of CrkII and CrkL. The ISRE-Luc reporter
plasmid was obtained from James E. Darnell Jr. (Rockefeller University, New York) and
contains an interferon-stimulated response element (ISRE) -containing fragment in front
of a minimal thymidine kinase promoter driving firefly luciferase expression. Renilla
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luciferase  cDNA  from  pRL-null  vector  (Promega)  was  cloned  into  pcDNA3.1  vector  to
create pcDNA-Renilla.
      Table 2. NS1 and p85β mutants used in this study.
3.2.2   Bacterial expression vectors (I,II)
The GST (Gluthathione S-transferase) and MBP (maltose binding protein) –NS1
constructs were generated by cloning the cDNAs of A/Mallard and A/Brevig into pGEX-
4T-1 vector (GE Healthcare) and pMAL-c2x (New England Biolabs), respectively. GST-PP-
SH3 constructs for CrkII, CrkL, p85α, p85β, and Eps8L1 SH3 domains were generated by
transferring the codon optimized cDNAs from the human SH3 domain library
(Kärkkäinen et al., 2006) into pGEX-4T-1 which had a PP-domain inserted between the
GST and multiple cloning site. Coding sequence for the peptide CLNCFRPLPPLPPPPR was
cloned into the pMAL-c2x vector to generate the construct for p85α-BP (p85α binding
peptide).
3.3   Viruses and virus infections (I,III)
The wt IAV strains used in this study were: A/mallard/Netherlands/12/2000 (H7N3),
A/Udorn/72 (H3N2), and A/WSN/1933 (H1N1). The recombinant IAVs were generated
as previously described (Neumann et al., 1999). The background virus for the
recombinant IAV viruses used in this study was A/WSN/1933. The NS-segment
originated either from A/WSN/1933 or A/mallard/Netherlands/12/2000 virus strains.
The codon changes to the NS1 sequence in the NS-segment were done by overlapping
Mutation Acronym Functional consequence Study
A/Mallard or A/Brevig NS1
P212A,P215A AxxA/M1 Disrupts the SH3 binding consensus I,II
P213A, P216A M2 No effect I
K217E M3 Disrupts the SH3 binding consensus I
K217R M4 Alters the specificity of SH3 binding site I
P215T M5 Disrupts the SH3 binding consensus, I
mimics the human IAV NS1 sequence I
Y89F Prevents binding to p85β II
R38A, K41A + additional NES NS1-Cyto Prevents nuclear localization III
p85β
V573M Prevents binding to NS1 II
P294A,P297A Prevents binding to Crk nSH3 domain II
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PCR mutagenesis. The recombinant IAVs and their mutations used in study III are
summarized in Table 3.
IAVs were propagated in 11-day-old embryonated chicken eggs at 34 °C for 3 days. Virus
infections of A549 cells were carried out in normal medium supplemented with 2 % FBS
and in the presence of 5 μg/ml of TPCK-treated trypsin (Sigma Aldrich) for 20-24 hours
at a multiplicity of infection (MOI) of 0.5 to 5 depending on the assay. To metabolically
label virus-infected cells, the medium was changed 4 hours post-infection to a medium
that was supplemented with [35S]Met (GE Healthcare).
Table 3. Recombinant IAVs used in study III.
3.4   Antibodies (I-III)
The following primary antibodies were used in this study: mouse anti-Myc (Sigma-
Aldrich), mouse anti-HA (Santa Cruz Biotechnology), mouse anti-α-tubulin (Sigma-
Aldrich), rabbit anti-Histone H3 (Cell Signaling Technologies), mouse anti-CrkL
(Millipore), mouse anti-Crk (BD Transduction Laboratories), mouse anti-Akt (Cell
Signaling Technologies), rabbit anti-phospho Akt (Ser473) (Cell Signaling Technologies),
mouse anti-p85β (AbD Serotec) mouse anti-phosphotyrosine (PY20, Santa Cruz
Biotechnologies), rabbit anti-NP (Ronni et al., 1995), and guinea-pig anti-NS1 (Melen et
al., 2007). The secondary antibodies for Western blotting were purchased from LI-COR
Biotechnology: IRDye680CW goat anti-mouse, IRDye800CW goat anti-mouse, IRDye680
goat anti-rabbit, IRDye800CW goat anti-rabbit, IRDye800CW rabbit anti-guinea-pig,
Streptavidin IRDye680CW, and Streptavidin IRDye800CW. AlexaFluor 488 goat anti-
guinea-pig (Abcam) and AlexaFluor 546 anti-mouse (Molecular Probes) were used as
secondary antibodies for immuno fluorescence staining and nuclei were stained with
Hoechst (Sigma Aldrich).
3.5   Protein sequence alignment (I)
The amino acid sequences for different NS1 proteins were obtained from the NCBI
Influenza Virus Resource data base. The sequence alignment of multiple NS1 proteins
was done with ClustalW software.
Recombinant virus name Backbone virus Description
A/WSN-NS1Mallard(wt) A/WSN/33 A/Mallard NS1 wt
A/WSN-NS1Mallard(K217E) A/WSN/33 A/Mallard NS1 K217E (SH3-binding disrupting
mutation)
A/WSN-NS1WSN(wt) A/WSN/33 A/WSN NS1 wt
A/WSN-NS1WSN(T215P) A/WSN/33 A/WSN NS1 T215P (SH3-binding competent
mutation)
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PCR mutagenesis. The recombinant IAVs and their mutations used in study III are
summarized in Table 3.
IAVs were propagated in 11-day-old embryonated chicken eggs at 34 °C for 3 days. Virus
infections of A549 cells were carried out in normal medium supplemented with 2 % FBS
and in the presence of 5 μg/ml of TPCK-treated trypsin (Sigma Aldrich) for 20-24 hours
at a multiplicity of infection (MOI) of 0.5 to 5 depending on the assay. To metabolically
label virus-infected cells, the medium was changed 4 hours post-infection to a medium
that was supplemented with [35S]Met (GE Healthcare).
Table 3. Recombinant IAVs used in study III.
3.4   Antibodies (I-III)
The following primary antibodies were used in this study: mouse anti-Myc (Sigma-
Aldrich), mouse anti-HA (Santa Cruz Biotechnology), mouse anti-α-tubulin (Sigma-
Aldrich), rabbit anti-Histone H3 (Cell Signaling Technologies), mouse anti-CrkL
(Millipore), mouse anti-Crk (BD Transduction Laboratories), mouse anti-Akt (Cell
Signaling Technologies), rabbit anti-phospho Akt (Ser473) (Cell Signaling Technologies),
mouse anti-p85β (AbD Serotec) mouse anti-phosphotyrosine (PY20, Santa Cruz
Biotechnologies), rabbit anti-NP (Ronni et al., 1995), and guinea-pig anti-NS1 (Melen et
al., 2007). The secondary antibodies for Western blotting were purchased from LI-COR
Biotechnology: IRDye680CW goat anti-mouse, IRDye800CW goat anti-mouse, IRDye680
goat anti-rabbit, IRDye800CW goat anti-rabbit, IRDye800CW rabbit anti-guinea-pig,
Streptavidin IRDye680CW, and Streptavidin IRDye800CW. AlexaFluor 488 goat anti-
guinea-pig (Abcam) and AlexaFluor 546 anti-mouse (Molecular Probes) were used as
secondary antibodies for immuno fluorescence staining and nuclei were stained with
Hoechst (Sigma Aldrich).
3.5   Protein sequence alignment (I)
The amino acid sequences for different NS1 proteins were obtained from the NCBI
Influenza Virus Resource data base. The sequence alignment of multiple NS1 proteins
was done with ClustalW software.
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A/WSN-NS1Mallard(K217E) A/WSN/33 A/Mallard NS1 K217E (SH3-binding disrupting
mutation)
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A/WSN-NS1WSN(T215P) A/WSN/33 A/WSN NS1 T215P (SH3-binding competent
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3.6   Recombinant protein production, purification and phage screening
(I,II)
The fusion proteins with GST and MBP were expressed in E. coli strain BL21 and purified
by  using  glutathione-Sepharose  4B  agarose  (GE  Healthcare)  or  amylose  resin  (New
England Biolabs), respectively. The human proteome SH3 domain library used in this
study is characterized and the phage screening was done as described (Kärkkäinen et
al., 2006).
3.7   Protein precipitation and Western blot (I-III)
For immunoprecipitation and protein pulldown experiments, transfected or infected
cells were collected and lysed in 1 % NP40 lysis buffer (150 mM NaCl; 50 mM Tris-HCl,
pH 7.9; 1 % NP40) in the presence of protease and phosphatase inhibitors. Cell lysates
were used for immunoprecipitation with anti-CrkL (I-III)  or  anti-HA  (II) antibodies
coupled to Dynabeads protein G magnetic beads (Invitrogen) or for streptavidin
pulldown (I,II) with Tetralink tetrameric avidin resin (Promega) (I) or Dynabeads
streptavidin coated magnetic beads (Invitrogen) (II).
For total protein samples, the protein concentrations were determined by Bio-Rad
Protein Assay (Bio-Rad). Immunocomplexes and total protein samples were separated
by SDS-PAGE and transferred onto nitrocellulose membrane (Bio-Rad) for subsequent
immunoblotting with specific antibodies. Western blots were visualized with the
Odyssey infrared imaging system (LI-COR Biosciences).
3.8   Detection of phosphorylated proteins (I-III)
To determine the phosphorylation status of Akt, Huh7 cells were transfected with
different NS1 expression constructs (I-III) alone or together with Crk or CrkL expression
constructs (II). Transfected cells were serum starved with a medium containing 2 % FBS
for 12 hours prior the collection 48 hours post-transfection. Collected cells were lysed
with NP40 lysis buffer supplied with protease and phosphatase inhibitors and subjected
to Western blotting with anti-pAkt (S473) antibody. To study the tyrosine
phosphorylation of nuclear proteins (III), A549 cells were infected with recombinant
IAVs for 24 hours. To enhance the accumulation of tyrosine phosphorylated proteins,
cells were treated with phosphotyrosine phosphatase inhibitor pervanadate for 10
minutes. The fractions were then prepared as described in section 3.10 and the lysates
were subjected to Western blot analysis with anti-pTyr antibody.
3.9   Dual-luciferase assays (I)
ISRE-Luc reporter plasmid was transfected together with pcDNA-Renilla and NS1
expression constructs or empty vector into Huh7 cells. 22 hours after transfection, the
cells were treated with 100 IU/ml of IFNβ (Betaferon, Schering) for 7 hours to induce the
reporter gene. The luciferase activities were measured using a dual-luciferase assay
(Promega). Renilla luciferase construct was used as an internal control for transfection.
3.10 In vitro protein binding assays (I,II)
Purified recombinant MBP-fusion proteins (I) were coated on 96-well plates (200
ng/well) and blocked with 1.5 % BSA in TBS (Tris-buffered saline) for 1 hour. The wells
were washed twice with TBST (TBS + 0.05 % Tween 20). Bacterial purified GST-PP-fused
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SH3 domains were added in 2-fold dilutions and incubated for 1.5 hours. After three
washes with TBST, the wells were incubated with streptavidin-biotinylated horseradish
peroxidase complex (GE Healthcare) in TBS for 1 hour. The wells were again washed for
three times with TBST and 50 μl substrate reagent ABTS Single Solution (Invitrogen) was
added. The absorbance was measured 20 minutes later at 405 nm.
To examine the formation of the trimolecular complex of NS1, Crk and p85β in vitro, PP-
tagged p85β was purified from 293T transfected cells with Dynabeads streptavidin
coated magnetic beads (Invitrogen) (II). Bacterial purified, GST-fused NS1 and CrkL-SH3
proteins were mixed together with purified p85β and the formed complexes were
analyzed with Western blotting.
3.11   Cell fractionation (III)
A549 cells  were infected with influenza A viruses at  an MOI 2 for  24 hours.  The cells
were scraped into 500 μl of ice cold Buffer A (20 mM Tris-HCl, pH7.5; 100 mM NaCl; 300
mM sucrose, 3 mM MgCl2) supplemented with 0.5  % Triton X-100 (Sigma Aldrich). After
10 minutes of incubation on ice, the nuclei were pelleted at 800xg for 10 minutes. The
cytoplasmic fraction (C) was collected and was centrifuged for an additional 15 minutes
at 16100xg. The nuclear pellet was washed once with Buffer A +0.5 % Triton X-100 and
twice with Buffer A. The nuclear proteins were collected by dissolving the nuclear pellet
into Buffer B (20 mM Tris-Hcl, pH 8.0; 500 mM NaCl, 2 mM EDTA, pH8.0; 0.1 % NP40)
and sonicating for 3 seconds. The nuclear extract (N) was cleared by centrifugation at
16100xg for 15 minutes.
3.12   Immunostaining and imaging (III)
A549 cells grown on coverslips were infected with IAVs at an MOI of 0.5 for 20 hours.
The  cells  were  then  fixed  with  ice  cold  methanol  for  10  minutes  at  -20  °C  and
permeabilized with 0.1 % Triton X-100 for 10 minutes. The cells were blocked with 5 %
BSA and 10 % FBS in PBS. NS1 and CrkL were stained with guinea-pig anti-NS1 and mouse
anti-CrkL antibodies, respectively, for 40 minutes in the blocking buffer. After three
washes, the cells were incubated with secondary antibodies AlexaFluor 488 goat anti-
guinea pig or AlexaFluor 546 goat anti-mouse and washed again three times. The nuclei
were stained with Hoechst for 5 minutes. The cells were visualized with Leica TCS SP8
confocal microscope scanning the channels sequentially. Open source software Fiji was
used to analyze the mean intensities of the CrkL fluorescence signal (Schindelin et al.,
2012).
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4 RESULTS
4.1   Novel SH3 domain interaction partner for IAV NS1 protein (I-III)
4.1.1   Characterization of a novel interaction partner for NS1 protein (I-III)
Sequence analysis of different viral proteins revealed that the NS1 protein of the Spanish
Flu IAV (A/Brevig Mission/1/18; A/Brevig) contains a potential class II SH3 domain
binding motif near the C-terminus of the protein sequence (see fig. 1A in I). The SH3
binding  motif  was  noted  to  be  very  common  among  avian  isolated  IAVs  but  only
occasionally found in NS1 proteins of human IAVs (see fig. 1B in I).  The A/Brevig and
many avian isolated NS1 proteins contain a consensus sequence of PxɸPx+, whereas in
most human isolated IAV NS1 proteins the second proline has been substituted with
threonine (PxɸTPx+). In addition, this SH3 binding sequence motif is not present in the
NS1  proteins  of  IAV  strains  commonly  used  in  laboratory  studies,  such  as  A/WSN/33
(H1N1), A/PR/8/34 (H1N1), and A/Udorn/72 (H3N2) (see fig 1B in I).
To identify possible SH3 interaction partners for NS1, we expressed the NS1 proteins of
A/Brevig and A/Mallard as GST-fusion proteins and subjected them to affinity screening
with human SH3 phage display library. An increased binding of SH3 domain clones to
both NS1 proteins was observed as compared with the plain GST protein that was used
as a control. The identity of NS1-selected phagemids was determined by sequencing,
and more than 90 % of the phages contained the nSH3 domain of the adaptor proteins
CrkII or CrkL. To confirm the interaction of NS1 with Crk SH3 domain found with phage
screening, we expressed recombinant GST-PP-fusion proteins of the nSH3 domains of
CrkII and CrkL. Since NS1 has been reported to interact with the SH3 domain of p85
regulatory subunit of PI3K (Shin et al., 2007a), we also generated GST-PP-fusion proteins
of SH3 domains of p85α and p85β. As a negative control, we used the SH3 domain of
Eps8L1, which prefers ligands containing PXXDY-motif. The A/Mallard and A/Udorn NS1
proteins were expressed as MBP-fusion proteins. In vitro protein binding assay with
these proteins revealed the avid binding of the nSH3 domain of CrkII and CrkL to the
A/Mallard NS1 (see fig. 2A in I), which was in line with our phage screening result. In
contrast, the A/Udorn NS1, which lacks the consensus SH3 binding motif, did not show
any measurable binding to the CrkII and CrkL SH3 domains (see fig. 2B in I). In addition,
neither of the NS1 proteins showed binding to the SH3 domains of p85α, p85β, or to the
negative control Eps8L1 (see fig. 1A and B in I).
To study Crk-NS1 interaction with full-length proteins, we transfected PP-tagged (biotin
acceptor domain) expression constructs of CrkII and CrkL together with myc-tagged NS1
proteins of A/Brevig, A/Mallard, or A/Udorn.  While A/Brevig and A/Mallard NS1
proteins readily co-precipitated with both CrkII and CrkL, A/Udorn NS1 failed to co-
precipitate with either one of them (see fig. 3 in I). To further characterize the capacity
of all three Crk family members, CrkI, CrkII and CrkL, to interact with NS1 proteins, we
co-transfected different Crk-proteins together with A/Mallard NS1-wt or its SH3 binding
incompetent mutant (AxxA; P212A, P215A). We could not see any differences of the
binding capacity of A/Mallard NS1 wt to CrkI, CrkII or CrkL, while the AxxA-mutation of
A/Mallard NS1 totally abrogated the binding (see fig. 1B in II).
To extend these finding to IAV infection model, we used an avian IAV strain, A/Mallard
and  a  typical  human  IAV  strain,  A/Udorn  to  infect  A549  cells.  The  NS1  protein  from
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A/Mallard infected cells readily co-precipitated with endogenous CrkL, whereas the NS1
protein from A/Udorn infected cells did not (see fig. 4 in I). In addition, we generated a
set of recombinant viruses (see fig. 1A in III). The viruses express the NS1 protein from
either A/WSN or A/Mallard IAV strains. Mutation to the NS1 gene of A/Mallard (K217E)
generated an SH3-binding deficient NS1 protein, whereas the mutation T215P in A/WSN
NS1 gene transformed the A/WSN NS1 protein from SH3 binding incompetent to SH3
binding competent. We immunoprecipated endogenous CrkL from cells infected with
these recombinant IAVs and examined NS1 co-precipitation by Western blotting. As
expected based on our earlier results, A/Mallard NS1-wt was seen to co-precipitate with
CrkL, while the mutant, A/Mallard NS1-K217E, did not (see fig. 1B in III). Likewise, the
mutant A/WSN NS1-T215P was observed to co-precipitate with CrkL, but the A/WSN-wt
was not (see fig. 1C in III).
To further characterize the critical amino acids involved in association of class II SH3
binding motif containing NS1 with Crk proteins, we generated a series of point mutation
variants of the binding site in A/Brevig NS1 (see fig. 5A in I). We transfected these mutant
variants into cells and performed immunoprecipitation of endogenous CrkL protein.
While the wt A/Brevig NS1 co-precipitated with CrkL, the mutant variants with class II
binding motif disrupting mutation (M1; AxxA and M3; PxxPx-) could not be co-
precipitated with CrkL (see fig. 5B in I). Likewise, the mutation T215P (M5), mimicking
the sequence of A/Udorn NS1, could not be co-precipitated with CrkL. In addition,
swapping the lysine residue to arginine in the consensus sequence in A/Brevig NS1 (M4)
diminished the binding to CrkL for ~50 %, which is in agreement with the binding
preference of nSH3 domain of Crk proteins to sequences with lysine as a positively
charged residue (Knudsen et al., 1995).
4.1.2   Functional role for the Crk-NS1 interaction (I,II)
To study the biological relevance of Crk SH3-NS1 interaction, we tested the activities of
A/Brevig and A/Mallard NS1 proteins and their SH3 binding-deficient mutants in two
different cellular functions found in the literature for NS1 protein. To test the ability of
these NS1 proteins to repress the expression of an interferon-stimulated gene, we co-
transfected cells with the ISRE-Luc (interferon-stimulated response element-containing
fragment) reporter plasmid together with an empty control expression vector or vector
expressing NS1 of A/Brevig, A/Mallard, or A/Udorn, or the SH3-binding mutant versions
of A/Brevig (A/Brevig NS1-AxxA) and A/Mallard (A/Mallard NS1-AxxA). After the
induction of the reporter vector with IFNβ, the luciferase activity was measured. All NS1
proteins, including the SH3-binding mutants of A/Brevig and A/Mallard were able to
inhibit the luciferase expression from ISRE-Luc reporter vector compared to the control
where an empty expression vector was transfected (see fig. 6A in I). This indicated that
the binding of NS1 to Crk and CrkL SH3 domains was not required for the capacity of IAV
NS1 proteins to inhibit interferon-stimulated gene expression.
To test the effect of the Crk-NS1 interaction to another known function for NS1, the
activation of PI3K pathway, we transfected the same set of NS1 proteins and their
mutants and analyzed the ability of these proteins to activate the PI3K signaling by
determining the phosphorylation status of Akt (pAkt S473) by Western blotting. The
levels of pAkt were significantly higher in cells transfected with A/Brevig or A/Mallard
NS1-wt compared with the NS1 constructs lacking the SH3 binding motif either naturally,
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as in A/Udorn and A/WSN or by mutation A/Brevig NS1-AxxA and A/Mallard NS1-AxxA
(see fig. 6B in I). Thus, the SH3 binding motif provides the NS1 with enhanced capacity
to induce PI3K activation compared to NS1 proteins lacking the binding site.
Tyrosine residue at position 89 in NS1 has been reported to be critical for NS1- p85β
interaction, and NS1-Y89F mutant is not able to interact with p85β or to activate PI3K
signaling (Hale et al., 2006). To further analyze the amino acid residues important for
the enhanced PI3K activation by SH3 binding competent NS1 proteins, we generated
Y89F-mutant construct of A/Mallard NS1. Cells were transfected with A/Mallard NS1-
wt, NS1-AxxA (SH3 binding incompetent mutant), or NS1-Y89F (p85β binding mutant),
and the phosphorylation status of Akt was examined. While the expression of A/Mallard
NS1-AxxA showed reduced PI3K activation compared to the NS1-wt, the Y89F mutation
totally abrogated the induction (see fig. 2A in II). Thus, while the SH3 binding capacity
potentiates the PI3K activation by NS1, the binding of NS1 to p85β through Y89 is
indispensable for the activation.
4.1.3   Trimeric complex formation upon Crk-NS1 interaction (II)
In addition to the Crk-NS1 interaction reported here, both NS1 and Crk have been
described to interact with p85 (see fig. 3A in II). The Crk-p85 interaction has been
reported to be mediated by the Crk nSH3 domain (Gelkop et  al.,  2001;  Sattler  et  al.,
1997), the same SH3 domain that we have described to mediate the Crk-NS1 interaction.
To study whether these three proteins are in the same complex, we performed
immunoprecipitation of endogenous CrkL from cells transfected with A/Mallard NS1-wt,
NS1-AxxA, or NS1-Y89F. In agreement with our earlier results, the A/Mallard NS1 protein
readily co-precipitated with CrkL when the SH3 binding motif was intact (NS1-wt and
NS1-Y89F), but binding was abrogated when the SH3 binding site was mutated (NS1-
AxxA) (see fig. 2B in II). p85β was seen to co-precipitate with CrkL when NS1 was not
expressed. The expression of NS1-wt or NS1-AxxA did not affect the net association of
p85β with CrkL. However, transfection of NS1-Y89F potently inhibited the association of
p85β with CrkL. Since the binding of p85β to Crk is mediated by the nSH3 domain of Crk,
we hypothesized that NS1 could displace p85β from binding to the nSH3 domain of Crk
proteins.
To demonstrate that NS1 could disrupt the preformed p85β-CrkL complex, we co-
transfected cells with p85β together with CrkL. The lysates were mixed with increasing
amounts of recombinant GST-NS1-Y89F of A/Mallard, or NS1-AxxA as a control. We
examined the amounts of p85β that co-precipitated with CrkL by Western blotting.
Recombinant NS1-Y89F was able to displace p85β from its complex with CrkL in a dose-
dependent manner (see fig. 2C in II). To further prove that NS1 is able to displace p85β
from a preformed complex with CrkL,  we used a mutant construct  of  p85β (V573M),
which prevents the NS1-p85β interaction, and recombinant A/Mallard NS1-wt protein
in a similar experiment as above. We obtained a similar result, where NS1-wt could
displace p85β-V573M from CrkL in a dose-dependent manner (see supplementary fig. 1
in II). From these results and the already known interactions of these proteins (see fig.
3A in II), we hypothesized that two alternative trimeric complexes could be formed (see
fig. 3B in II). The interaction between CrkL and p85β may be indirectly mediated via the
dual capacity of NS1 to bind both p85β and CrkL when SH3 binding-competent NS1 is
expressed (Complex 1). On the other hand, we also hypothesized, that SH3 binding
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deficient NS1 could form a complex with CrkL through association with p85β (Complex
2). The modest affinity of CrkL nSH3 to p85β and/or low abundance of p85β compared
to CrkL and NS1 could explain why we cannot detect the association of SH3 binding
deficient NS1 with CrkL.
To test our hypothesis, we co-transfected increasing amounts of p85β together with a
constant amount of A/Mallard NS1-wt or NS1-AxxA. Co-precipitation of NS1-wt with
CrkL was already detectable in the absence of p85β transfection, and the overexpression
of p85β did not affect the association (see fig. 4A in II). In contrast, increasing amounts
of p85β enabled the CrkL-NS1-AxxA co-precipitation in a dose-dependent manner.
Likewise, co-precipitation of naturally SH3 binding-incompetent NS1 proteins, A/Udorn
and A/WSN, with CrkL was evident when p85β was overexpressed (see fig. 4B in II). In
strong support for our hypothesis of two alternative complexes, the ability of CrkL to
precipitate NS1 proteins of A/Udorn and A/WSN through p85β was abrogated by the
p85β-(P294A,  P297A)  mutation,  which  impairs  the  Crk-p85β interaction.  Thus,  CrkL-
p85β-NS1 complex (Complex 2) may exist when an SH3 binding-incompetent NS1 is
expressed and it is mediated through the p85β interaction with Crk-SH3 domain.
However, assembly of Complex 2, where p85β is bridging the interaction between CrkL
and SH3 binding deficient NS1, could only be seen when p85β was overexpressed. Thus,
the recruitment of CrkL to p85β-NS1 complexes via p85β seems to be less efficient than
recruitment via an SH3 domain mediated CrkL-NS1 interaction.
To  further  study  the  model  of  two  alternative  trimeric  complexes,  we  made  an
experiment where A/Mallard NS1-wt, -AxxA or -Y89F were co-transfected with p85β wt,
or its mutantsP294A/ P297A, and V573M in all relevant combinations.
To  further  study  the  model  of  two  alternative  trimeric  complexes,  we  made  an
experiment where A/Mallard NS1-wt, -AxxA or -Y89F were co-transfected with p85β wt,
or its mutants P294A, P297A and V573M in all relevant combinations. The p85β-wt could
be co-precipitated with CrkL from cells co-transfected with NS1-wt and NS1-AxxA,
whereas expression of NS1-Y89F inhibited this association, which was in line with the
earlier results (see fig. 5, panel II, lanes 3-5 in II). p85β-V573M, the NS1-binding deficient
mutant, had no effect on binding to CrkL but reduced the p85β-CrkL association in cells
transfected with NS1-wt and NS1-Y89F (lanes 10 and 13). The expression of p85β-
(P294A, P297A), the SH3 binding site mutant, abolished the p85β-CrkL binding (lane 6).
This association could be rescued by expression of NS1-wt (lane 7) but not of NS1-AxxA
(lane 8) or NS1-Y89F (lane 9). In addition, NS1-wt increased the association of p85β and
CrkL (see fig. 5, panel VI, lanes 3 and 7 in II). These results confirm that NS1 can serve as
a bridging factor between p85β and CrkL in Complex 1 (see fig. 3B in II).
To confirm that the trimeric complex of NS1, p85β and CrkL can assemble in the absence
of additional cellular factors, we expressed and purified full-length p85β-wt, p85β-
(P294A, P297A), NS1-wt and NS1-AxxA proteins, as well as the nSH3 domain fragment
of CrkL. The recombinant proteins were mixed in different combinations and proteins
associated with p85β were precipitated. p85β-(P294A, P297A) could associate with CrkL-
nSH3 only when NS1-wt was present, attesting that Complex 1 could be assembled in
vitro from purified recombinant proteins (see supplementary fig. 2A in II). The SH3
binding-deficient NS1-AxxA could associate with CrkL-nSH3 only when p85β-wt was
present, resulting in the assembly of Complex 2. p85β with the SH3 binding site mutation
(P294A, P297A) could not mediate the formation of the trimeric complex.
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4.1.4   Functional consequences of the trimeric complex (II)
Based on results concerning the rearrangement of the p85β-CrkL complex by NS1, we
reasoned that the lower PI3K induction by SH3 binding deficient NS1 proteins could be
rescued by overexpression of Crk proteins. To test the idea, we transfected A/Mallard
NS1-wt, NS1-AxxA and A/Udorn NS1 with or without CrkL. Overexpression of CrkL had a
modest enhancing effect on NS1-wt induced Akt phosphorylation (see fig. 6A and B in
II),  while  the weaker PI3K activation by NS1-AxxA was significantly  enhanced by CrkL
overexpression. A similar potentiation of PI3K activation by A/Udorn NS1 was observed
when CrkL was overexpressed.
The  SH3  binding  function  of  NS1  has  been  reported  to  regulate  the  activity  of  c-Abl
(Hrincius et al., 2014) Moreover c-Abl phosphorylates p85β (Sattler et al., 1996). We
tested  whether  c-Abl  has  a  role  in  regulation  of  PI3K  activation  by  SH3  binding
competent NS1 proteins. The inhibition of c-Abl with a potent c-Abl inhibitor, imatinib,
suppressed the tyrosine phosphorylation of CrkL but did not have an effect on NS1-
induced Akt phosphorylation (see supplementary fig. 3 in II). Thus, c-Abl does not seem
to have a critical role in this regulation.
4.2   Localization of the Crk-NS1 complex (III)
4.2.1   NS1 mediates nuclear translocation of Crk proteins (III)
To study the localization of NS1 and Crk proteins in IAV infected cells, we analyzed cells
infected with recombinant IAVs (see Table 3) by immunostaining and confocal imaging.
A/Mallard NS1-wt and NS1-K217E proteins were predominantly seen to localize in the
nucleus  of  infected  cells  (see  fig.  2A  in III). In mock-infected cells, CrkL was mainly
localized in the cytoplasm, while in A/Mallard NS1-wt expressing cells CrkL signal was
observed to co-localize with NS1 signal  in  the nucleus.  In  contrast,  the localization of
CrkL in A/Mallard NS1-K217E (SH3 binding deficient mutation) expressing cells did not
differ from mock-infected cells. Statistical analysis of CrkL nuclear signal confirmed that
the distribution of Crk proteins was strikingly different in A/WSN-NS1Mallard(wt) –infected
cells compared to A/WSN-NS1Mallard(K217E) –infected or mock-infected cells (see fig. 2B in
III). To confirm the translocation of Crk proteins seen with imaging studies, we prepared
cytoplasmic and nuclear fractions of cells infected with recombinant viruses. Strong
signals of CrkI, CrkII and CrkL proteins could be detected from the cytoplasmic fractions
(C) of mock infected cells (see fig. 3A and B in III), whereas nuclear fractions (N) did not
contain any detectable amounts of these proteins. The distribution of Crk proteins in
cells infected with viruses expressing an SH3 binding deficient NS1 protein
(NS1Mallard(K217E) or NS1WSN(wt)) was identical to mock-infected cells. Remarkably, in cells
infected with viruses that contain an SH3 binding competent NS1 (NS1Mallard(wt) or
NS1WSN(T215P)) all Crk proteins were found in the nuclear fractions, especially CrkL. Thus,
the SH3 binding motif of NS1 mediates the translocation of Crk proteins into the nucleus
in IAV infected cells.
4.2.2   Functional role of Crk translocation into the nucleus by NS1 (III)
To study whether the NS1-SH3 domain binding mediated translocation of Crk proteins
into the nucleus is responsible for enhancing the NS1-induced PI3K activation, we
constructed an A/Mallard NS1 protein, which remains predominantly in the cytoplasm
(NS1-Cyto).  CrkL  was  observed  to  co-localize  with  NS1-Cyto  in  the  cytoplasm  in
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transfected cells (see fig. 4A in III).  However,  the  NS1-Cyto  was  able  to  induce  the
phosphorylation  of  Akt  in  similar  level  as  NS1-wt  (see  fig.  4B  in III). Thus, the NS1-
mediated translocation of Crk proteins is not involved in the activation of PI3K.
Since Crk proteins are involved in the regulation of many tyrosine kinases, we next
investigated, whether the nuclear translocation of these proteins by NS1 would have an
effect on tyrosine phosphorylation of cellular proteins. Cells infected with recombinant
viruses were subjected to cytoplasmic and nuclear fractionation. A new, approximately
135 kDa tyrosine phosphorylated protein could be observed from the nuclear fractions
of cells infected with viruses having SH3 binding competent NS1 (NS1Mallard(wt) or
NS1WSN(T215P))  (see  fig.  5  in III). This phosphotyrosine-containing protein was not
detectable from the nuclear fractions of cells infected with viruses containing SH3
binding deficient NS1 protein (NS1Mallard(K217E) or NS1WSN(wt)) or mock-infected cells. Thus,
we concluded that the nuclear translocation of Crk proteins by NS1 results in novel
tyrosine phosphorylation of a nuclear protein.
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5 DISCUSSION
The NS1 protein of IAV is the key factor regulating the host cell responses to facilitate
efficient  virus  replication.  It  is  also  considered  to  be  a  major  virulence  factor  in  IAV
infected cells. It inhibits the host cell IFN and antiviral responses by blocking the
activation of RIG-I and preventing the processing of cellular mRNA. NS1 also inhibits
specific antiviral effector proteins such as OAS and PKR, and modulates apoptosis. In
addition, the binding of NS1 to p85β regulatory subunit of PI3K and the subsequent
activation of PI3K/Akt pathway is conserved among NS1 proteins of diverse IAV strains
(Ehrhardt and Ludwig, 2009; Hale and Randall, 2007). The IAV NS1 protein has been
reported to have numerous functions and host cell interaction partners in the infected
cell (Ayllon and Garcia-Sastre, 2015). Despite the wealth of such previous data on NS1
and its  cellular  partners,  the exact  mechanism by which NS1 acts  as  an IAV virulence
factor, and especially NS1 functions beyond its role as an antagonist of interferon
signaling, have remained elusive. In studies reported in this thesis we investigated novel
host cell proteins that could be involved in NS1 mediated pathogenesis of different IAV
strains.
5.1   Crk-NS1 interaction and PI3K activation
Many  viral  proteins  have  evolved  an  SH3  binding  motif  in  order  to  exploit  host  SH3
domain containing proteins to support virus growth and replication. In this thesis, we
focused on IAV-host cell interactions mediated by SH3 domains. The sequence analysis
of NS1 proteins of different IAV strains revealed that the NS1 protein of Spanish Flu and
many avian IAV isolates contain an SH3 binding motif, which was not found in most of
the seasonal human IAV strains. To identify new host SH3 interaction partners for the
NS1  protein,  we  used  a  phage  display  library  that  contains  virtually  all  human  SH3
domain sequences.  We were able to show that  this  motif  mediates avid and specific
binding to the nSH3 domain of closely related Crk family adaptor proteins. We also
demonstrated that the Crk-SH3 binding motif provided the NS1 proteins with enhanced
capacity to activate the PI3K/Akt signaling compared to the NS1 proteins which lack the
SH3 binding site. The Crk proteins have been reported to interact with the p85
regulatory subunit of PI3K and to be involved in the activation of the pathway (Akagi et
al., 2000; Gelkop et al., 2001; Sattler et al., 1996). Since both p85β and NS1 bind to the
same nSH3 domain of Crk proteins, we further sought to examine the biochemical
mechanism responsible for the superactivation of PI3K/Akt signaling by SH3 binding
competent NS1 proteins. We demonstrated that NS1 proteins with SH3 binding capacity
can disrupt naturally occurring p85-Crk interaction, by competing with p85 for binding
to the Crk nSH3 domain.  This  was shown to result  in  rearrangement of  the Crk-p85β
complex and in the assembly of a novel trimeric complex of Crk-NS1-p85β (Complex 1)
where NS1 is the bridging factor. We also noticed that when SH3 binding incompetent
NS1 is expressed, an alternative trimeric complex is formed, where instead of NS1, the
p85β serves as the bridging factor by binding to both NS1 and nSH3 domain of Crk. This
leads to the formation of NS1-p85β-Crk complex (Complex 2). Because subcellular
localization has been shown to be important for the function of both NS1 and Crk (Ayllon
and Garcia-Sastre, 2015; Fish et al., 1999; Smith et al., 2002), we also wanted to study
the distribution of the Crk-NS1 complex in the host cell. We demonstrated that the SH3
binding motif containing NS1 proteins were able to induce a robust translocation of Crk
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5 DISCUSSION
The NS1 protein of IAV is the key factor regulating the host cell responses to facilitate
efficient  virus  replication.  It  is  also  considered  to  be  a  major  virulence  factor  in  IAV
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signaling, have remained elusive. In studies reported in this thesis we investigated novel
host cell proteins that could be involved in NS1 mediated pathogenesis of different IAV
strains.
5.1   Crk-NS1 interaction and PI3K activation
Many  viral  proteins  have  evolved  an  SH3  binding  motif  in  order  to  exploit  host  SH3
domain containing proteins to support virus growth and replication. In this thesis, we
focused on IAV-host cell interactions mediated by SH3 domains. The sequence analysis
of NS1 proteins of different IAV strains revealed that the NS1 protein of Spanish Flu and
many avian IAV isolates contain an SH3 binding motif, which was not found in most of
the seasonal human IAV strains. To identify new host SH3 interaction partners for the
NS1  protein,  we  used  a  phage  display  library  that  contains  virtually  all  human  SH3
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SH3 binding site. The Crk proteins have been reported to interact with the p85
regulatory subunit of PI3K and to be involved in the activation of the pathway (Akagi et
al., 2000; Gelkop et al., 2001; Sattler et al., 1996). Since both p85β and NS1 bind to the
same nSH3 domain of Crk proteins, we further sought to examine the biochemical
mechanism responsible for the superactivation of PI3K/Akt signaling by SH3 binding
competent NS1 proteins. We demonstrated that NS1 proteins with SH3 binding capacity
can disrupt naturally occurring p85-Crk interaction, by competing with p85 for binding
to the Crk nSH3 domain.  This  was shown to result  in  rearrangement of  the Crk-p85β
complex and in the assembly of a novel trimeric complex of Crk-NS1-p85β (Complex 1)
where NS1 is the bridging factor. We also noticed that when SH3 binding incompetent
NS1 is expressed, an alternative trimeric complex is formed, where instead of NS1, the
p85β serves as the bridging factor by binding to both NS1 and nSH3 domain of Crk. This
leads to the formation of NS1-p85β-Crk complex (Complex 2). Because subcellular
localization has been shown to be important for the function of both NS1 and Crk (Ayllon
and Garcia-Sastre, 2015; Fish et al., 1999; Smith et al., 2002), we also wanted to study
the distribution of the Crk-NS1 complex in the host cell. We demonstrated that the SH3
binding motif containing NS1 proteins were able to induce a robust translocation of Crk
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proteins from the cytoplasm to the nucleus where the Crk proteins co-localized with NS1
protein  in  IAV  infected  cells.  The  nuclear  localization  of  Crk  proteins  could  not  be
observed when cells were infected with virus that contains an NS1 protein that lacks the
SH3 binding motif. We further showed that this relocalization of Crk by NS1 did not
mediate activation of PI3K/Akt by NS1. Instead, we demonstrated that the translocation
of Crk into nucleus by NS1 protein was associated with a dramatic change in the tyrosine
phosphorylation pattern of nuclear proteins.
The activation of PI3K/Akt pathway by NS1 protein has been reported to be beneficial
for the replication and virulence of several IAV strains (Ayllon et al., 2012a; Hale et al.,
2006; Hrincius et al., 2012; Shin et al., 2007a). In study I we reported that NS1 proteins
of Spanish Flu and many avian origin IAV strains has evolved with an enhanced capacity
to activate the PI3K/Akt pathway. This potentiation was shown to be dependent on the
SH3 binding motif found in these proteins. Although the NS1-induced activation of
PI3K/Akt signaling is conserved among different IAV strains, the requirement of the
induction for the virus replication and pathogenesis has been shown to be virus strain
dependent (Ayllon et al., 2012b). Since the SH3 binding motif is highly conserved in
especially avian IAV strains, and only seldom found in human isolated IAV strains, the
ability to activate the PI3K pathway more effectively must provide the avian viruses with
direct replicative advantage in avian host. Even though many human IAV strains require
the NS1 induced PI3K activation for efficient virus replication, providing the viruses with
SH3 binding competent NS1 protein does not have positive (or negative) effect on viral
replication  or  virulence  (Hale  et  al.,  2010b;  Hsiang  et  al.,  2012).  However,  some
exceptions  also  exist.  The  human  isolated  A/PR8  IAV  strain  was  shown  to  be  more
pathogenic in mice when the SH3 binding motif was introduced to its NS1 protein
(Hrincius et al., 2015).
5.2   Crk-NS1-PI3K complex formation
The NS1-mediated activation of the PI3K pathway has been reported to require a direct
association of NS1 with the p85β regulatory subunit of PI3K (Hale et al., 2006; Shin et
al., 2007b). The results by Shin et al. indicated that NS1-p85 interaction is mediated by
the SH3 domain of p85 (Shin et al.,  2007a). However, in study I,  we were not able to
observe any measurable association between SH3 domains of p85α or p85β and NS1.
The proposed SH3 binding motif located around amino acid 164, different from the Crk-
binding site, was later demonstrated to be important for binding to p85 but not through
SH3 domain (Hale et al., 2010a). Earlier studies have also linked the Crk proteins to the
activation of PI3K signaling by binding to a proline-rich motif in p85 regulatory subunit
of PI3K via their nSH3 domain (Akagi et al., 2002; Akagi et al., 2000; Gelkop et al., 2001;
Sattler  et  al.,  1997).  Our results  in  study II confirmed that Crk proteins are physically
coupled to the activation of PI3K/Akt pathway. We described that the potentiation of
pathway activation by SH3 binding competent NS1 proteins is caused by their ability to
recruit Crk adaptor proteins to the PI3K complex more efficiently than the SH3 binding
incompetent NS1 proteins. The SH3 binding motif in NS1 directs the assembly of a novel
trimeric complex (p85β-NS1-Crk; Complex 1), where NS1 connects the p85β and Crk.
Interestingly, we could also demonstrate that Crk proteins are involved in PI3K activation
also by NS1 proteins that lack the SH3 binding site. In this case, another trimeric complex
of NS1, Crk, and p85β-Crk formed, where instead of NS1, the p85β serves as a bridging
factor by binding to both NS1 and Crk (NS1-p85β-Crk; Complex 2). Yet, we could only
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observe the Complex 2 when p85β was overexpressed, which led us to speculate that
the weaker activation of PI3K/Akt observed by SH3 binding incompetent NS1 proteins
might be because of the low cellular levels of p85β and lower affinity of p85β to the Crk
nSH3 domain. Indeed, we could demonstrate that overexpression of Crk proteins could
compensate the lower PI3K/Akt induction seen by the SH3 binding incompetent NS1
proteins compared to SH3 binding competent NS1. Thus, indicating that the SH3 binding
competent NS1 provides more efficient recruitment of Crk to the PI3K leading to the
formation of Complex 1 and enhanced activation of the pathway. However, the NS1-
mediated PI3K/Akt activation was seen to be solely depended on the interaction of NS1
with p85β, which was in line with earlier studies by others (Hale et al., 2006; Shin et al.,
2007b), and the association of NS1 with Crk-SH3 domain was able to only enhance the
capacity of NS1 to induce the pathway.
Structural studies on NS1-PI3K complex have revealed the mechanism of NS1-induced
activation of PI3K, but the precise role of Crk proteins in this requires further studies.
Binding of NS1 to the p85β breaks up the inhibitory contacts between the p110 and
p85β (Hale et al., 2010a). A possible scenario is that Crk proteins or some Crk associated
protein directly contributes to the activation of the complex or is involved in dissociation
of the negative regulation between p110 and p85β. Studies by others have reported that
the Crk SH2 domain mediates the activation of PI3K by binding to Cbl and activating the
Src kinases (Akagi et al., 2002; Song et al., 2010). Thus, the role of Crk in NS1-induced
PI3K signaling could be to recruit Src kinases to the NS1-PI3K complex through binding
to the Cbl. Since several alternative p85 and p110 isoforms contribute to the formation
of PI3K signaling complex depending on the initial stimulus (Vanhaesebroeck et al.,
2010), another possibility for the role of Crk in NS1-mediated PI3K activation could be
that Crk anchors the PI3K-NS1 complex to a subcellular compartment that is beneficial
for the pathway activation by NS1. Yet, we could only observe the Complex 2 when p85β
was overexpressed, which led us to speculate that the weaker activation of PI3K/Akt
observed by SH3 binding incompetent NS1 proteins might be because of the low cellular
levels  of  p85β and  lower  affinity  of  p85β to  the  Crk  nSH3  domain.  Indeed,  we  could
demonstrate that overexpression of Crk proteins could compensate the lower PI3K/Akt
induction seen by the SH3 binding incompetent NS1 proteins compared to SH3 binding
competent NS1. Thus, indicating that the SH3 binding competent NS1 provides more
efficient recruitment of Crk to the PI3K leading to the formation of Complex 1 and
enhanced activation of the pathway. However, the NS1-mediated PI3K/Akt activation
was seen to be solely depended on the interaction of NS1 with p85β, which was in line
with earlier studies by others (Hale et al., 2006; Shin et al., 2007b), and the association
of NS1 with Crk-SH3 domain was able to only potentiate the capacity of NS1 to induce
the pathway.
5.3   Nuclear localization of Crk-NS1 complex
Since the replication of IAV occurs in the nucleus of the host cell, manipulation of nuclear
environment during the infection is important for promoting virus propagation. Both
NS1 and Crk proteins have described to carry out distinct functions in the nucleus. The
NLS sequences efficiently target the NS1 protein into the nucleus, where it, for example,
inhibits host gene expression by binding to CPSF30. Crk proteins have also been
described with different nuclear functions but since they lack any NLS, their transport
from the cytoplasm to the nucleus is regulated by their interaction partners. In study III,
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we reported a robust nuclear translocation of Crk proteins by SH3 binding competent
NS1 which was further associated with tyrosine phosphorylation of an approximately
135 kDa nuclear protein. The size of the protein correlates with the cytoplasmic tyrosine
phosphorylated p130Cas, an adaptor protein that binds to the Crk SH2-domain (Birge et
al., 1992; Sakai et al., 1994). Another tyrosine phosphorylated Crk-interaction partner
that also correlates with the size of the unknown tyrosine phosphorylated protein in the
nuclear fraction is c-Abl. Crk associates with c-Abl through the nSH3 domain and the
interaction causes the autophosphorylation and activation of c-Abl (Brasher and Van
Etten, 2000; Shishido et al., 2001). So far we have not been able to show that either one
of these proteins would be a part of Crk-NS1 complex in the nucleus. Since the
association of Crk with c-Abl is mediated by the nSH3 domain, the Crk-NS1 interaction
would have to be disrupted before the Crk-c-Abl interaction could happen. Additionally,
the  association  of  c-Abl  with  Crk  could  happen  indirectly  since  NS1  has  also  been
reported to interact with c-Abl (Hrincius et al., 2014). Although this remains an
interesting scenario, the interaction of NS1 with c-Abl was linked to inhibition of the c-
Abl, not activation. The tyrosine phosphorylated protein observed in the nuclear fraction
could  also  be  a  protein  that  is  not  physically  linked  to  Crk.  As  the  Crk  proteins  are
involved in the regulation of a large number of different protein kinases both in the
cytoplasm and the nucleus, the translocation of Crk into nucleus by NS1 may initiate a
signaling cascade of different kinases and the tyrosine phosphorylated protein we
observe  could  be  acting  somewhere  downstream  of  Crk.  Further  work  is  needed  to
reveal the identity of the tyrosine phosphorylated protein and its role in IAV infection.
Previous studies have described different nuclear functions for Crk proteins. It has been
shown  that  in  response  to  type  I  IFNs  and  various  cytokines,  CrkL  binds  to
phosphorylated Stat5 via the CrkL SH2 domain (Fish et al., 1999; Grumbach et al., 2001;
Lekmine et al., 2002; Rhodes et al., 2000; Uddin et al., 2003). The resulting CrkL-Stat5
complex translocates into the nucleus where it binds to Stat5-responsive elements to
induce the expression of IFN stimulated genes. Thus, the NS1-mediated translocation of
CrkL to the nucleus we reported in study III could provide another layer of the inhibition
of IFN stimulated genes already described for NS1 protein. Importantly, transportation
of CrkII into the nucleus has been reported to be pro-apoptotic by activating caspases
and binding to the cell cycle regulator Wee1 through the CrkII SH2 domain (Smith et al.,
2000;  Smith  et  al.,  2002).  Apoptosis  and  the  activation  of  caspases  is  important  for
efficient nuclear exit of IAV vRNP complexes (Muhlbauer et al., 2015; Wurzer et al.,
2003). Thus, another interesting scenario for NS1-mediated Crk nuclear translocation
would be to induce apoptosis in order to promote the exit of vRNP from the nucleus.
Underneath the nuclear envelope lies a protein meshwork called the nuclear lamina,
composed of nuclear lamins, which is thought to be a common target especially for
nuclear replicating viruses. Our unpublished data indicates that viruses expressing SH3
binding competent NS1 may induce the cleavage and dispersion of nuclear lamins
compared to viruses in which NS1 lacks the Crk binding capacity. Targeting lamins could
be a possible mechanism for viruses bearing Crk binding competent NS1 to promote viral
replication.
5.4   Multiple functions of Crk-NS1 interaction
Crk proteins regulate a large set of cellular signaling events. Similarly, NS1 has multiple
functions and numerous interaction partners in the host cell. Considering this, it is not a
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surprise that Crk-NS1 interaction has been reported to be involved in several cell
functions as well. In addition to our observations that Crk-NS1 interaction is involved in
the superactivation of PI3K and in manipulating the intracellular distribution of Crk
proteins, which leads to changes in tyrosine phosphorylation of nuclear proteins, others
have noticed additional functions for this interaction, namely the suppression of c-Abl
and  JNK  signaling  (Hrincius  et  al.,  2014;  Hrincius  et  al.,  2010).  How  is  the  Crk-NS1
complex able to conduct all these functions in infected cell? NS1 protein is expressed in
considerable amounts in infected cells and the expression level of Crk proteins is also
high. Thus, Crk-NS1 complex would probably be able to participate in different signaling
routes at the same time and either one of the proteins could be the limiting factor. NS1
protein has been speculated to be temporally regulated in order to execute all its
different tasks at the right time, thus all the distinct functions described for Crk-NS1
complex could also be coordinated to happen in different time points of infection. In
addition, one has to bear in mind the differences in the signaling characteristics of the
three Crk family members. Hrincius et al. reported that CrkI was the main family member
participating in the inhibition of JNK pathway and apoptosis (Hrincius et al., 2010). We
were not able to see any variation between the different Crk proteins in the ability to
enhance the NS1-induced PI3K activation in study II. When we studied the localization
of the Crk-NS1 complex in study III, we could observe more pronounced translocation
of CrkL than CrkI or CrkII into nucleus, but the possible differences of these proteins for
the tyrosine phosphorylation of the nuclear protein observed or other possible nuclear
functions remain to be studied.
5.5   Diversity in the SH3 binding motif of NS1
The NS1 sequence at the SH3 binding motif (amino acids 212-217) is diverse among
different IAV strains. While most avian IAV NS1 proteins contain the Crk-SH3 binding
motif, only few human IAV NS1 proteins contain the motif. The critical amino acids, that
we reported to be important for the SH3-mediated binding of NS1 to Crk in study I (P212,
P215, and K217) provides the major variation sites observed for NS1 proteins of different
IAV strains. Sequence alignment of multiple NS1 proteins from avian IAV isolates until
this date reveals a consensus sequence of 212PPLPPK217 (NCBI, 2016), showing that the
SH3 binding site is highly conserved in NS1 proteins avian IAVs. In contrast, sequence
alignment of human IAV isolate NS1 proteins reveals that these NS1 proteins contain a
consensus sequence of 212PPLTPK217 (virus isolates from years 2009-2016). Thus, most
of the avian influenza A viruses have a proline at amino acid 215, whereas human IAV
strains contain a threonine in this position but variations at different positions also
occur. Avian IAV subtype H5N1 offers an exception to this rule, since the consensus for
NS1 in these viruses is 212LPLPPN217 (virus isolates from years 2009-2016), where two
amino acids important for the binding have been substituted with other residues (P212L
and K217N). Interestingly, the NS1 protein of famous human pandemic IAV strain, the
1918 Spanish Flu, possessed the SH3 domain binding site, but the motif was lost during
further adaptation of the virus to human.
5.6   Significance of the NS1 SH3 binding motif for IAV
The NS1 gene of most seasonal IAV strains would need just a single nucleotide change
to provide the NS1 protein with the capacity to bind Crk SH3 domain. If it would be
beneficial for viral replication and virulence, it could be expected to happen quickly.
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5.5   Diversity in the SH3 binding motif of NS1
The NS1 sequence at the SH3 binding motif (amino acids 212-217) is diverse among
different IAV strains. While most avian IAV NS1 proteins contain the Crk-SH3 binding
motif, only few human IAV NS1 proteins contain the motif. The critical amino acids, that
we reported to be important for the SH3-mediated binding of NS1 to Crk in study I (P212,
P215, and K217) provides the major variation sites observed for NS1 proteins of different
IAV strains. Sequence alignment of multiple NS1 proteins from avian IAV isolates until
this date reveals a consensus sequence of 212PPLPPK217 (NCBI, 2016), showing that the
SH3 binding site is highly conserved in NS1 proteins avian IAVs. In contrast, sequence
alignment of human IAV isolate NS1 proteins reveals that these NS1 proteins contain a
consensus sequence of 212PPLTPK217 (virus isolates from years 2009-2016). Thus, most
of the avian influenza A viruses have a proline at amino acid 215, whereas human IAV
strains contain a threonine in this position but variations at different positions also
occur. Avian IAV subtype H5N1 offers an exception to this rule, since the consensus for
NS1 in these viruses is 212LPLPPN217 (virus isolates from years 2009-2016), where two
amino acids important for the binding have been substituted with other residues (P212L
and K217N). Interestingly, the NS1 protein of famous human pandemic IAV strain, the
1918 Spanish Flu, possessed the SH3 domain binding site, but the motif was lost during
further adaptation of the virus to human.
5.6   Significance of the NS1 SH3 binding motif for IAV
The NS1 gene of most seasonal IAV strains would need just a single nucleotide change
to provide the NS1 protein with the capacity to bind Crk SH3 domain. If it would be
beneficial for viral replication and virulence, it could be expected to happen quickly.
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Instead, the requirement of the Crk-binding motif in NS1 protein for IAV replication and
pathogenesis seems to be virus strain specific. For example, a single nucleotide change
in the NS1 sequence of the 2009 pandemic Swine Flu (A/California/04/09) created a
functional Crk-binding motif (E217K), but did not enhance virus replication in human or
swine cells (Hale et al., 2010b). The virulence or the transmission of the virus was also
not affected. Likewise, mutation of T215 to proline to create an SH3 binding site in
human IAVs of A/Udorn and the Swine Flu strains did not affect virus replication (Hsiang
et al., 2012). Similarly the avian H5N1 subtype IAV, in which NS1 naturally lacks the Crk-
binding site, did not benefit from the introduction of the SH3 binding motif into its NS1
protein (Hrincius et al., 2014). In contrast, avian IAV strain that expresses SH3 binding
competent NS1 replicated less efficiently when the motif was mutated. On the other
hand, human IAV virus, A/PR8 was more pathogenic in mice, when SH3 binding site was
introduced in NS1 (Hrincius et al., 2015). Thus, the requirement for the Crk binding site
in NS1 is strikingly virus strain dependent, and the viruses naturally lacking the site do
not (with some notable exceptions) benefit from the addition of this site. The reason
why most avian IAVs seem to benefit from the ability to modulate Crk signaling in the
host cell and why it is lost when the virus is transmitted to human host may lie in the
natural environment these viruses encounter. The major replication site for avian IAVs
in their natural host is the intestine tract, whereas human IAVs infect mainly the trachea.
The differences in protein expression and in the temperature of the environment may
dictate the necessity of the Crk binding property of NS1 protein for the virus. The Crk
proteins are ubiquitously expressed in different human tissues and they are well
conserved between different species. However, the expression levels of these proteins
in the avian tissues is not known and should be studied. Remarkably, in study  I we
showed that the NS1 protein of the IAV strain that caused the most severe pandemic
known of all time, the highly pathogenic Spanish Flu, contain a functional SH3 binding
motif. The Spanish Flu IAV has been reported to be extraordinarily virulent and possess
higher replication capacity in cell culture and mice than the reference IAVs (Kash et al.,
2006;  Tumpey et  al.,  2005).  Moreover,  the Spanish Flu NS1 has been reported to be
more potent in regulating gene expression in host cell compared to NS1 proteins of
other IAV strains (Geiss et al., 2002). The SH3 binding site that provides the Spanish Flu
NS1 protein with capacity to exploit the host cell signaling machinery by binding to Crk
proteins may have contributed to the very highly pathogenic nature the virus had. The
adaptation of the virus to contain the SH3 binding site might provide the virus with
increased replicative advantage or pathogenic potential also in human cells, which
provides a potential threat in novel zoonotic pandemic viruses.
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6 CONCLUSIONS
In this thesis, we found a novel, functional SH3 binding motif in the NS1 protein of
Spanish Flu and most avian isolated IAV strains but not in NS1 proteins of most human
IAV strains. The site was shown to mediate interaction with the nSH3 domain of the Crk-
family adaptor proteins. This association provides NS1 protein with enhanced capacity
to induce PI3K/Akt signaling. We also described the molecular mechanism behind the
PI3K superactivation by SH3 binding competent NS1 proteins. The potentiation of the
pathway was shown to be a result of a reorganization of the natural PI3K-Crk complex
and the formation of a novel trimeric complex of PI3K, NS1 and Crk. Moreover, we found
that Crk proteins also have a general role in NS1-mediated activation of PI3K that is
independent from the SH3 binding capacity of NS1. In addition, we described another
function for Crk-NS1 interaction. The binding of Crk to NS1 was shown to lead to a robust
translocation of cytoplasmic Crk proteins into the nucleus. This function was
independent from the induction of the PI3K pathway. Instead, the potent translocation
of Crk proteins into the nucleus was linked to tyrosine phosphorylation of a nuclear
protein.
The results presented here describe two new mechanisms for IAV to regulate host cell
signaling by exploiting host cell SH3 domains. While the capability to activate PI3K
signaling by NS1 protein is conserved among most IAV strains, our studies revealed that
the  SH3  binding  competent  NS1  proteins  are  exceptionally  potent  PI3K  activators.  In
addition, the SH3 binding site enables the NS1 proteins to drag the Crk proteins into the
nucleus and consequently manipulate the nuclear environment. Importantly, the
presented data also reveal that Crk proteins are important general host cell co-factors
of IAV infection, independent from the NS1 Crk SH3 binding motif. The fact that some
IAV  strains  have  evolved  a  more  efficient  strategy  to  take  maximal  use  of  the  Crk
proteins to regulate host cell signaling in the cytoplasm and nucleus emphasizes the
importance of these proteins as NS1-interactor partners in IAV infection.
Further studies on this subject will provide deeper knowledge on the cell biology of IAV
replication. They will provide a new perspective to the IAV strain-specific variation of
the SH3-binding capacity of NS1, and hopefully open new avenues for anti-IAV
therapeutic development. It would be important to study the relevance of the NS1 SH3
binding motif in avian cells. Detailed characterization of the changes in the nuclear
protein phosphorylation pattern is also clearly needed in order to understand better the
importance of the relocalization of Crk proteins from the cytoplasm to the nucleus by
NS1 for IAV replication and pathogenesis. The role of NS1-Crk interaction for IAV cell
biology is undoubtedly important, and deserves special attention also in the future.
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NS1 (nonstructural protein 1) is an important virulence factor
of the influenza A virus. We observed that NS1 proteins of the
1918 pandemic virus (A/Brevig Mission/1/18) and many avian
influenza A viruses contain a consensus Src homology 3 (SH3)
domain-binding motif. Screening of a comprehensive human
SH3 phage library revealed theN-terminal SH3 of Crk andCrkL
as the preferred binding partners. Studies with recombinant
proteins confirmed avid binding of NS1 proteins of the 1918
virus and a representative avian H7N3 strain to Crk/CrkL SH3
but not to other SH3 domains tested, including p85 and p85.
Endogenous CrkL readily co-precipitated NS1 from cells
infected with the H7N3 virus. In transfected cells association
with CrkL was observed for NS1 of the 1918 and H7N3 viruses
but not A/Udorn/72 or A/WSN/33 NS1 lacking this sequence
motif. SH3 binding was dispensable for suppression of inter-
feron-induced gene expression by NS1 but was associated
with enhanced phosphatidylinositol 3-kinase signaling, as
evidenced by increased Akt phosphorylation. Thus, the Span-
ish Flu virus resembles avian influenza A viruses in its ability
to recruit Crk/CrkL to modulate host cell signaling.
Pandemic as well as seasonal outbreaks of influenza A virus
represent major threats to global public health. In the last cen-
tury three major pandemics have occurred, in 1918, 1957, and
1968, caused by H1N1 (Spanish flu), H2N2 (Asian flu), and
H3N2 (HongKong flu) viruses, respectively.Of these, the Span-
ish flu was themost severe and is estimated to have caused over
40 million deaths worldwide (1). Recent human infections by
highly pathogenic H5N1 avian influenza A viruses have
increased the concern that another global pandemicmay occur.
Influenza A virus belongs to the Orthomyxoviridae family of
enveloped viruses. Its genome is organized into eight single-
stranded, negative-sense RNA segments that code for 11 iden-
tified viral proteins (2). NS1 (nonstructural protein 1) is
encoded by the shortest RNA segment 8. It is expressed early in
viral replication cycle, and it is not a component of the virus
particle (2). Instead, NS1 is a multifunctional virulence factor
that promotes virus replication in the host cell and helps to
evade antiviral immunity (3–5). In particular, NS1 uses several
mechanisms to prevent suppression of influenza A virus repli-
cation by the type I interferon system of the host.
Recent studies have demonstrated that during influenza A
virus infection NS1 protein activates the phosphatidylinositol
3-kinase (PI3K)3 signaling pathway, apparently via its associa-
tion with the p85 regulatory subunit of PI3K (6–9). Activation
of the PI3Kpathway seems to be important for influenzaAvirus
replication, because in cell culture studies recombinant viruses
with mutations that prevented binding of NS1 to p85 formed
much smaller plaques and grew to 10-fold lower titers than the
wild-type virus (9).Moreover, compounds that inhibit PI3K can
strongly suppress influenza A virus replication (7, 9, 10).
Hale et al. (9) showed that the tyrosine residue 89 (Tyr-89) of
NS1 protein serves a critical role in mediating binding to p85.
This tyrosine lies in the context similar to aYXNMmotif, which
upon tyrosine phosphorylation can serve as a high affinity bind-
ing site for the SH2 domain of p85 (11), but apparently NS1
interacts with p85 in an SH2-independent manner (12). In
addition, p85 contains an SH3 domain, and Zhou and co-work-
ers (6, 13) have suggested that a PXXP sequence in NS1, which
resembles the consensus of an SH3-binding motif (see below),
may also contribute to the p85 interaction.
SH3 domains are small protein modules that mediate inter-
and intramolecular protein interactions and are often found in
proteins regulating cellular signaling pathways, cytoskeletal
organization, and membrane trafficking (14, 15). SH3 domains
recognize short proline-rich sequences, which are typically
characterized by ()-XPXXP (class I) or PXPX-() (class II)
consensus sequences (where X is any amino acid; () indicates
a positively charged residue; and  indicates a hydrophobic
residue) (15–17). Since the discovery that the human immuno-
deficiency virus type 1 pathogenicity factor Nef regulates the
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NS1 (nonstructural protein 1) is an important virulence factor
of the influenza A virus. We observed that NS1 proteins of the
1918 pandemic virus (A/Brevig Mission/1/18) and many avian
influenza A viruses contain a consensus Src homology 3 (SH3)
domain-binding motif. Screening of a comprehensive human
SH3 phage library revealed theN-terminal SH3 of Crk andCrkL
as the preferred binding partners. Studies with recombinant
proteins confirmed avid binding of NS1 proteins of the 1918
virus and a representative avian H7N3 strain to Crk/CrkL SH3
but not to other SH3 domains tested, including p85 and p85.
Endogenous CrkL readily co-precipitated NS1 from cells
infected with the H7N3 virus. In transfected cells association
with CrkL was observed for NS1 of the 1918 and H7N3 viruses
but not A/Udorn/72 or A/WSN/33 NS1 lacking this sequence
motif. SH3 binding was dispensable for suppression of inter-
feron-induced gene expression by NS1 but was associated
with enhanced phosphatidylinositol 3-kinase signaling, as
evidenced by increased Akt phosphorylation. Thus, the Span-
ish Flu virus resembles avian influenza A viruses in its ability
to recruit Crk/CrkL to modulate host cell signaling.
Pandemic as well as seasonal outbreaks of influenza A virus
represent major threats to global public health. In the last cen-
tury three major pandemics have occurred, in 1918, 1957, and
1968, caused by H1N1 (Spanish flu), H2N2 (Asian flu), and
H3N2 (HongKong flu) viruses, respectively.Of these, the Span-
ish flu was themost severe and is estimated to have caused over
40 million deaths worldwide (1). Recent human infections by
highly pathogenic H5N1 avian influenza A viruses have
increased the concern that another global pandemicmay occur.
Influenza A virus belongs to the Orthomyxoviridae family of
enveloped viruses. Its genome is organized into eight single-
stranded, negative-sense RNA segments that code for 11 iden-
tified viral proteins (2). NS1 (nonstructural protein 1) is
encoded by the shortest RNA segment 8. It is expressed early in
viral replication cycle, and it is not a component of the virus
particle (2). Instead, NS1 is a multifunctional virulence factor
that promotes virus replication in the host cell and helps to
evade antiviral immunity (3–5). In particular, NS1 uses several
mechanisms to prevent suppression of influenza A virus repli-
cation by the type I interferon system of the host.
Recent studies have demonstrated that during influenza A
virus infection NS1 protein activates the phosphatidylinositol
3-kinase (PI3K)3 signaling pathway, apparently via its associa-
tion with the p85 regulatory subunit of PI3K (6–9). Activation
of the PI3Kpathway seems to be important for influenzaAvirus
replication, because in cell culture studies recombinant viruses
with mutations that prevented binding of NS1 to p85 formed
much smaller plaques and grew to 10-fold lower titers than the
wild-type virus (9).Moreover, compounds that inhibit PI3K can
strongly suppress influenza A virus replication (7, 9, 10).
Hale et al. (9) showed that the tyrosine residue 89 (Tyr-89) of
NS1 protein serves a critical role in mediating binding to p85.
This tyrosine lies in the context similar to aYXNMmotif, which
upon tyrosine phosphorylation can serve as a high affinity bind-
ing site for the SH2 domain of p85 (11), but apparently NS1
interacts with p85 in an SH2-independent manner (12). In
addition, p85 contains an SH3 domain, and Zhou and co-work-
ers (6, 13) have suggested that a PXXP sequence in NS1, which
resembles the consensus of an SH3-binding motif (see below),
may also contribute to the p85 interaction.
SH3 domains are small protein modules that mediate inter-
and intramolecular protein interactions and are often found in
proteins regulating cellular signaling pathways, cytoskeletal
organization, and membrane trafficking (14, 15). SH3 domains
recognize short proline-rich sequences, which are typically
characterized by ()-XPXXP (class I) or PXPX-() (class II)
consensus sequences (where X is any amino acid; () indicates
a positively charged residue; and  indicates a hydrophobic
residue) (15–17). Since the discovery that the human immuno-
deficiency virus type 1 pathogenicity factor Nef regulates the
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host cell via binding to SH3 domains of Src family protein
kinases (18), SH3 domain binding capacity has been demon-
strated for many other proteins encoded by viral as well as bac-
terial pathogens (19–24).
We noted that, unlike most other NS1 proteins from human
strains of influenza, the NS1 sequence of the 1918 pandemic
influenza virus (A/Brevig Mission/1/18/H1N1 (25)) contains a
perfect class II consensus SH3-binding sequence, and in this
regard it resembles many avian strains of influenza (26).
We have recently generated an essentially complete (n 
296) collection of human SH3 domains in the form of a phage
display library to allow comprehensive and unbiased identifica-
tion of preferred SH3 partners for cellular and viral ligand pro-
teins of interest (27). In this study we have made use of this
novel research tool to identify the Crk family adapter proteins
as high affinity ligands for the NS1 protein of the 1918 virus.
EXPERIMENTAL PROCEDURES
Cells and Viral Infections—Human embryonic kidney
293FT, human hepatocellular carcinoma Huh-7, and human
A549 lung carcinoma cell lines were maintained in Dulbecco’s
modified Eagle’s medium high glucose supplemented with 0.6
g/ml penicillin, 60 g/ml streptomycin, 10% fetal bovine
serum, and 2 mM glutamine. Influenza A virus strains A/mal-
lard/Netherlands/12/2000 (H7N3) and A/Udorn/72 (H3N2)
were grown in 11-day-old embryonated eggs, and the virus
stock was aliquoted and stored at 70 °C. The hemagglutina-
tion titers of the viruses were 256, and their infectivity in A549
cells was 1  107 and 2  107 plaque-forming units per ml,
respectively. Virus infection of A549 cells was carried out in
Dulbecco’s modified Eagle’s medium supplemented with 2%
fetal bovine serum and antibiotics for 20 h at a multiplicity of
infection of 5 plaque-forming units/cell.
To metabolically label virus-infected cells with [35S]methi-
onine, the cells were washed with and changed into methio-
nine-free media supplemented with 2% fetal bovine serum and
0.5 mCi of [35S]Met (GE Healthcare) 4 h after infection and
grown for an additional 16 h. At 20 h after infection cells were
collected, washed twice with cold phosphate-buffered saline,
and lysed.
Plasmid Constructs—A synthetic gene fragment encoding
A/Brevig Mission/1/18 NS1 was purchased from GENEART
(Regensburg, Germany). A/mallard/Netherlands/12/2000/
H7N3 cDNA was cloned from total cellular RNA of virus-in-
fected cells by standard methods. A/Udorn/72 and A/WSN/33
NS1 inserts were derived from pcDNA3.1-based constructs
already described (28). To generate the mammalian NS1
expression vectors, these fragments were inserted into the
EF1 enhancer-driven vector pEBB-mycN by PCR-mediated
cloning and confirmed by DNA sequencing. pEBB-mycN is a
derivative of pEBB (from Bruce Mayer, University of Connect-
icut) (29), in which translation starts upstream of the insert to
include a Myc epitope-containing peptide (MEQKLISEED-
LGS) at the N terminus. Codon changes to A/Brevig and
A/Mallard NS1 gene were generated by overlap PCRmutagen-
esis, cloned into pEBB-mycN, and verified by sequencing. Bac-
terial GST and MBP fusion protein expression vectors for NS1
proteins were constructed by inserting the corresponding NS1
cDNAs into pGEX-4T1 (GE Healthcare) and pMAL-c2x (New
England Biolabs) vectors, respectively. To generate the plasmid
p85-BP, an oligonucleotide duplex encoding for the peptide
CLNCFRPLPPLPPPPR (30) was inserted into the polylinker of
pMAL-c2x.
A DNA fragment encoding for a 123-amino acid biotin
acceptor domain from Propionibacterium shermanii transcar-
boxylase (start, MKLK; end, IKIG) was PCR-amplified from the
PinPoint-Xa1 T-vector (Promega) and inserted between the
GST gene and the multiple cloning site of pGEX-4T1 to gener-
ate pGEX-PP. Codon optimized cDNAs for the SH3 domains of
Crk, CrkL, p85, p85, and Eps8L1 derived from the human
SH3 library (27) were subsequently cloned in-frame after the
biotin acceptor domain in pGEX-PP. To generate C-terminally
biotinylated Crk and CrkL expression constructs, human CrkII
andCrkL cDNAswith stop codons replaced by a KpnI site were
fused with the above-described biotin acceptor domain frag-
ment in pEBB.
ISRE-Luc reporter plasmid contains a 30-bp interferon-
stimulated response element-containing fragment from the
ISG15 gene (31) in front of a minimal thymidine kinase pro-
moter driving firefly luciferase expression (obtained from J.
Darnell Jr., Rockefeller University, New York). As a control
for transfection efficiency and cell viability, we used the plas-
mid pcDNA-Renilla, which was created by inserting Renilla
luciferase cDNA from pRL-null (Promega) into pcDNA3.1/
Hygro vector (Invitrogen).
Antibodies and Other Reagents—The following antibodies
were used in this study: mouse anti-Myc (Sigma), mouse anti-
CrkL (Upstate), mouse anti-phospho-Akt(Ser-473) (Cell
Signaling Technology), rabbit anti-NP (32), mouse anti-he-
magglutinin (HA, Santa Cruz Biotechnology), and guinea pig
anti-NS1 (28). Streptavidin IRDye800CW, IRDye 800CW
goat anti-mouse IgG, and IRDye680 goat anti-mouse IgG
were from LI-COR Biotechnology. Secondary horseradish
peroxidase-conjugated anti-guinea pig antibodies were from
Jackson ImmunoResearch.
Recombinant Proteins and Binding Assays—GST and MBP
fusion proteins expressed frompGEX-4T1 and pMAL-c2x pro-
tein expression vectors were purified using glutathione-Sepha-
rose 4B (GE Healthcare) or amylose resin (New England Bio-
labs), according to the manufacturer’s instructions. Screening
of the human SH3 phage library using the GST-NS1 fusion
proteins was done as described previously (27). Recombinant
protein binding assay was done as in Ka¨rkka¨inen et al. (27) with
some modifications. MBP-NS1 proteins, MBP-p85-BP, or
plain MBP was coated on 96-well plates (200 ng/well). Wells
were blocked with 1.5% bovine serum albumin in Tris-buffered
saline (TBS) for 1 h andwashed twice with TBS 0.05%Tween
20 (TBST).MBP proteins were then incubated with 2-fold dilu-
tions of GST-biotin-SH3 domains in TBS for 1.5 h. Wells were
then washed three times with TBST, followed by a 1-h incuba-
tion with streptavidin-biotinylated horseradish peroxidase
complex (1:2000 dilution in TBS; GE Healthcare). After three
washes with TBST, 50 l of substrate reagent ABTS Single
Solution (Invitrogen) was added, and the absorbance at 405 nm
was measured 20 min later.
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terial pathogens (19–24).
We noted that, unlike most other NS1 proteins from human
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influenza virus (A/Brevig Mission/1/18/H1N1 (25)) contains a
perfect class II consensus SH3-binding sequence, and in this
regard it resembles many avian strains of influenza (26).
We have recently generated an essentially complete (n 
296) collection of human SH3 domains in the form of a phage
display library to allow comprehensive and unbiased identifica-
tion of preferred SH3 partners for cellular and viral ligand pro-
teins of interest (27). In this study we have made use of this
novel research tool to identify the Crk family adapter proteins
as high affinity ligands for the NS1 protein of the 1918 virus.
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g/ml penicillin, 60 g/ml streptomycin, 10% fetal bovine
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stock was aliquoted and stored at 70 °C. The hemagglutina-
tion titers of the viruses were 256, and their infectivity in A549
cells was 1  107 and 2  107 plaque-forming units per ml,
respectively. Virus infection of A549 cells was carried out in
Dulbecco’s modified Eagle’s medium supplemented with 2%
fetal bovine serum and antibiotics for 20 h at a multiplicity of
infection of 5 plaque-forming units/cell.
To metabolically label virus-infected cells with [35S]methi-
onine, the cells were washed with and changed into methio-
nine-free media supplemented with 2% fetal bovine serum and
0.5 mCi of [35S]Met (GE Healthcare) 4 h after infection and
grown for an additional 16 h. At 20 h after infection cells were
collected, washed twice with cold phosphate-buffered saline,
and lysed.
Plasmid Constructs—A synthetic gene fragment encoding
A/Brevig Mission/1/18 NS1 was purchased from GENEART
(Regensburg, Germany). A/mallard/Netherlands/12/2000/
H7N3 cDNA was cloned from total cellular RNA of virus-in-
fected cells by standard methods. A/Udorn/72 and A/WSN/33
NS1 inserts were derived from pcDNA3.1-based constructs
already described (28). To generate the mammalian NS1
expression vectors, these fragments were inserted into the
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derivative of pEBB (from Bruce Mayer, University of Connect-
icut) (29), in which translation starts upstream of the insert to
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LGS) at the N terminus. Codon changes to A/Brevig and
A/Mallard NS1 gene were generated by overlap PCRmutagen-
esis, cloned into pEBB-mycN, and verified by sequencing. Bac-
terial GST and MBP fusion protein expression vectors for NS1
proteins were constructed by inserting the corresponding NS1
cDNAs into pGEX-4T1 (GE Healthcare) and pMAL-c2x (New
England Biolabs) vectors, respectively. To generate the plasmid
p85-BP, an oligonucleotide duplex encoding for the peptide
CLNCFRPLPPLPPPPR (30) was inserted into the polylinker of
pMAL-c2x.
A DNA fragment encoding for a 123-amino acid biotin
acceptor domain from Propionibacterium shermanii transcar-
boxylase (start, MKLK; end, IKIG) was PCR-amplified from the
PinPoint-Xa1 T-vector (Promega) and inserted between the
GST gene and the multiple cloning site of pGEX-4T1 to gener-
ate pGEX-PP. Codon optimized cDNAs for the SH3 domains of
Crk, CrkL, p85, p85, and Eps8L1 derived from the human
SH3 library (27) were subsequently cloned in-frame after the
biotin acceptor domain in pGEX-PP. To generate C-terminally
biotinylated Crk and CrkL expression constructs, human CrkII
andCrkL cDNAswith stop codons replaced by a KpnI site were
fused with the above-described biotin acceptor domain frag-
ment in pEBB.
ISRE-Luc reporter plasmid contains a 30-bp interferon-
stimulated response element-containing fragment from the
ISG15 gene (31) in front of a minimal thymidine kinase pro-
moter driving firefly luciferase expression (obtained from J.
Darnell Jr., Rockefeller University, New York). As a control
for transfection efficiency and cell viability, we used the plas-
mid pcDNA-Renilla, which was created by inserting Renilla
luciferase cDNA from pRL-null (Promega) into pcDNA3.1/
Hygro vector (Invitrogen).
Antibodies and Other Reagents—The following antibodies
were used in this study: mouse anti-Myc (Sigma), mouse anti-
CrkL (Upstate), mouse anti-phospho-Akt(Ser-473) (Cell
Signaling Technology), rabbit anti-NP (32), mouse anti-he-
magglutinin (HA, Santa Cruz Biotechnology), and guinea pig
anti-NS1 (28). Streptavidin IRDye800CW, IRDye 800CW
goat anti-mouse IgG, and IRDye680 goat anti-mouse IgG
were from LI-COR Biotechnology. Secondary horseradish
peroxidase-conjugated anti-guinea pig antibodies were from
Jackson ImmunoResearch.
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rose 4B (GE Healthcare) or amylose resin (New England Bio-
labs), according to the manufacturer’s instructions. Screening
of the human SH3 phage library using the GST-NS1 fusion
proteins was done as described previously (27). Recombinant
protein binding assay was done as in Ka¨rkka¨inen et al. (27) with
some modifications. MBP-NS1 proteins, MBP-p85-BP, or
plain MBP was coated on 96-well plates (200 ng/well). Wells
were blocked with 1.5% bovine serum albumin in Tris-buffered
saline (TBS) for 1 h andwashed twice with TBS 0.05%Tween
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Protein Pulldowns andWestern Blots—For protein pulldown
experiments, 293FT cells were transfected by standard calcium
phosphate precipitation method with 10 g of NS1 expression
vectors in 10-cm plates. For avidin pulldown experiments cells
were transfected also with 3 g of Crk or CrkL expression con-
structs encoding for C-terminally biotinylated proteins. 48 h
after transfection, cells were lysed on ice with 1% Nonidet P-40
lysis buffer (150mMNaCl; 50mMTris-HCl, pH 7.9; 1%Nonidet
P-40). Cell lysates were used for immunoprecipitation with
anti-CrkL antibody and Dynabeads protein A magnetic beads
(Invitrogen) or avidin pulldowns with Tetralink tetrameric avi-
din resin (Promega). To examine the phosphorylation status of
Akt, Huh-7 cells in 6-well plates were transfected with 4 g of
Myc-tagged NS1 expression plasmids or empty plasmid using
Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s instructions. 48 h after transfection cells were lysed on ice
with 1% Nonidet P-40 lysis buffer, and lysates were used for
Western blotting to detect phospho-Akt or myc-NS1. Immo-
bilon Western chemiluminescent horseradish peroxidase sub-
strate (Millipore) or Odyssey infrared imaging system (LI-COR
Biosciences) was used for detection.
ReporterGeneAssays—Tomeasure the activation of the ISRE
promoter, Huh-7 cells were transfected in 12-well plates with
0.2 g of ISRE-Luc, 5 ng of pcDNA-Renilla, and 1 g of NS1
expression vectors or empty vector using Lipofectamine 2000
(Invitrogen). 22 h post-transfection, the reporter gene was
induced by treatment with 100 IU/ml of IFN- (Betaferon,
Schering) for 7 h. Cells were lysed with Passive Lysis Buffer
(Promega), and the luciferase activity wasmeasured using dual-
luciferase assay system (Promega) and Sirius luminometer
(Berthold detection systems). Renilla luciferase construct was
used as an internal control to normalize relative luciferase
activity.
RESULTS
Consensus SH3-binding Motif in NS1—To look for potential
virally encoded ligands for cellular SH3 proteins, we used the
ScanProsite search engine to identify consensus SH3 domain-
binding motifs in viral protein sequences in the Swiss-Prot/
TrEMBL data base. One interesting protein that was noted to
contain a perfect class II SH3-binding motif was NS1 of the
1918 pandemic influenza A virus (A/Brevig Mission/1/18/
H1N1; A/Brevig below). Analysis of NS1 protein sequences
from other strains of influenza A revealed that this sequence
motif is very common among avian influenzaA viruses but only
rarely found in viruses isolated from humans (Fig. 1). In addi-
tion to A/Brevig, only three other human-derived NS1
sequences containing this motif could be found from the NCBI
Influenza Virus Resource data base. Notably, two of these
viruses represented recent zoonotic transmissions from birds
with an H5N1 virus (A/Hong Kong/481/97/H5N1 (33)) and an
H7N3 virus (A/Canada/rv504/2004/H7N3 (26)). Accordingly,
this sequencemotif is not present in theNS1 proteins of human
influenza A viruses commonly used for laboratory studies, such
as A/WSN/33 (H1N1), A/PR/8/34 (H1N1), and A/Udorn/72
(H3N2) (see Fig. 1).
Identification of SH3 Partners of NS1—To examine their
SH3 binding potential and preferences, NS1 proteins
encoded by A/Brevig and an avian strain containing the same
consensus motif (A/mallard/Netherlands/12/00/H7N3;
A/Mallard below) were expressed as GST fusion proteins in
Escherichia coli and used as ligands for affinity screening of our
comprehensive human SH3 phage display library (27). Both
proteins bound avidly to SH3 clones in the library as compared
with plain GST protein used as a control for nonspecific bind-
ing (not shown). Sequencing of the phagemid genomes
obtained after a single roundof affinity selectionwith theseNS1
proteins revealed that more than 90% of the phages contained
the N-terminal SH3 domain of the adapter protein Crk or its
close homologue CrkL.
To confirm and study in more detail the NS1/SH3 interac-
tions revealed by phage screening, we generated recombinant
GST fusion proteins of theN-terminal SH3 domains of Crk and
CrkL. Because the SH3 of p85 has been suggested to bind to
PXXP sequences found in many influenza A NS1 proteins (6)
(see Fig. 1) we also generated GST-SH3 fusion proteins of p85
and p85. In addition, the SH3 of Eps8L1, which is known to
prefer atypical PXXDY-containing ligands (34), was included as
a negative control. Between the GST and SH3moieties in these
FIGURE 1. Amino acid sequences of selected influenza A virus NS1 pro-
teins.A, alignment of the complete influenzaA virusNS1 sequences of A/Bre-
vig Mission/1/18/H1N1 (Brevig) and A/Udorn/72/H3N2 (Udorn) sequences.
Residues in Udorn that differ from the corresponding amino acids in Brevig
are highlighted in gray. Tyrosine (position 89) and proline (positions 164, 167,
213, and216) previously implicated inbinding to the SH2andSH3domainsof
PI3K-p85 (6, 9) are underlined. The region containing a consensus SH3-bind-
ingmotif in the Brevig sequence is boxed. B, shown are amino acid sequences
within in the region boxed in A in NS1 proteins from the indicated influenza A
viruses, aswell as chicken (basedon1996 isolates) andhuman (basedon2005
isolates) consensus sequences. The sequence PxPx (where x denotes any
aminoacid, indicates ahydrophobic residue, and indicates anarginineor
a lysine) indicates a class II SH3-binding consensusmotif (critical amino acids
in boldface).
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Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s instructions. 48 h after transfection cells were lysed on ice
with 1% Nonidet P-40 lysis buffer, and lysates were used for
Western blotting to detect phospho-Akt or myc-NS1. Immo-
bilon Western chemiluminescent horseradish peroxidase sub-
strate (Millipore) or Odyssey infrared imaging system (LI-COR
Biosciences) was used for detection.
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H1N1; A/Brevig below). Analysis of NS1 protein sequences
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motif is very common among avian influenzaA viruses but only
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with plain GST protein used as a control for nonspecific bind-
ing (not shown). Sequencing of the phagemid genomes
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proteins revealed that more than 90% of the phages contained
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To confirm and study in more detail the NS1/SH3 interac-
tions revealed by phage screening, we generated recombinant
GST fusion proteins of theN-terminal SH3 domains of Crk and
CrkL. Because the SH3 of p85 has been suggested to bind to
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FIGURE 1. Amino acid sequences of selected influenza A virus NS1 pro-
teins.A, alignment of the complete influenzaA virusNS1 sequences of A/Bre-
vig Mission/1/18/H1N1 (Brevig) and A/Udorn/72/H3N2 (Udorn) sequences.
Residues in Udorn that differ from the corresponding amino acids in Brevig
are highlighted in gray. Tyrosine (position 89) and proline (positions 164, 167,
213, and216) previously implicated inbinding to the SH2andSH3domainsof
PI3K-p85 (6, 9) are underlined. The region containing a consensus SH3-bind-
ingmotif in the Brevig sequence is boxed. B, shown are amino acid sequences
within in the region boxed in A in NS1 proteins from the indicated influenza A
viruses, aswell as chicken (basedon1996 isolates) andhuman (basedon2005
isolates) consensus sequences. The sequence PxPx (where x denotes any
aminoacid, indicates ahydrophobic residue, and indicates anarginineor
a lysine) indicates a class II SH3-binding consensusmotif (critical amino acids
in boldface).
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fusion proteins, we inserted a biotin acceptor domain from P.
shermanii transcarboxylase, which during expression in E. coli
becomes efficiently biotinylated at a single lysine residue, and
can be conveniently detected with avidin-based reagents (35).
As targets for these SH3 domains, we expressed maltose-bind-
ing protein (MBP) fusion constructs A/Udorn, A/Mallard, and
A/Brevig NS1 proteins. The latter were coated onto the bottom
of 96-well plates and probedwith serial dilutions of biotinylated
Crk, CrkL, p85, p85, or Eps8L1 SH3 domains in an enzyme-
linked immunosorbent assay-like sandwich assay.
As shown in Fig. 2, SH3 domains of Crk and CrkL bound
avidly to A/Mallard NS1-coated wells, showing significant
binding signals even when tested at sub-micromolar concen-
trations (see Fig. 2A). By contrast, p85 and p85 SH3 domains
were equally negative in binding to A/Mallard NS1 as was
Eps8L1 SH3 or CrkL SH3 in binding to the control wells coated
with plain MBP. Although the absolute binding to Crk/CrkL
SH3 domains was slightly weaker, very similar results were
obtained by using A/Brevig NS1 as the immobilized ligand
(data not shown). In agreement with the lack of a consensus
SH3-binding motif in A/Udorn NS1, none of the tested SH3
domains showed measurable binding to Udorn NS1 protein
(Fig. 2B). To confirm the functionality of the p85 SH3 domain
proteins used in this study, we fused MBP with a peptide
(CLNCFRPLPPLPPPPR) that has been optimized for binding to
p85 using phage display (30). Positive binding to this peptide
under identical assay conditions (Fig. 2C) indicated that the
failure of p85 and p85 SH3 domains to bind to the NS1 pro-
teins of A/Mallard and A/Udorn (Fig. 2, A and B) as well as
A/Brevig and A/WSN (data not shown) was indeed a valid
result and not because of a general lack of functionality of our
p85 SH3 proteins.
Binding of Crk and CrkL to NS1 in Transfected Cells—To
extend these findings to full-length proteins expressed in
human cells and to compare NS1-binding by Crk and CrkL, we
generated expression vectors for these proteins tagged at their
N terminiwith the transcarboxylase biotin acceptor domain.As
in our previous studies on divergent protein interactions (36),
this strategy allowed sensitive and equal detection of the tagged
Crk and CrkL proteins when co-transfected into 293FT cells
together with NS1 proteins from different influenza A viruses
(Fig. 3). To ensure equal detection of the different NS1 proteins
used in this experiment, these expression constructs were
tagged with a Myc peptide epitope. Similar expression of all
NS1 proteins in the lysates of transfected cells and equal recov-
ery of the biotinylated Crk and CrkL proteins using avidin-
coated beads were observed, whereas the amounts of co-pre-
cipitated NS1 proteins differed dramatically (Fig. 3, top panel).
Both Crk and CrkL associated strongly with A/Brevig and
FIGURE 2. Semi-quantitative analysis of binding of recombinant SH3
domains to NS1 proteins. A/Mallard (A) and A/Udorn (B) NS1 proteins were
expressed as MBP in E. coli and used to coat 96-well plates. These wells were
incubatedwith 2-fold dilutions (ranging from 2.5 to 0.16M) of the indicated
recombinant SH3 domains expressed as biotinylated GST fusion proteins,
followed by detection of binding with an enzymatically labeled streptavidin.
As a control for nonspecific binding, additional wells were coated with plain
MBP and similarly probed with CrkL SH3 domains (CrkL/MBP). In addition, an
artificial protein (p85-BP) consistingofMBP fused toahighaffinityp85-SH3
ligand peptide (CLNCFRPLPPLPPPPR) (30) was used as an immobilized target
protein to test bindingof p85-SH3andp85-SH3. As inA andB,wells coated
with plain MBP (p85-SH3/MBP and p85/MBP) were used as controls (C).
FIGURE 3.Co-precipitation of A/Brevig, A/Mallard, andA/UdornNS1pro-
teins with full-length Crk and CrkL proteins from transfected cells.Myc-
tagged expression vectors for the indicated NS1 proteins were transfected
into293FTcells togetherwithabiotin-acceptordomain-taggedvector forCrk
(C) or CrkL (L). Material precipitated with avidin-coated beads from lysates of
the co-transfected cells were analyzed byWestern blotting using an anti-Myc
antibodyor a labeledavidin reagent, as indicated. Aliquots of the lysateswere
collected before avidin pulldown and subjected directly into Western blot
analysis (two bottom panels).
Enhanced PI3K Activation by NS1 via SH3 Binding
5722 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 9•FEBRUARY 29, 2008
fusion proteins, we inserted a biotin acceptor domain from P.
shermanii transcarboxylase, which during expression in E. coli
becomes efficiently biotinylated at a single lysine residue, and
can be conveniently detected with avidin-based reagents (35).
As targets for these SH3 domains, we expressed maltose-bind-
ing protein (MBP) fusion constructs A/Udorn, A/Mallard, and
A/Brevig NS1 proteins. The latter were coated onto the bottom
of 96-well plates and probedwith serial dilutions of biotinylated
Crk, CrkL, p85, p85, or Eps8L1 SH3 domains in an enzyme-
linked immunosorbent assay-like sandwich assay.
As shown in Fig. 2, SH3 domains of Crk and CrkL bound
avidly to A/Mallard NS1-coated wells, showing significant
binding signals even when tested at sub-micromolar concen-
trations (see Fig. 2A). By contrast, p85 and p85 SH3 domains
were equally negative in binding to A/Mallard NS1 as was
Eps8L1 SH3 or CrkL SH3 in binding to the control wells coated
with plain MBP. Although the absolute binding to Crk/CrkL
SH3 domains was slightly weaker, very similar results were
obtained by using A/Brevig NS1 as the immobilized ligand
(data not shown). In agreement with the lack of a consensus
SH3-binding motif in A/Udorn NS1, none of the tested SH3
domains showed measurable binding to Udorn NS1 protein
(Fig. 2B). To confirm the functionality of the p85 SH3 domain
proteins used in this study, we fused MBP with a peptide
(CLNCFRPLPPLPPPPR) that has been optimized for binding to
p85 using phage display (30). Positive binding to this peptide
under identical assay conditions (Fig. 2C) indicated that the
failure of p85 and p85 SH3 domains to bind to the NS1 pro-
teins of A/Mallard and A/Udorn (Fig. 2, A and B) as well as
A/Brevig and A/WSN (data not shown) was indeed a valid
result and not because of a general lack of functionality of our
p85 SH3 proteins.
Binding of Crk and CrkL to NS1 in Transfected Cells—To
extend these findings to full-length proteins expressed in
human cells and to compare NS1-binding by Crk and CrkL, we
generated expression vectors for these proteins tagged at their
N terminiwith the transcarboxylase biotin acceptor domain.As
in our previous studies on divergent protein interactions (36),
this strategy allowed sensitive and equal detection of the tagged
Crk and CrkL proteins when co-transfected into 293FT cells
together with NS1 proteins from different influenza A viruses
(Fig. 3). To ensure equal detection of the different NS1 proteins
used in this experiment, these expression constructs were
tagged with a Myc peptide epitope. Similar expression of all
NS1 proteins in the lysates of transfected cells and equal recov-
ery of the biotinylated Crk and CrkL proteins using avidin-
coated beads were observed, whereas the amounts of co-pre-
cipitated NS1 proteins differed dramatically (Fig. 3, top panel).
Both Crk and CrkL associated strongly with A/Brevig and
FIGURE 2. Semi-quantitative analysis of binding of recombinant SH3
domains to NS1 proteins. A/Mallard (A) and A/Udorn (B) NS1 proteins were
expressed as MBP in E. coli and used to coat 96-well plates. These wells were
incubatedwith 2-fold dilutions (ranging from 2.5 to 0.16M) of the indicated
recombinant SH3 domains expressed as biotinylated GST fusion proteins,
followed by detection of binding with an enzymatically labeled streptavidin.
As a control for nonspecific binding, additional wells were coated with plain
MBP and similarly probed with CrkL SH3 domains (CrkL/MBP). In addition, an
artificial protein (p85-BP) consistingofMBP fused toahighaffinityp85-SH3
ligand peptide (CLNCFRPLPPLPPPPR) (30) was used as an immobilized target
protein to test bindingof p85-SH3andp85-SH3. As inA andB,wells coated
with plain MBP (p85-SH3/MBP and p85/MBP) were used as controls (C).
FIGURE 3.Co-precipitation of A/Brevig, A/Mallard, andA/UdornNS1pro-
teins with full-length Crk and CrkL proteins from transfected cells.Myc-
tagged expression vectors for the indicated NS1 proteins were transfected
into293FTcells togetherwithabiotin-acceptordomain-taggedvector forCrk
(C) or CrkL (L). Material precipitated with avidin-coated beads from lysates of
the co-transfected cells were analyzed byWestern blotting using an anti-Myc
antibodyor a labeledavidin reagent, as indicated. Aliquots of the lysateswere
collected before avidin pulldown and subjected directly into Western blot
analysis (two bottom panels).
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A/Mallard NS1 proteins, but they failed to co-precipitate any
A/Udorn NS1. Binding to A/WSN NS1 was equally negative
(data not shown). Thus, in good agreement with the recombi-
nant protein data involving isolated Crk/CrkL SH3 domains, in
transfected cells full-length Crk/CrkL proteins bound well to
NS1 proteins containing a class II SH3-binding consensus site
but not detectably to NS1 proteins lacking this motif.
CrkL-NS1 Complex in Influenza A Virus-infected Cells—Be-
cause of the similar NS1 binding profiles of Crk and CrkL, lack
of known differences in their cellular functions, and the avail-
ability of a good antibody against Crk, NS1 binding byCrkLwas
chosen as the subject of our subsequent studies. To examine
whether binding of endogenous cellular CrkL withNS1 protein
produced during influenza A virus infection could be demon-
strated, we infected A549 cells with A/Mallard and examined
the presence of NS1 in anti-CrkL immunoprecipitates from
lysates of these cells. As shown in Fig. 4A, a readily detectable
amount of NS1 co-precipitated from the A/Mallard-infected
cells using the -CrkL antibody, corresponding in intensity to
the NS1 signal derived from a fraction of the total lysate equal-
ing 10% of the fraction used for the -CrkL immunoprecipita-
tion. By contrast, no such signal was seen in anti-CrkL immu-
noprecipitates from uninfected cells or from control (-HA)
immunoprecipitates from the A/Mallard-infected cells, thus
confirming the specificity of the observed CrkL/NS1
co-precipitation.
A similar A549 infection experiment was carried out in
which A/Udorn was included for comparison. Because of the
sequence divergence of the A/Mallard and A/Udorn NS1 pro-
teins, quantitative comparison of the expression levels of these
proteins in their native form was not possible using any of the
immunological reagents that we tested (data not shown).
Therefore, we chose to infect A549 cells with matched titers of
A/Mallard and A/Udorn viruses, and subjected the infected
cells to metabolic labeling with [35S]methionine. Because
A/Mallard and A/Udorn NS1 proteins contain a comparable
number of methionine residues, their presence in anti-CrkL
immunoprecipitates could be accurately compared by autora-
diography (Fig. 4B).
In good agreement with the Western blotting data (Fig. 4A)
an NS1-sized protein was co-precipitated by the anti-CrkL
antibody from A/Mallard-infected cells but not from unin-
fected cells (Fig. 4B). A faint signal corresponding to a slightly
larger protein (as expected for A/Udorn NS1) could also be
detected from A/Udorn-infected cells in overexposures of the
autoradiogram shown in Fig. 4B and other similar experiments
(data not shown). Thus, despite its lack of direct CrkL binding
capacity (Figs. 2 and 3), in infected cells A/UdornNS1might yet
beweakly associatedwithCrkL. Equal infection of the cells with
the A/Mallard andA/Udorn viruses was confirmed byWestern
blotting using an antiserum against nucleoprotein, which
shows high amino acid sequence conservation between differ-
ent influenza A strains (Fig. 4B, right panel). Together these
data confirmed binding of endogenous CrkL to NS1 in virus-
infected cells, and underscore the important role of the SH3
binding capacity ofNS1 alleles likeA/Mallard in promoting this
interaction.
Characterization of the Crk/CrkL SH3-binding Site in NS1—
To confirm that the class II SH3-binding motif in A/Mallard
and A/Brevig NS1 protein was indeed critical for their capacity
to bind to theCrk family proteins, we generated a series of point
mutated variants of A/Brevig NS1 shown in Fig. 5A. Mutant 1
(M1) contained alanine residues in place of both of the PXXP-
defining proline residues of the class II consensus motif
(P212A/P215A).Mutant 2 (M2) contained a similar double ala-
nine substitution but affected the additional PXXP sequence
that is embedded within but is not part of the consensus SH3-
binding motif in A/Brevig NS1 (P213A/P216A). These proline
residues are conserved in NS1 proteins of most human and
avian influenza viruses, including A/Udorn, and were pointed
out by Shin et al. (6) as a potential docking site for p85-SH3.
Mutants 3 and 4 involved changes in the positively charged
residue of the consensus motif. In M3 this charge was reversed
by a lysine to glutamic acid substitution (K217E), whereas the
lysine to arginine substitution in M4 (K217R) maintained this
functionally important positive charge. In fact, arginine is the
positively charged residue in most class II SH3-binding sites,
FIGURE 4. Co-precipitation of NS1 with endogenous CrkL from influ-
enza A virus-infected cells. A, lysates from control A549 cells () and
cells infected with A/mallard/Netherlands/12/00/H7N3 virus (M) were
subjected to immunoprecipitation (IP) with anti-CrkL (-CrkL) or control
(-HA) monoclonal antibodies. These precipitates and aliquots of the cor-
responding lysates were analyzed by Western blotting using a polyclonal
anti-NS1 antiserum. B, lysates of [35S]methionine-labeled control A549
cells () or similarly labeled cells infectedwith A/mallard/Netherlands/12/
00/H7N3 (M) or A/Udorn/72 (U) viruses were subjected to immunoprecipi-
tation with an anti-CrkL antibody, followed by SDS-PAGE and autoradiog-
raphy (left panel). The labeled lysates were also subjected to Western
blotting with an anti-nucleoprotein (NP) antibody (right panel).
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A/Mallard NS1 proteins, but they failed to co-precipitate any
A/Udorn NS1. Binding to A/WSN NS1 was equally negative
(data not shown). Thus, in good agreement with the recombi-
nant protein data involving isolated Crk/CrkL SH3 domains, in
transfected cells full-length Crk/CrkL proteins bound well to
NS1 proteins containing a class II SH3-binding consensus site
but not detectably to NS1 proteins lacking this motif.
CrkL-NS1 Complex in Influenza A Virus-infected Cells—Be-
cause of the similar NS1 binding profiles of Crk and CrkL, lack
of known differences in their cellular functions, and the avail-
ability of a good antibody against Crk, NS1 binding byCrkLwas
chosen as the subject of our subsequent studies. To examine
whether binding of endogenous cellular CrkL withNS1 protein
produced during influenza A virus infection could be demon-
strated, we infected A549 cells with A/Mallard and examined
the presence of NS1 in anti-CrkL immunoprecipitates from
lysates of these cells. As shown in Fig. 4A, a readily detectable
amount of NS1 co-precipitated from the A/Mallard-infected
cells using the -CrkL antibody, corresponding in intensity to
the NS1 signal derived from a fraction of the total lysate equal-
ing 10% of the fraction used for the -CrkL immunoprecipita-
tion. By contrast, no such signal was seen in anti-CrkL immu-
noprecipitates from uninfected cells or from control (-HA)
immunoprecipitates from the A/Mallard-infected cells, thus
confirming the specificity of the observed CrkL/NS1
co-precipitation.
A similar A549 infection experiment was carried out in
which A/Udorn was included for comparison. Because of the
sequence divergence of the A/Mallard and A/Udorn NS1 pro-
teins, quantitative comparison of the expression levels of these
proteins in their native form was not possible using any of the
immunological reagents that we tested (data not shown).
Therefore, we chose to infect A549 cells with matched titers of
A/Mallard and A/Udorn viruses, and subjected the infected
cells to metabolic labeling with [35S]methionine. Because
A/Mallard and A/Udorn NS1 proteins contain a comparable
number of methionine residues, their presence in anti-CrkL
immunoprecipitates could be accurately compared by autora-
diography (Fig. 4B).
In good agreement with the Western blotting data (Fig. 4A)
an NS1-sized protein was co-precipitated by the anti-CrkL
antibody from A/Mallard-infected cells but not from unin-
fected cells (Fig. 4B). A faint signal corresponding to a slightly
larger protein (as expected for A/Udorn NS1) could also be
detected from A/Udorn-infected cells in overexposures of the
autoradiogram shown in Fig. 4B and other similar experiments
(data not shown). Thus, despite its lack of direct CrkL binding
capacity (Figs. 2 and 3), in infected cells A/UdornNS1might yet
beweakly associatedwithCrkL. Equal infection of the cells with
the A/Mallard andA/Udorn viruses was confirmed byWestern
blotting using an antiserum against nucleoprotein, which
shows high amino acid sequence conservation between differ-
ent influenza A strains (Fig. 4B, right panel). Together these
data confirmed binding of endogenous CrkL to NS1 in virus-
infected cells, and underscore the important role of the SH3
binding capacity ofNS1 alleles likeA/Mallard in promoting this
interaction.
Characterization of the Crk/CrkL SH3-binding Site in NS1—
To confirm that the class II SH3-binding motif in A/Mallard
and A/Brevig NS1 protein was indeed critical for their capacity
to bind to theCrk family proteins, we generated a series of point
mutated variants of A/Brevig NS1 shown in Fig. 5A. Mutant 1
(M1) contained alanine residues in place of both of the PXXP-
defining proline residues of the class II consensus motif
(P212A/P215A).Mutant 2 (M2) contained a similar double ala-
nine substitution but affected the additional PXXP sequence
that is embedded within but is not part of the consensus SH3-
binding motif in A/Brevig NS1 (P213A/P216A). These proline
residues are conserved in NS1 proteins of most human and
avian influenza viruses, including A/Udorn, and were pointed
out by Shin et al. (6) as a potential docking site for p85-SH3.
Mutants 3 and 4 involved changes in the positively charged
residue of the consensus motif. In M3 this charge was reversed
by a lysine to glutamic acid substitution (K217E), whereas the
lysine to arginine substitution in M4 (K217R) maintained this
functionally important positive charge. In fact, arginine is the
positively charged residue in most class II SH3-binding sites,
FIGURE 4. Co-precipitation of NS1 with endogenous CrkL from influ-
enza A virus-infected cells. A, lysates from control A549 cells () and
cells infected with A/mallard/Netherlands/12/00/H7N3 virus (M) were
subjected to immunoprecipitation (IP) with anti-CrkL (-CrkL) or control
(-HA) monoclonal antibodies. These precipitates and aliquots of the cor-
responding lysates were analyzed by Western blotting using a polyclonal
anti-NS1 antiserum. B, lysates of [35S]methionine-labeled control A549
cells () or similarly labeled cells infectedwith A/mallard/Netherlands/12/
00/H7N3 (M) or A/Udorn/72 (U) viruses were subjected to immunoprecipi-
tation with an anti-CrkL antibody, followed by SDS-PAGE and autoradiog-
raphy (left panel). The labeled lysates were also subjected to Western
blotting with an anti-nucleoprotein (NP) antibody (right panel).
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but Crk and CrkL SH3 domains have a characteristic property
of preferring a lysine residue in this position (37). Mutant 5
(M5) contained a proline to threonine substitution (P215T)
affecting the first proline residue of the consensus motif, thus
mimicking the NS1 protein sequence in this region of A/Udorn
(and practically all human influenza A virus NS1 proteins; see
Fig. 1).
The capacity of Myc epitope-tagged NS1 proteins carrying
these mutations to bind to endogenous CrkL protein in trans-
fected 293FT cells was studied by a co-immunoprecipitation
assay. As shown in Fig. 5B, NS1 was equally expressed in all
transfected cells, butM1 andM3 that carried class II consensus
motif-disrupting mutations could not be co-precipitated with
CrkL. The single P215T change (M5) resembling NS1 proteins
like that of A/Udorn also abolished binding to CrkL. Instead,
association of M2 with CrkL was indistinguishable of unmodi-
fied A/Brevig NS1 (WT). In agreement with the published
binding preferences of Crk/CrkL SH3 (37), binding of M4 to
CrkL was diminished 50% compared with WT (Fig. 4B and
data not shown). These data formally establish the critical role
of the class II SH3-binding motif found in A/Brevig and many
avian strains of influenza A in Crk/CrkL association, and con-
firm the preference of Crk/CrkL SH3 domains for lysine-con-
taining class II-binding sites.
Role of SH3 Binding in Cellular Functions of NS1—To study
the functional role and relevance of Crk/CrkL binding by NS1,
we tested the activities of A/Brevig andA/MallardNS1 proteins
and their SH3 binding-deficient derivatives in two different cel-
lular functions that have been reported for NS1, namely inhibi-
tion of interferon-induced gene expression and activation of
the PI3K signaling pathway. The former apparently involves
multiple effector functions of NS1, notably the ability of NS1 to
interfere with post-transcriptional mRNA processing (38–40).
As already discussed, the latter involves association ofNS1with
the p85 subunit of PI3K and can be followed by examining the
phosphorylation status of the protein kinase Akt/PKB (6, 8, 41).
WhenHuh-7 cells were transfected with an ISRE-containing
reporter plasmid together with an empty control expression
vector (p), a robust increase in luciferase activity was observed
upon stimulation of these cells with interferon (IFN-) (com-
pare the two leftmost bars in Fig. 6A).When a vector expressing
NS1 of A/Brevig (B), A/Mallard (M), or A/Udorn (U) was
included, the IFN--induced increase in reporter gene expres-
sion was strongly suppressed. Similar inhibition was also seen
when SH3 binding-deficient mutants (corresponding toM1 in
Fig. 5A) of A/Brevig (Bm) orA/Mallard (Mm)were tested, which
together with the activity of A/Udorn in this assay indicated
that binding to Crk/CrkL was not required for the capacity of
influenza A NS1 proteins to suppress interferon-induced gene
expression.
By contrast, SH3 binding by NS1 was found to correlate with
a significant increase in Akt phosphorylation in Huh-7 cells
transfected with these vectors. As noted by others (6), cationic
lipid-mediated transfection of an empty expression vector plas-
mid was sufficient to induce a minor activation of PI3K signal-
ing. However, in agreement with earlier reports (6, 8), the use of
vectors encoding NS1 of A/Udorn (U) or A/WSN (W) resulted
FIGURE 5.Mutational analysis of NS1 residues involved in binding to cel-
lular CrkL.A, class II SH3-bindingmotif-containing regionofwild-typeA/Bre-
vigNS1protein (WT) and its derivatives (M1–M5) carrying the indicatedmuta-
tions are shown.B,Myc-taggedexpressionvectors forWTormutatedvariants
of A/BrevigNS1protein (M1–M5) or an empty control vectorwere transfected
into 293FT cells. Lysates of these cells were subjected to anti-CrkL immuno-
precipitation (IP), and these precipitates along with aliquots of the original
lysates were analyzed by Western blotting with an anti-Myc antibody.
FIGURE 6. Functional analysis of the role of Crk/CrkL SH3domainbinding
capacity in regulation of cellular signaling pathways by NS1. A, Huh-7
cells were transfected with an ISRE-dependent firefly luciferase reporter vec-
tor together with an expression vector for A/Brevig (B), A/Mallard (M), or
A/Udorn (U) NS1 or SH3 binding-deficient mutants (M1 in Fig. 5) of A/Brevig
(Bm) or A/Mallard (Mm) NS1proteins, or an empty control plasmid vector (p). In
addition, a vector stably expressing Renilla luciferasewas included in all cases
to monitor transfection efficiency and cell viability. After 22 h, one culture of
cells transfected with the control vector was left untreated, and the other
plates were stimulated for 7 h with 100 IU/ml of IFN-, followed by determi-
nation of firefly and Renilla luciferase activities of lysates prepared from these
cells. ISRE-dependent gene expression is shown as mean values of the ratios
of firefly and Renilla luciferase activities. B, Huh-7 cells were transfected with
the NS1 or control expression vectors used in A plus a vector for A/WSN/33
NS1 (W). 48 h later the cells were collected and analyzed for their PI3K path-
way activity by Western blot analysis of their lysates using an antibody spe-
cific for the phosphorylated form of Akt. Uniform expression of the NS1 pro-
teins was confirmed by probing the blots with an anti-Myc tag antibody.
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but Crk and CrkL SH3 domains have a characteristic property
of preferring a lysine residue in this position (37). Mutant 5
(M5) contained a proline to threonine substitution (P215T)
affecting the first proline residue of the consensus motif, thus
mimicking the NS1 protein sequence in this region of A/Udorn
(and practically all human influenza A virus NS1 proteins; see
Fig. 1).
The capacity of Myc epitope-tagged NS1 proteins carrying
these mutations to bind to endogenous CrkL protein in trans-
fected 293FT cells was studied by a co-immunoprecipitation
assay. As shown in Fig. 5B, NS1 was equally expressed in all
transfected cells, butM1 andM3 that carried class II consensus
motif-disrupting mutations could not be co-precipitated with
CrkL. The single P215T change (M5) resembling NS1 proteins
like that of A/Udorn also abolished binding to CrkL. Instead,
association of M2 with CrkL was indistinguishable of unmodi-
fied A/Brevig NS1 (WT). In agreement with the published
binding preferences of Crk/CrkL SH3 (37), binding of M4 to
CrkL was diminished 50% compared with WT (Fig. 4B and
data not shown). These data formally establish the critical role
of the class II SH3-binding motif found in A/Brevig and many
avian strains of influenza A in Crk/CrkL association, and con-
firm the preference of Crk/CrkL SH3 domains for lysine-con-
taining class II-binding sites.
Role of SH3 Binding in Cellular Functions of NS1—To study
the functional role and relevance of Crk/CrkL binding by NS1,
we tested the activities of A/Brevig andA/MallardNS1 proteins
and their SH3 binding-deficient derivatives in two different cel-
lular functions that have been reported for NS1, namely inhibi-
tion of interferon-induced gene expression and activation of
the PI3K signaling pathway. The former apparently involves
multiple effector functions of NS1, notably the ability of NS1 to
interfere with post-transcriptional mRNA processing (38–40).
As already discussed, the latter involves association ofNS1with
the p85 subunit of PI3K and can be followed by examining the
phosphorylation status of the protein kinase Akt/PKB (6, 8, 41).
WhenHuh-7 cells were transfected with an ISRE-containing
reporter plasmid together with an empty control expression
vector (p), a robust increase in luciferase activity was observed
upon stimulation of these cells with interferon (IFN-) (com-
pare the two leftmost bars in Fig. 6A).When a vector expressing
NS1 of A/Brevig (B), A/Mallard (M), or A/Udorn (U) was
included, the IFN--induced increase in reporter gene expres-
sion was strongly suppressed. Similar inhibition was also seen
when SH3 binding-deficient mutants (corresponding toM1 in
Fig. 5A) of A/Brevig (Bm) orA/Mallard (Mm)were tested, which
together with the activity of A/Udorn in this assay indicated
that binding to Crk/CrkL was not required for the capacity of
influenza A NS1 proteins to suppress interferon-induced gene
expression.
By contrast, SH3 binding by NS1 was found to correlate with
a significant increase in Akt phosphorylation in Huh-7 cells
transfected with these vectors. As noted by others (6), cationic
lipid-mediated transfection of an empty expression vector plas-
mid was sufficient to induce a minor activation of PI3K signal-
ing. However, in agreement with earlier reports (6, 8), the use of
vectors encoding NS1 of A/Udorn (U) or A/WSN (W) resulted
FIGURE 5.Mutational analysis of NS1 residues involved in binding to cel-
lular CrkL.A, class II SH3-bindingmotif-containing regionofwild-typeA/Bre-
vigNS1protein (WT) and its derivatives (M1–M5) carrying the indicatedmuta-
tions are shown.B,Myc-taggedexpressionvectors forWTormutatedvariants
of A/BrevigNS1protein (M1–M5) or an empty control vectorwere transfected
into 293FT cells. Lysates of these cells were subjected to anti-CrkL immuno-
precipitation (IP), and these precipitates along with aliquots of the original
lysates were analyzed by Western blotting with an anti-Myc antibody.
FIGURE 6. Functional analysis of the role of Crk/CrkL SH3domainbinding
capacity in regulation of cellular signaling pathways by NS1. A, Huh-7
cells were transfected with an ISRE-dependent firefly luciferase reporter vec-
tor together with an expression vector for A/Brevig (B), A/Mallard (M), or
A/Udorn (U) NS1 or SH3 binding-deficient mutants (M1 in Fig. 5) of A/Brevig
(Bm) or A/Mallard (Mm) NS1proteins, or an empty control plasmid vector (p). In
addition, a vector stably expressing Renilla luciferasewas included in all cases
to monitor transfection efficiency and cell viability. After 22 h, one culture of
cells transfected with the control vector was left untreated, and the other
plates were stimulated for 7 h with 100 IU/ml of IFN-, followed by determi-
nation of firefly and Renilla luciferase activities of lysates prepared from these
cells. ISRE-dependent gene expression is shown as mean values of the ratios
of firefly and Renilla luciferase activities. B, Huh-7 cells were transfected with
the NS1 or control expression vectors used in A plus a vector for A/WSN/33
NS1 (W). 48 h later the cells were collected and analyzed for their PI3K path-
way activity by Western blot analysis of their lysates using an antibody spe-
cific for the phosphorylated form of Akt. Uniform expression of the NS1 pro-
teins was confirmed by probing the blots with an anti-Myc tag antibody.
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in further accumulation of pAkt as an indication of PI3K acti-
vation (see Fig. 6B). By comparison, the levels of pAkt were
significantly higher in cells transfected with A/Brevig (B) or
A/Mallard (M) NS1 constructs (Fig. 6B and data not shown).
This increased capacity of A/Brevig and Mallard NS1 to acti-
vate PI3K signaling was lost when the class II consensus SH3-
binding motif of these proteins was disrupted by the M1muta-
tion (lanes Bm andMm in Fig. 6B).
DISCUSSION
Influenza A viruses are highly virulent and can infect a broad
range of mammalian and avian species. Several influenza A
virus gene products such as HA, viral polymerases, nucleopro-
tein, and NS1 play a role in the virulence of the virus (42, 43).
Although the HA protein largely determines the pathogenicity
and species specificity of the virus, NS1 protein has a uniform
role in regulating host cell responses during the infection inde-
pendent of the virus type or the animal species the virus is
infecting. NS1 protein is a double strand RNA-binding protein,
and it can interfere with the functions of other double strand
RNA-binding proteins such as the RIG-I, protein kinase R, and
oligoadenylate synthetases (44–46) that regulate the induction
and antiviral effects of interferons, respectively. NS1 protein is
also targeted into the host cells nucleus (28), where it can inter-
fere with the processing of host cell pre-mRNAs, including
those of antiviral mRNAs rendering them susceptible for deg-
radation (47). Influenza A virus also takes advantage of the host
cell signaling pathways activated during the infection in such a
way that signal transduction involving, for example, NF-B,
mitogen-activated kinase cascades, and the PI3K pathway is
altered to optimize virus replication.
In this study we have shown that the NS1 protein of the 1918
pandemic influenza A virus (A/Brevig) contains a functional
SH3 interaction motif that mediates avid binding to the N-ter-
minal SH3 domain of the adapter proteins Crk and CrkL. This
sequencemotif is common inNS1 proteins of avian influenzaA
viruses, but besides A/Brevig can be found only in three of the
4505 human-derived NS1 protein sequences available in the
NCBI influenza A data base. Interestingly, two of these cases
represent zoonotic infections of humans with avian H5N1 and
H7N3 viruses.
Amino acid variation in the NS1 gene has been shown to
correlate with the pathogenicity of H5N1 strains of avian
influenza virus in chickens (48), and the NS1 gene of A/Bre-
vig has been found to be more potent than the reference NS1
proteins in regulating host cell gene expression (49). Thus,
although human influenza A infection clearly differs from
that of avian hosts in that the capacity of NS1 for Crk/CrkL
SH3 binding appears to be generally counter-selected in the
formed case, adaptation of the virus to exploit this connec-
tion to the cellular signaling machinery also in human cells
might provide the virus with increased replicative or patho-
genic potential. It was recently shown that the 1918 virus
shows a higher replication capacity in tissue culture and in
animal models (50, 51).
Several different viral species have been found to stimulate
PI3K signaling to increase their replication and/or to prevent
apoptotic death of the host cell (for a review, see Ref. 52).
Indeed,NS1-mediated activation of PI3K signalingwas recently
shown to enhance influenza A virus replication (9, 10) and limit
apoptosis in infected cell cultures (8). Our observation that a
functional Crk/CrkL-binding motif provided the NS1 proteins
of A/Brevig and A/Mallard with an increased ability to induce
PI3K signaling could therefore readily explain a potentially
higher replicative capacity of viruses expressing Crk/CrkL
binding-competent NS1 proteins.
Crk/CrkL proteins were first identified as cellular counter-
parts of the protein encoded by the v-crk oncogene of the avian
sarcoma virus CT10 (53), and have since been found to be ubiq-
uitously involved in numerous signaling pathways regulating
diverse functions in different cell types (54). Of note, several
studies have reported physical and functional interactions
between Crk/CrkL proteins and the PI3K signaling pathway
(55–57), thus providing a plausible framework for the mecha-
nistic basis of the observed enhancement of NS1-mediated
PI3K activation via the NS1-Crk/CrkL interaction. However,
additional roles for the NS1-Crk/CrkL complex in cell biology
of influenza A virus should obviously not be ruled out.
Previous studies concerning the activation of the PI3K path-
way by NS1 have shown that this regulation involves an associ-
ation of NS1 with the p85 regulatory subunit of PI3K (6, 8, 9),
and subsequent studies even further suggested that there is a
direct binding of NS1 to the SH3 domain of p85 (6). However,
our studies failed to reveal measurable binding of the SH3
domains of p85 or p85 to NS1 proteins like A/Udorn and
A/WSN, which contain the PXXP sequences pointed out by
Shin et al. (6) or to A/Brevig or A/Mallard NS1 proteins, which
contain the additional class II consensus SH3-binding motif
described in this study. Our results do not exclude the possibil-
ity that weak binding of p85 SH3 to one of these nonconsensus
PXXP motifs in NS1 might play a subtle role in stabilizing or
coordinating NS1/p85 binding, but argue against a major role
of such contacts in driving NS1-p85 complex formation.
It should be noted, however, that the ability of recombi-
nant p85 SH3 to precipitate NS1 protein from lysates of
influenza A-infected cells as reported by Shin et al. (6) does
not prove this interaction to be direct rather than mediated
by one or more additional factors. In fact, it has been
reported that although association of NS1 with p85 can be
readily detected in influenza A virus-infected cells, this is
less true in the case of NS1 gene-transfected cells, leading
Ehrhardt et al. (8) to propose that a cellular bridging factor is
required for NS1-p85 complex formation. In this regard, it is
interesting to note that although we found A/Udorn NS1 to
be completely negative in the CrkL co-precipitation assay in
transfected cells (Fig. 3), we did observe a weak association of
NS1 and CrkL in cells infected with A/Udorn (data not
shown). Thus, in influenza A virus-infected cells expressing
high levels of NS1 (as well as other viral proteins that could
also be involved) a large protein complex involving NS1,
PI3K, and Crk/CrkL might form independently of direct
binding of NS1 to Crk/CrkL or the p85 subunit of PI3K.
However, NS1 proteins like those of A/Brevig and A/Mallard
that can directly recruit Crk/CrkL via SH3 binding would
serve to promote and strengthen the assembly of this multi-
protein “signalosome” complex.
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in further accumulation of pAkt as an indication of PI3K acti-
vation (see Fig. 6B). By comparison, the levels of pAkt were
significantly higher in cells transfected with A/Brevig (B) or
A/Mallard (M) NS1 constructs (Fig. 6B and data not shown).
This increased capacity of A/Brevig and Mallard NS1 to acti-
vate PI3K signaling was lost when the class II consensus SH3-
binding motif of these proteins was disrupted by the M1muta-
tion (lanes Bm andMm in Fig. 6B).
DISCUSSION
Influenza A viruses are highly virulent and can infect a broad
range of mammalian and avian species. Several influenza A
virus gene products such as HA, viral polymerases, nucleopro-
tein, and NS1 play a role in the virulence of the virus (42, 43).
Although the HA protein largely determines the pathogenicity
and species specificity of the virus, NS1 protein has a uniform
role in regulating host cell responses during the infection inde-
pendent of the virus type or the animal species the virus is
infecting. NS1 protein is a double strand RNA-binding protein,
and it can interfere with the functions of other double strand
RNA-binding proteins such as the RIG-I, protein kinase R, and
oligoadenylate synthetases (44–46) that regulate the induction
and antiviral effects of interferons, respectively. NS1 protein is
also targeted into the host cells nucleus (28), where it can inter-
fere with the processing of host cell pre-mRNAs, including
those of antiviral mRNAs rendering them susceptible for deg-
radation (47). Influenza A virus also takes advantage of the host
cell signaling pathways activated during the infection in such a
way that signal transduction involving, for example, NF-B,
mitogen-activated kinase cascades, and the PI3K pathway is
altered to optimize virus replication.
In this study we have shown that the NS1 protein of the 1918
pandemic influenza A virus (A/Brevig) contains a functional
SH3 interaction motif that mediates avid binding to the N-ter-
minal SH3 domain of the adapter proteins Crk and CrkL. This
sequencemotif is common inNS1 proteins of avian influenzaA
viruses, but besides A/Brevig can be found only in three of the
4505 human-derived NS1 protein sequences available in the
NCBI influenza A data base. Interestingly, two of these cases
represent zoonotic infections of humans with avian H5N1 and
H7N3 viruses.
Amino acid variation in the NS1 gene has been shown to
correlate with the pathogenicity of H5N1 strains of avian
influenza virus in chickens (48), and the NS1 gene of A/Bre-
vig has been found to be more potent than the reference NS1
proteins in regulating host cell gene expression (49). Thus,
although human influenza A infection clearly differs from
that of avian hosts in that the capacity of NS1 for Crk/CrkL
SH3 binding appears to be generally counter-selected in the
formed case, adaptation of the virus to exploit this connec-
tion to the cellular signaling machinery also in human cells
might provide the virus with increased replicative or patho-
genic potential. It was recently shown that the 1918 virus
shows a higher replication capacity in tissue culture and in
animal models (50, 51).
Several different viral species have been found to stimulate
PI3K signaling to increase their replication and/or to prevent
apoptotic death of the host cell (for a review, see Ref. 52).
Indeed,NS1-mediated activation of PI3K signalingwas recently
shown to enhance influenza A virus replication (9, 10) and limit
apoptosis in infected cell cultures (8). Our observation that a
functional Crk/CrkL-binding motif provided the NS1 proteins
of A/Brevig and A/Mallard with an increased ability to induce
PI3K signaling could therefore readily explain a potentially
higher replicative capacity of viruses expressing Crk/CrkL
binding-competent NS1 proteins.
Crk/CrkL proteins were first identified as cellular counter-
parts of the protein encoded by the v-crk oncogene of the avian
sarcoma virus CT10 (53), and have since been found to be ubiq-
uitously involved in numerous signaling pathways regulating
diverse functions in different cell types (54). Of note, several
studies have reported physical and functional interactions
between Crk/CrkL proteins and the PI3K signaling pathway
(55–57), thus providing a plausible framework for the mecha-
nistic basis of the observed enhancement of NS1-mediated
PI3K activation via the NS1-Crk/CrkL interaction. However,
additional roles for the NS1-Crk/CrkL complex in cell biology
of influenza A virus should obviously not be ruled out.
Previous studies concerning the activation of the PI3K path-
way by NS1 have shown that this regulation involves an associ-
ation of NS1 with the p85 regulatory subunit of PI3K (6, 8, 9),
and subsequent studies even further suggested that there is a
direct binding of NS1 to the SH3 domain of p85 (6). However,
our studies failed to reveal measurable binding of the SH3
domains of p85 or p85 to NS1 proteins like A/Udorn and
A/WSN, which contain the PXXP sequences pointed out by
Shin et al. (6) or to A/Brevig or A/Mallard NS1 proteins, which
contain the additional class II consensus SH3-binding motif
described in this study. Our results do not exclude the possibil-
ity that weak binding of p85 SH3 to one of these nonconsensus
PXXP motifs in NS1 might play a subtle role in stabilizing or
coordinating NS1/p85 binding, but argue against a major role
of such contacts in driving NS1-p85 complex formation.
It should be noted, however, that the ability of recombi-
nant p85 SH3 to precipitate NS1 protein from lysates of
influenza A-infected cells as reported by Shin et al. (6) does
not prove this interaction to be direct rather than mediated
by one or more additional factors. In fact, it has been
reported that although association of NS1 with p85 can be
readily detected in influenza A virus-infected cells, this is
less true in the case of NS1 gene-transfected cells, leading
Ehrhardt et al. (8) to propose that a cellular bridging factor is
required for NS1-p85 complex formation. In this regard, it is
interesting to note that although we found A/Udorn NS1 to
be completely negative in the CrkL co-precipitation assay in
transfected cells (Fig. 3), we did observe a weak association of
NS1 and CrkL in cells infected with A/Udorn (data not
shown). Thus, in influenza A virus-infected cells expressing
high levels of NS1 (as well as other viral proteins that could
also be involved) a large protein complex involving NS1,
PI3K, and Crk/CrkL might form independently of direct
binding of NS1 to Crk/CrkL or the p85 subunit of PI3K.
However, NS1 proteins like those of A/Brevig and A/Mallard
that can directly recruit Crk/CrkL via SH3 binding would
serve to promote and strengthen the assembly of this multi-
protein “signalosome” complex.
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Further characterization of this NS1/PI3K/Crk-containing
signalosome is clearly warranted and will shed new light into
the cell biology of influenza A replication. Small molecular
inhibitors of PI3K are already under evaluation as drugs in
cancer (58, 59), and have been shown to reduce influenza A
replication in vitro (7, 9). Thus, cellular signaling involving
NS1/PI3K/Crk could also provide a useful target for the
development of novel anti-influenza drugs. In this regard,
possible involvement of the enhanced PI3K activation medi-
ated via Crk/CrkL binding by NS1 proteins of avian strains of
influenza in regulating interspecies transmission or patho-
genicity in human hosts deserves special attention.
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Further characterization of this NS1/PI3K/Crk-containing
signalosome is clearly warranted and will shed new light into
the cell biology of influenza A replication. Small molecular
inhibitors of PI3K are already under evaluation as drugs in
cancer (58, 59), and have been shown to reduce influenza A
replication in vitro (7, 9). Thus, cellular signaling involving
NS1/PI3K/Crk could also provide a useful target for the
development of novel anti-influenza drugs. In this regard,
possible involvement of the enhanced PI3K activation medi-
ated via Crk/CrkL binding by NS1 proteins of avian strains of
influenza in regulating interspecies transmission or patho-
genicity in human hosts deserves special attention.
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The non-structural protein-1 (NS1) of inﬂuenza A virus binds the p85β subunit of phosphoinositide 3-
kinase (PI3K) to induce PI3K activity in the infected cells. Some virus strains encode NS1 containing a
motif that binds tightly to the SH3 domain of the cellular adapter proteins Crk and CrkL to potentiate
NS1-induced PI3K activation. Here we show that this potentiation involves reorganization of the natural
CrkL–p85β complex into a novel trimeric complex where NS1 serves as a bridging factor. Of note, NS1
proteins that lack the SH3 binding capacity can also associate with CrkL, but in a less stable trimeric
complex mediated by p85β. The data presented here establish Crk proteins as general host cell cofactors
of NS1, and show that the enhanced PI3K activation by SH3 binding-competent NS1 variants is mediated
by a more efﬁcient tethering of Crk proteins to the NS1–PI3K complex.
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Introduction
Inﬂuenza A virus belongs to the Orthomyxoviridae family of
enveloped viruses (Palese and Shaw, 2007). Its genome is orga-
nized into eight single stranded negative-sense RNA segments and
encodes up to 12 different proteins (Medina and Garcia-Sastre,
2011). The non-structural protein-1 (NS1) is a multifunctional
virulence factor that is expressed at high levels in infected cells.
The multiple protein binding motifs and conformational plasticity
of NS1 enables it to interact with a plethora of host cell factors
(Hale, 2014).
NS1 is the key innate immunity evasion factor of inﬂuenza
viruses, and can hinder the interferon response via multiple
mechanisms (Krug and Garcia-Sastre, 2013). In addition, NS1
contributes to activation of the phosphoinositide 3-kinase (PI3K)
signaling in inﬂuenza A virus-infected cells. NS1 binds speciﬁcally
to the regulatory PI3K subunit p85β (Hale et al., 2006; Shin et al.,
2007) via an interaction that involves the NS1 residues Tyr89 and
Pro164 contacting the linker region between the two Src-
homology-2 (SH2) domains of p85β (Hale et al., 2010). Together
biochemical and structural studies on this interaction have led to a
model in which NS1 activates PI3K catalytic activity both by
neutralizing a negative regulatory element in the inter-SH2 region
of p85β as well as via direct contacts with the catalytic PI3K
subunit p110 (Hale et al., 2008, 2010).
Activation of PI3K signaling is not speciﬁc for IAV infection, and
instead is a common theme observed in host cell interactions of a
variety of RNA and DNA viruses. Increased PI3K activity can beneﬁt
viral replication via several mechanisms, including promotion of
viral entry, enhanced viral replication and gene expression, and
blocking of premature apoptosis of the host cell (Buchkovich et al.,
2008; Cooray, 2004; Dunn and Connor, 2012; Ehrhardt and
Ludwig, 2009), but has also been shown to be involved in
induction of antiviral innate immunity (Hrincius et al., 2011).
Nevertheless, the net effect of PI3K activity on IAV replication is
typically positive, as demonstrated by reports on profound sup-
pression of viral replication observed upon treatment of infected
cultures with PI3K inhibitors (Ehrhardt et al., 2006; Hale et al.,
2006).
While NS1 proteins from most if not all inﬂuenza A viruses are
capable of inducing at least some level of PI3K activation, our
studies have revealed that the 1918 pandemic inﬂuenza virus and
many avian IAVs are exceptionally potent PI3K activators
(Heikkinen et al., 2008). This distinct capacity was found to be
due to the presence of a functional SH3 domain-binding site close
to the C-termini of these NS1 proteins, which is lacking from NS1
proteins of inﬂuenza A strains causing seasonal epidemics in
humans.
Although the p85β protein also contains an SH3 domain, we
could not observe any binding of NS1 to this SH3 domain
(Heikkinen et al., 2008). Instead, we found that the NS1 SH3-
binding motif mediated strong and selective binding to the
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aminoterminal SH3 domains of the two related adapter proteins,
Crk and CrkL (Heikkinen et al., 2008). In the following we use the
term Crk(L) for all Crk-family proteins, and CrkI, CrkII, or CrkL only
when speciﬁcally referring to one of them. SH3-dependent bind-
ing of NS1 to Crk(L) has subsequently been conﬁrmed by Ehrhardt
and colleagues, who also reported on the role of this interaction in
suppression of the JNK–ATF2 pathway (Hrincius et al., 2010).
Moreover, a functional Crk(L) binding motif has also been linked
to NS1-induced increased in cell viability in a complex also
involving NS1-binding protein-1 (Miyazaki et al., 2013), as well
as in dissociation of cellular Crk–Abl protein complexes and in
supression of the tyrosine kinase activity of Abl (Hrincius et al.,
2014).
Crk proteins are involved in PI3K signaling by binding to a
proline-rich motif in p85 via their N-terminal Crk(L) SH3 domain
(Brehme et al., 2009; Gelkop et al., 2001; Sattler et al., 1996). This
interaction has been studied especially regarding its role in PI3K
regulation upon immune cell activation. Studies in T cells have
shown that the interaction between Crk and p85 is coordinated and
facilitated by the ubiquitin ligase Cbl, which can engage in addi-
tional interactions both with Crk and p85 (Gelkop et al., 2001). The
Crk–p85–Cbl protein complex has also been characterized as an
important co-factor in oncogenic signaling by the Bcr–Abl fusion
protein in chronic myeloid leukemia (Sattler et al., 1996). Indeed, an
extensive proteomic characterization of the molecular network
involved in Bcr–Abl function by Superti-Furga and colleagues
identiﬁed Crk, p85, and Cbl among the seven most highly inter-
connected core components of this signaling network (Brehme et
al., 2009).
In order to elucidate the biochemical mechanism underlying
the PI3K superactivation by the SH3 binding-competent NS1
proteins we now have characterized in detail the mutual interac-
tion between NS1, p85β, and CrkL. Because both NS1 and p85β
interact with the Crk proteins via the same N-terminal Crk(L) SH3
domain it was of speciﬁc interest to investigate whether a trimeric
complex involving p85β, Crk(L) and NS1 can form.
Results
Association of different Crk proteins with NS1 and p85β
The family of Crk adapter proteins includes three members,
CrkI, CrkII, and CrkL. Of these CrkII (40 kDa) and CrkI (28 kDa) are
products of the same gene, whereas CrkL (39 kDa) is encoded by a
different gene. CrkII and CrkL consist of one SH2 and two SH3
domains, while CrkI is truncated before the second SH3 domain
due to alternative mRNA splicing (Fig. 1a).
To extend our previous ﬁndings on NS1/Crk(L) binding
(Heikkinen et al., 2008), we compared the capacity of these three
different Crk proteins to interact with a representative avian NS1
protein containing a functional SH3 binding site (NS1 from A/
Mallard/Netherlands/12/2000/H7N3; “Mallard” in the following).
To examine the role of NS1 SH3 binding, we also included in these
experiments a mutated version of Mallard NS1 protein (NS1-
AxxA), carrying an SH3 binding site disrupted by alanine substitu-
tion of two critical proline residues (P212 and P215). As shown in
Fig. 1b, NS1 associated readily with CrkI, CrkII, as well as CrkL,
correlating with the presence of an N-terminal SH3 domain in all
of these Crk proteins (Fig. 1a). In contrast, none of the Crk proteins
co-precipitated the SH3 binding-deﬁcient NS1-AxxA. The blotting
data shown in Fig. 1b are representative of several experiments,
and all results shown have been reproduced at least three times.
The same holds true for the blotting data shown in Figs. 2, 4, 5 and
6.
Relative roles of p85β and Crk-SH3 binding in PI3K activation by NS1
Hale and colleagues reported the critical contribution of the
tyrosine 89 of NS1 in direct binding to the regulatory PI3K subunit
p85β (Hale et al., 2006). On the other hand, we have shown that
NS1 containing a functional Crk-SH3 binding site show greatly
enhanced PI3K activation compared to SH3 binding-deﬁcient NS1
(Heikkinen et al., 2008). To investigate if the increased PI3K
activation provided by NS1 SH3 binding was directly coupled to
the NS1–p85β interaction or represented an independent regula-
tory event, we compared the effects of the AxxA (P212A/P215A;
disrupting Crk SH3 binding) and Y89F (disrupting p85β binding)
mutations.
In agreement with our earlier study (Heikkinen et al., 2008) we
found that the PI3K-activating capacity of Mallard NS1 (induction
of Akt phosphorylation) was reduced but not abrogated by the
AxxA mutation (Fig. 2a). By contrast, the Y89F mutant NS1 was
completely inactive in inducing Akt phosphorylation. Thus, we
conclude that Crk(L) recruitment by NS1 indeed serves to enhance
PI3K activation triggered by binding of NS1 to p85β, but this
enhancement remains entirely dependent on the latter
interaction.
Rearrangement of the endogenous p85β/CrkL complex by NS1
Because p85 binds not only to NS1 (Hale et al., 2006; Shin et al.,
2007) but is also an established interaction partner of the Crk
proteins (Brehme et al., 2009; Sattler et al., 1996, 1997) we
examined the association of p85β with CrkL in untransfected cells
and in cells transfected with the mutant NS1 proteins. Indeed,
p85β could be readily co-precipitated with CrkL from untrans-
fected cells that did not express any NS1 (Fig. 2b, leftmost lane).
Transfection of the CrkL binding-competent (WT) or incompetent
(AxxA) NS1 proteins did not signiﬁcantly inﬂuence the net
association of p85β with CrkL. However, transfection of the Y89F
mutant of NS1 (which is CrkL binding-competent but p85β
binding-deﬁcient) potently inhibited p85β/CrkL association. Since
Fig. 1. All Crk proteins have a comparable and SH3 domain-dependent capacity to
bind NS1. (a) Domain organization of CrkI, CrkII, and CrkL. (b) Co-precipitation of
wild-type (WT) and SH3 binding deﬁcient mutant (AxxA) Mallard NS1 proteins
with CrkI, CrkII, and CrkL from 293T cells. Crk proteins fused with a biotinylation
domain were cotransfected into cells with myc-tagged NS1 proteins. The amounts
of NS1 in the transfected lysates (bottom panel) or co-precipitated with Crk
proteins by streptavidin-coated beads (middle panel) were examined by anti-Myc
Western blotting. Equal precipitation of the biotinylated Crk proteins was con-
ﬁrmed by blotting with labeled streptavidin (top panel).
L. Ylösmäki et al. / Virology 484 (2015) 146–152 147
aminoterminal SH3 domains of the two related adapter proteins,
Crk and CrkL (Heikkinen et al., 2008). In the following we use the
term Crk(L) for all Crk-family proteins, and CrkI, CrkII, or CrkL only
when speciﬁcally referring to one of them. SH3-dependent bind-
ing of NS1 to Crk(L) has subsequently been conﬁrmed by Ehrhardt
and colleagues, who also reported on the role of this interaction in
suppression of the JNK–ATF2 pathway (Hrincius et al., 2010).
Moreover, a functional Crk(L) binding motif has also been linked
to NS1-induced increased in cell viability in a complex also
involving NS1-binding protein-1 (Miyazaki et al., 2013), as well
as in dissociation of cellular Crk–Abl protein complexes and in
supression of the tyrosine kinase activity of Abl (Hrincius et al.,
2014).
Crk proteins are involved in PI3K signaling by binding to a
proline-rich motif in p85 via their N-terminal Crk(L) SH3 domain
(Brehme et al., 2009; Gelkop et al., 2001; Sattler et al., 1996). This
interaction has been studied especially regarding its role in PI3K
regulation upon immune cell activation. Studies in T cells have
shown that the interaction between Crk and p85 is coordinated and
facilitated by the ubiquitin ligase Cbl, which can engage in addi-
tional interactions both with Crk and p85 (Gelkop et al., 2001). The
Crk–p85–Cbl protein complex has also been characterized as an
important co-factor in oncogenic signaling by the Bcr–Abl fusion
protein in chronic myeloid leukemia (Sattler et al., 1996). Indeed, an
extensive proteomic characterization of the molecular network
involved in Bcr–Abl function by Superti-Furga and colleagues
identiﬁed Crk, p85, and Cbl among the seven most highly inter-
connected core components of this signaling network (Brehme et
al., 2009).
In order to elucidate the biochemical mechanism underlying
the PI3K superactivation by the SH3 binding-competent NS1
proteins we now have characterized in detail the mutual interac-
tion between NS1, p85β, and CrkL. Because both NS1 and p85β
interact with the Crk proteins via the same N-terminal Crk(L) SH3
domain it was of speciﬁc interest to investigate whether a trimeric
complex involving p85β, Crk(L) and NS1 can form.
Results
Association of different Crk proteins with NS1 and p85β
The family of Crk adapter proteins includes three members,
CrkI, CrkII, and CrkL. Of these CrkII (40 kDa) and CrkI (28 kDa) are
products of the same gene, whereas CrkL (39 kDa) is encoded by a
different gene. CrkII and CrkL consist of one SH2 and two SH3
domains, while CrkI is truncated before the second SH3 domain
due to alternative mRNA splicing (Fig. 1a).
To extend our previous ﬁndings on NS1/Crk(L) binding
(Heikkinen et al., 2008), we compared the capacity of these three
different Crk proteins to interact with a representative avian NS1
protein containing a functional SH3 binding site (NS1 from A/
Mallard/Netherlands/12/2000/H7N3; “Mallard” in the following).
To examine the role of NS1 SH3 binding, we also included in these
experiments a mutated version of Mallard NS1 protein (NS1-
AxxA), carrying an SH3 binding site disrupted by alanine substitu-
tion of two critical proline residues (P212 and P215). As shown in
Fig. 1b, NS1 associated readily with CrkI, CrkII, as well as CrkL,
correlating with the presence of an N-terminal SH3 domain in all
of these Crk proteins (Fig. 1a). In contrast, none of the Crk proteins
co-precipitated the SH3 binding-deﬁcient NS1-AxxA. The blotting
data shown in Fig. 1b are representative of several experiments,
and all results shown have been reproduced at least three times.
The same holds true for the blotting data shown in Figs. 2, 4, 5 and
6.
Relative roles of p85β and Crk-SH3 binding in PI3K activation by NS1
Hale and colleagues reported the critical contribution of the
tyrosine 89 of NS1 in direct binding to the regulatory PI3K subunit
p85β (Hale et al., 2006). On the other hand, we have shown that
NS1 containing a functional Crk-SH3 binding site show greatly
enhanced PI3K activation compared to SH3 binding-deﬁcient NS1
(Heikkinen et al., 2008). To investigate if the increased PI3K
activation provided by NS1 SH3 binding was directly coupled to
the NS1–p85β interaction or represented an independent regula-
tory event, we compared the effects of the AxxA (P212A/P215A;
disrupting Crk SH3 binding) and Y89F (disrupting p85β binding)
mutations.
In agreement with our earlier study (Heikkinen et al., 2008) we
found that the PI3K-activating capacity of Mallard NS1 (induction
of Akt phosphorylation) was reduced but not abrogated by the
AxxA mutation (Fig. 2a). By contrast, the Y89F mutant NS1 was
completely inactive in inducing Akt phosphorylation. Thus, we
conclude that Crk(L) recruitment by NS1 indeed serves to enhance
PI3K activation triggered by binding of NS1 to p85β, but this
enhancement remains entirely dependent on the latter
interaction.
Rearrangement of the endogenous p85β/CrkL complex by NS1
Because p85 binds not only to NS1 (Hale et al., 2006; Shin et al.,
2007) but is also an established interaction partner of the Crk
proteins (Brehme et al., 2009; Sattler et al., 1996, 1997) we
examined the association of p85β with CrkL in untransfected cells
and in cells transfected with the mutant NS1 proteins. Indeed,
p85β could be readily co-precipitated with CrkL from untrans-
fected cells that did not express any NS1 (Fig. 2b, leftmost lane).
Transfection of the CrkL binding-competent (WT) or incompetent
(AxxA) NS1 proteins did not signiﬁcantly inﬂuence the net
association of p85β with CrkL. However, transfection of the Y89F
mutant of NS1 (which is CrkL binding-competent but p85β
binding-deﬁcient) potently inhibited p85β/CrkL association. Since
Fig. 1. All Crk proteins have a comparable and SH3 domain-dependent capacity to
bind NS1. (a) Domain organization of CrkI, CrkII, and CrkL. (b) Co-precipitation of
wild-type (WT) and SH3 binding deﬁcient mutant (AxxA) Mallard NS1 proteins
with CrkI, CrkII, and CrkL from 293T cells. Crk proteins fused with a biotinylation
domain were cotransfected into cells with myc-tagged NS1 proteins. The amounts
of NS1 in the transfected lysates (bottom panel) or co-precipitated with Crk
proteins by streptavidin-coated beads (middle panel) were examined by anti-Myc
Western blotting. Equal precipitation of the biotinylated Crk proteins was con-
ﬁrmed by blotting with labeled streptavidin (top panel).
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p85β and NS1 compete for the same N-terminal SH3 domain of
CrkL, this observation suggested that NS1 could displace p85β
from binding to CrkL due to a higher afﬁnity for the CrkL SH3
domain.
To directly demonstrate that NS1 could displace p85β from a
preformed p85β–CrkL complex, we co-transfected cells with CrkL
and p85β without NS1, and added increasing amounts of recom-
binant NS1–Y89F into a lysate of these cells to examine whether
p85β or NS1 co-precipitated with CrkL. As shown in Fig. 2c
recombinant NS1–Y89F displaced p85β from its complex with
CrkL in a dose-dependent manner. The highest dose (12 μg) of
NS1–Y89F (corresponding to a 4-fold molar excess of p85β in the
lysate) completely abrogated association of p85β with CrkL. By
contrast, 12 μg of NS1-AxxA had no effect. As could be predicted, a
similar displacement of 85β from the complex with CrkL by wild-
type NS1 could be also demonstrated when NS1–p85β binding
was prevented by speciﬁc mutations in p85β (p85β-V573M)
(Supplementary Fig. 1).
These results suggested that co-precipitation of p85β with CrkL
observed in cells expressing wild-type NS1 (Fig. 2b) was probably
not direct, but instead indirectly mediated via the dual capacity of
NS1 to bind both CrkL and p85β, thus indicating a scenario where
the NS1-mediated enhancement of PI3K activation would involve
a rearrangement of the natural CrkL–p85β complex and lead to
formation of a trimeric CrkL–NS1–p85β complex (where NS1 is
the bridging factor; see Fig. 3). Assembly of such a trimeric
complex (as opposed to separate CrkL–NS1 and NS1–p85β com-
plexes) is enabled by the abundant cellular expression of CrkL.
On the other hand, based on the capacity of Crk(L), p85, and
NS1 to form dimeric complexes (see Fig. 3a), one could hypothe-
size that the complex of SH3 binding-deﬁcient NS1 with p85β
should also contain CrkL, thus representing an alternative trimeric
CrkL–p85β–NS1 complex (where p85β is the bridging factor).
Seemingly in conﬂict with this assumption, only the NS1
proteins capable of direct CrkL binding (WT and Y89F) but no
NS1-AxxA were found in anti-CrkL immunocomplexes (Fig. 2b).
Since this could be explained by a modest afﬁnity of the CrkL SH3
domain for p85β and/or a low abundance of p85β compared to
CrkL and NS1, we examined if overexpression of p85β would allow
us to detect p85β-mediated bridging of CrkL and NS1-AxxA. Thus,
we co-transfected increasing amounts of p85β into cells together
with a constant amount of wild-type NS1 or NS1-AxxA. As
expected, coprecipitation of wild-type NS1 with CrkL was already
efﬁcient in the absence of p85β transfection, and did not sig-
niﬁcantly change upon ectopic p85β expression (Fig. 4a). By
contrast, increasing amounts of p85β enabled coprecipitation of
NS1-AxxA with CrkL in a dose-dependent manner, resulting in
CrkL-association almost as efﬁcient as observed for wild-type NS1.
Thus, we concluded that a p85β-mediated CrkL–p85β–NS1 com-
plex does form in cells expressing an SH3 binding-incompetent
NS1 protein.
Fig. 2. Mutational analysis of the roles of SH3- and p85β-binding by NS1.
(a) Activation of PI3K signaling by wild-type (WT), SH3-binding deﬁcient (AxxA),
or p85β-binding deﬁcient (Y89F) NS1 proteins. Myc-tagged versions of the
indicated NS1 proteins were transfected into Huh7 cells. 48 h later activation of
PI3K signaling was assayed by Western blotting of lysates of the transfected cells
with an antibody speciﬁc for phospho-Akt (top panel). Equal amounts of the
different NS1 proteins in these lysates were conﬁrmed by anti-Myc Western
blotting (middle panel). (b) Co-precipitation of endogenous p85β and transfected
NS1 proteins (WT, AxxA, or Y89F) with endogenous CrkL. Lysates of cells
transfected as in A were subjected to anti-CrkL immunoprecipitation followed by
Western blotting analysis of the immunocomplexes with an anti-p85β (middle
panel) or an anti-Myc (NS1) antibody (bottom panel). Equal NS1 expression in the
total lysates was conﬁrmed as in (a). (c) Competitive disruption of the CrkL–p85β
complex by titration of recombinant NS1–Y89F. Increasing amounts (from 0 μg to
12 μg) of recombinant NS1–Y89F or 12 μg of NS1-AxxA expressed as GST fusion
proteins were added to lysates of cells transfected with biotinylation domain-
tagged CrkL and HA-tagged p85β (total protein amount 200 μg). The amount of
p85β and NS1 proteins associated with CrkL precipitated with streptavidin beads
was examined by Western blotting.
Fig. 3. Reported (a) and hypothesized (b) interactions among the Crk(L), p85β, and
NS1 proteins. Note that all natural NS1 proteins do not contain the SH3 target motif
(PxxP) formed by the NS1 residues P212 and P215. Hence this motif has been
drawn only when it is necessary for the indicated complex. As discussed in the text,
the afﬁnity of the Crk(L) SH3 domain for the NS1 PxxP motif appears to be greater
than its afﬁnity for the p85β PxxP motif. The presence or absence of this motif in
NS1 may therefore determine which of the two alternative trimeric complexes
illustrated in (b) is formed. The references for the previously reported dimeric
complexes shown in (a) are Crk(L)–p85β (Gelkop et al., 2001; Sattler et al., 1997),
NS1–p85β (Hale et al., 2006; Shin et al., 2007), and in (b) NS1–Crk(L) (Heikkinen et
al., 2008).
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p85β and NS1 compete for the same N-terminal SH3 domain of
CrkL, this observation suggested that NS1 could displace p85β
from binding to CrkL due to a higher afﬁnity for the CrkL SH3
domain.
To directly demonstrate that NS1 could displace p85β from a
preformed p85β–CrkL complex, we co-transfected cells with CrkL
and p85β without NS1, and added increasing amounts of recom-
binant NS1–Y89F into a lysate of these cells to examine whether
p85β or NS1 co-precipitated with CrkL. As shown in Fig. 2c
recombinant NS1–Y89F displaced p85β from its complex with
CrkL in a dose-dependent manner. The highest dose (12 μg) of
NS1–Y89F (corresponding to a 4-fold molar excess of p85β in the
lysate) completely abrogated association of p85β with CrkL. By
contrast, 12 μg of NS1-AxxA had no effect. As could be predicted, a
similar displacement of 85β from the complex with CrkL by wild-
type NS1 could be also demonstrated when NS1–p85β binding
was prevented by speciﬁc mutations in p85β (p85β-V573M)
(Supplementary Fig. 1).
These results suggested that co-precipitation of p85β with CrkL
observed in cells expressing wild-type NS1 (Fig. 2b) was probably
not direct, but instead indirectly mediated via the dual capacity of
NS1 to bind both CrkL and p85β, thus indicating a scenario where
the NS1-mediated enhancement of PI3K activation would involve
a rearrangement of the natural CrkL–p85β complex and lead to
formation of a trimeric CrkL–NS1–p85β complex (where NS1 is
the bridging factor; see Fig. 3). Assembly of such a trimeric
complex (as opposed to separate CrkL–NS1 and NS1–p85β com-
plexes) is enabled by the abundant cellular expression of CrkL.
On the other hand, based on the capacity of Crk(L), p85, and
NS1 to form dimeric complexes (see Fig. 3a), one could hypothe-
size that the complex of SH3 binding-deﬁcient NS1 with p85β
should also contain CrkL, thus representing an alternative trimeric
CrkL–p85β–NS1 complex (where p85β is the bridging factor).
Seemingly in conﬂict with this assumption, only the NS1
proteins capable of direct CrkL binding (WT and Y89F) but no
NS1-AxxA were found in anti-CrkL immunocomplexes (Fig. 2b).
Since this could be explained by a modest afﬁnity of the CrkL SH3
domain for p85β and/or a low abundance of p85β compared to
CrkL and NS1, we examined if overexpression of p85β would allow
us to detect p85β-mediated bridging of CrkL and NS1-AxxA. Thus,
we co-transfected increasing amounts of p85β into cells together
with a constant amount of wild-type NS1 or NS1-AxxA. As
expected, coprecipitation of wild-type NS1 with CrkL was already
efﬁcient in the absence of p85β transfection, and did not sig-
niﬁcantly change upon ectopic p85β expression (Fig. 4a). By
contrast, increasing amounts of p85β enabled coprecipitation of
NS1-AxxA with CrkL in a dose-dependent manner, resulting in
CrkL-association almost as efﬁcient as observed for wild-type NS1.
Thus, we concluded that a p85β-mediated CrkL–p85β–NS1 com-
plex does form in cells expressing an SH3 binding-incompetent
NS1 protein.
Fig. 2. Mutational analysis of the roles of SH3- and p85β-binding by NS1.
(a) Activation of PI3K signaling by wild-type (WT), SH3-binding deﬁcient (AxxA),
or p85β-binding deﬁcient (Y89F) NS1 proteins. Myc-tagged versions of the
indicated NS1 proteins were transfected into Huh7 cells. 48 h later activation of
PI3K signaling was assayed by Western blotting of lysates of the transfected cells
with an antibody speciﬁc for phospho-Akt (top panel). Equal amounts of the
different NS1 proteins in these lysates were conﬁrmed by anti-Myc Western
blotting (middle panel). (b) Co-precipitation of endogenous p85β and transfected
NS1 proteins (WT, AxxA, or Y89F) with endogenous CrkL. Lysates of cells
transfected as in A were subjected to anti-CrkL immunoprecipitation followed by
Western blotting analysis of the immunocomplexes with an anti-p85β (middle
panel) or an anti-Myc (NS1) antibody (bottom panel). Equal NS1 expression in the
total lysates was conﬁrmed as in (a). (c) Competitive disruption of the CrkL–p85β
complex by titration of recombinant NS1–Y89F. Increasing amounts (from 0 μg to
12 μg) of recombinant NS1–Y89F or 12 μg of NS1-AxxA expressed as GST fusion
proteins were added to lysates of cells transfected with biotinylation domain-
tagged CrkL and HA-tagged p85β (total protein amount 200 μg). The amount of
p85β and NS1 proteins associated with CrkL precipitated with streptavidin beads
was examined by Western blotting.
Fig. 3. Reported (a) and hypothesized (b) interactions among the Crk(L), p85β, and
NS1 proteins. Note that all natural NS1 proteins do not contain the SH3 target motif
(PxxP) formed by the NS1 residues P212 and P215. Hence this motif has been
drawn only when it is necessary for the indicated complex. As discussed in the text,
the afﬁnity of the Crk(L) SH3 domain for the NS1 PxxP motif appears to be greater
than its afﬁnity for the p85β PxxP motif. The presence or absence of this motif in
NS1 may therefore determine which of the two alternative trimeric complexes
illustrated in (b) is formed. The references for the previously reported dimeric
complexes shown in (a) are Crk(L)–p85β (Gelkop et al., 2001; Sattler et al., 1997),
NS1–p85β (Hale et al., 2006; Shin et al., 2007), and in (b) NS1–Crk(L) (Heikkinen et
al., 2008).
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Demonstration of a p85β-bridged association of CrkL and the
Mallard NS1-AxxA suggested that similar trimeric Crk(L)–p85β–
NS1 complexes would also be formed in cells expressing NS1
proteins encoded by prototypic viruses, such as A/WSN/33 and A/
Udorn/72, which represent seasonal human IAV strains lacking the
Crk(L) SH3 binding motif. Indeed, when WSN and Udorn NS1
proteins were co-transfected with p85β, they could be co-
precipitated with cellular CrkL as efﬁciently as the Mallard NS1
protein (Fig. 4b). In strong support of the model of the two
alternative CrkL–p85β–NS1 complexes (Fig. 3b), the capacity of
p85β to couple Udorn and WSN NS1 with CrkL completely
depended on the SH3 binding motif of p85β, and was disrupted
by the P294A/P297A mutation. Thus, we conclude that Crk
proteins are also associated with the PI3K-activating NS1/p85β
complexes involving NS1 proteins that lack direct Crk(L) binding
capacity.
To further test the model of two alternative trimeric complexes
(Fig. 3b), we co-expressed all relevant combinations of the
differentially mutated versions of these proteins, and investigated
in parallel which complexes could form (Fig. 5). For these studies
we generated an additional mutant of p85β (V573M), which
prevents the binding of p85β to NS1 (Li et al., 2008). As already
shown for endogenous p85β (Fig. 2b), transfected wild-type p85β-
HA could be co-precipitated with CrkL from wild-type NS1- and
NS1-AxxA-transfected cells (Fig. 5, panel II, lanes 3 and 4), as well
as in the absence of any NS1 (lane 2), whereas expression of NS1–
Y89F inhibited this association (lane 5). In the absence of NS1 the
V573M mutation in p85β did not affect binding to CrkL (lane 10),
but this mutation rendered p85β–CrkL association sensitive to
inhibition also by wild-type NS1 (lane 11). In keeping with the
earlier work (Gelkop et al., 2001; Sattler et al., 1997), disruption of
the SH3 binding site in p85β (P294A, P297A) abolished direct
binding of p85β to CrkL (lane 6). Attesting to the role of NS1 as a
bridging factor between CrkL and p85β in Complex 1 (Fig. 3b) co-
precipitation of p85β-P294A, P297A with CrkL could be rescued by
wild-type NS1 (Fig. 5, lane 7), but not by NS1-AxxA or NS1-Y89F
(lanes 8 and 9). The same was true for co-precipitation of CrkL
with p85β (panel VI). Only wild-type NS1 could mediate pull-
down of CrkL by p85β–P294A, P297A, whereas co-precipitation of
CrkL by wild-type p85β was observed even in the absence of any
NS1. Of note, however, wild-type NS1 further increased CrkL/
p85β-association, attesting to the efﬁcient formation of a trimeric
CrkL–NS1–p85β complex. This effect also evident in the reciprocal
co-IP (panel II), albeit less pronounced presumably because of the
higher relative abundance of transfected p85β compared to
endogenous CrkL.
In addition to the expected coprecipitation pattern of the p85β
variants, the presence of NS1 and its AxxA and Y89F mutants in
the anti-CrkL (panel III) or in the anti-p85β (anti-HA; panel V)
immunocomplexes correlated perfectly with the model presented
in Fig. 3(b). Speciﬁcally, V573M mutation in p85β or Y89F muta-
tion in NS1 prevented interaction of NS1 with p85β, while SH3
binding capacity of NS1 did not play a role. In contrast, whereas
the SH3 binding-competent NS1-WT and NS1–Y89F proteins could
be precipitated with CrkL regardless of the cotransfected p85β
variant, NS1-AxxA failed to associate with CrkL if either the SH3
binding site (P294A, P297A) or the NS1 binding site (V573M) of
p85β was mutated.
To conﬁrm that such trimolecular complexes can assemble as
depicted in Fig. 3b without the assistance of additional CrkL- or
p85β-associated cellular factors, we expressed and puriﬁed full-
length p85β (both wild-type and the P294A/P297A mutant) and
NS1 (both wild-type and the AxxA mutant) proteins, as well as a
CrkL protein fragment containing the SH3 domain in recombinant
Fig. 4. Overexpression of p85β reveals association of CrkL with NS1/p85β com-
plexes involving SH3 binding-incompetent NS1 proteins. (a) Increasing amounts of
HA-tagged p85β was transfected to 293T cells together with wild-type (WT) or
SH3-binding deﬁcient (AxxA) NS1. Proteins associated with anti-CrkL (endogenous)
precipitations from these cells were detected in Western blots with anti-HA (p85β),
anti-CrkL, or anti-NS1 antibodies. The levels of transfected p85β and NS1 in the
total lysates (WCE) were similarly detected. (b) NS1 proteins from Mallard (M),
WSN (W), or Udorn (U) strains were cotransfected to 293T cells together with a
wild-type (WT) or Crk(L) SH3 domain binding-deﬁcient mutant (P294A, P297A)
versions of p85β. The association of these NS1 with anti-CrkL immunocomplexes
was examined as in (a).
Fig. 5. Mutational characterization of the interaction interfaces involved in the
assembly of two alternative trimeric complexes between CrkL, NS1, and p85β.
Different combinations of wild-type and mutated versions of Mallard NS1 and p85β
were transfected into 293T cells as indicated. Immunocomplexes precipitated from
these cells by antibodies against CrkL (endogenous) (panels I-III) or p85β (anti-HA;
panels IV-VI) were examined by probing the Western blot with antibodies against
p85β (anti-HA), NS1, or CrkL as indicated. Expression of NS1 in all NS1-transfected
cells was conﬁrmed by Western blot analysis of total cell lysates (WCE).
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Demonstration of a p85β-bridged association of CrkL and the
Mallard NS1-AxxA suggested that similar trimeric Crk(L)–p85β–
NS1 complexes would also be formed in cells expressing NS1
proteins encoded by prototypic viruses, such as A/WSN/33 and A/
Udorn/72, which represent seasonal human IAV strains lacking the
Crk(L) SH3 binding motif. Indeed, when WSN and Udorn NS1
proteins were co-transfected with p85β, they could be co-
precipitated with cellular CrkL as efﬁciently as the Mallard NS1
protein (Fig. 4b). In strong support of the model of the two
alternative CrkL–p85β–NS1 complexes (Fig. 3b), the capacity of
p85β to couple Udorn and WSN NS1 with CrkL completely
depended on the SH3 binding motif of p85β, and was disrupted
by the P294A/P297A mutation. Thus, we conclude that Crk
proteins are also associated with the PI3K-activating NS1/p85β
complexes involving NS1 proteins that lack direct Crk(L) binding
capacity.
To further test the model of two alternative trimeric complexes
(Fig. 3b), we co-expressed all relevant combinations of the
differentially mutated versions of these proteins, and investigated
in parallel which complexes could form (Fig. 5). For these studies
we generated an additional mutant of p85β (V573M), which
prevents the binding of p85β to NS1 (Li et al., 2008). As already
shown for endogenous p85β (Fig. 2b), transfected wild-type p85β-
HA could be co-precipitated with CrkL from wild-type NS1- and
NS1-AxxA-transfected cells (Fig. 5, panel II, lanes 3 and 4), as well
as in the absence of any NS1 (lane 2), whereas expression of NS1–
Y89F inhibited this association (lane 5). In the absence of NS1 the
V573M mutation in p85β did not affect binding to CrkL (lane 10),
but this mutation rendered p85β–CrkL association sensitive to
inhibition also by wild-type NS1 (lane 11). In keeping with the
earlier work (Gelkop et al., 2001; Sattler et al., 1997), disruption of
the SH3 binding site in p85β (P294A, P297A) abolished direct
binding of p85β to CrkL (lane 6). Attesting to the role of NS1 as a
bridging factor between CrkL and p85β in Complex 1 (Fig. 3b) co-
precipitation of p85β-P294A, P297A with CrkL could be rescued by
wild-type NS1 (Fig. 5, lane 7), but not by NS1-AxxA or NS1-Y89F
(lanes 8 and 9). The same was true for co-precipitation of CrkL
with p85β (panel VI). Only wild-type NS1 could mediate pull-
down of CrkL by p85β–P294A, P297A, whereas co-precipitation of
CrkL by wild-type p85β was observed even in the absence of any
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length p85β (both wild-type and the P294A/P297A mutant) and
NS1 (both wild-type and the AxxA mutant) proteins, as well as a
CrkL protein fragment containing the SH3 domain in recombinant
Fig. 4. Overexpression of p85β reveals association of CrkL with NS1/p85β com-
plexes involving SH3 binding-incompetent NS1 proteins. (a) Increasing amounts of
HA-tagged p85β was transfected to 293T cells together with wild-type (WT) or
SH3-binding deﬁcient (AxxA) NS1. Proteins associated with anti-CrkL (endogenous)
precipitations from these cells were detected in Western blots with anti-HA (p85β),
anti-CrkL, or anti-NS1 antibodies. The levels of transfected p85β and NS1 in the
total lysates (WCE) were similarly detected. (b) NS1 proteins from Mallard (M),
WSN (W), or Udorn (U) strains were cotransfected to 293T cells together with a
wild-type (WT) or Crk(L) SH3 domain binding-deﬁcient mutant (P294A, P297A)
versions of p85β. The association of these NS1 with anti-CrkL immunocomplexes
was examined as in (a).
Fig. 5. Mutational characterization of the interaction interfaces involved in the
assembly of two alternative trimeric complexes between CrkL, NS1, and p85β.
Different combinations of wild-type and mutated versions of Mallard NS1 and p85β
were transfected into 293T cells as indicated. Immunocomplexes precipitated from
these cells by antibodies against CrkL (endogenous) (panels I-III) or p85β (anti-HA;
panels IV-VI) were examined by probing the Western blot with antibodies against
p85β (anti-HA), NS1, or CrkL as indicated. Expression of NS1 in all NS1-transfected
cells was conﬁrmed by Western blot analysis of total cell lysates (WCE).
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form. Experiments involving mixing of two or three of these
proteins together followed by pull-down analysis of proteins
associated with wild-type or mutant p85β conﬁrmed that Com-
plex I (where NS1 connects p85β and CrkL) as well as Complex II
(where p85β connects NS1 and CrkL) can be assembled in vitro
from puriﬁed recombinant components (Supplementary Fig. 2).
Moreover, conﬁrming our conclusions on the assembly of these
complexes in living cells, SH3 binding-deﬁcient NS1 could associ-
ate with CrkL in Complex II only if the SH3 binding site in p85β
was intact.
In conclusion, these data ﬁrmly established a model where a
trimeric complex involving NS1, CrkL, and p85β can assemble
according to two distinct principles, depending on the SH3 binding
capacity of NS1 (Fig. 3b).
Functional consequences of p85β/CrkL complex rearrangement by
NS1
As already discussed, Crk proteins are naturally associated with
PI3K via SH3-mediated binding to a proline-rich motif in p85β.
Because of this interaction recruitment of CrkL to NS1–p85β
complexes involving SH3 binding defective NS1 proteins was also
observed (Figs. 4 and 5). However, we could detect a p85β-bridged
CrkL–NS1 association (Complex 2) only when p85β was over-
expressed, suggesting that CrkL recruitment to PI3K–NS1 com-
plexes via p85β is less efﬁcient than recruitment via an NS1–CrkL
SH3 interaction. Thus, we reasoned that if the lower PI3K activa-
tion by SH3 binding-deﬁcient NS1 proteins might be rescued by
CrkL overexpression.
To test this idea we transfected wild-type Mallard NS1 and
NS1-AxxA with or without CrkL, and compared the activation of
PI3K in these cells (Fig. 6). Overexpression of CrkL had a relatively
modest enhancing effect on wild-type NS1-induced Akt phosphor-
ylation, whereas the weaker PI3K activation by NS1-AxxA was
signiﬁcantly potentiated by CrkL overexpression. When the natu-
rally Crk(L) binding-deﬁcient NS1 protein from the Udorn strain
was tested, a similar potentiation of PI3K activation by CrkL
overexpression could also be observed. Moreover, we also tested
the capacity of overexpressed CrkI and CrkII to potentiate PI3K/Akt
activation by Crk(L) binding-deﬁcient NS1, and obtained results
that were very similar to those seen with CrkL (data not shown).
Previously it was reported that the SH3 binding function of NS1
is involved in regulation of the c-Abl activity, a tyrosine kinase that
phosphorylates tyrosine residues Y221 and Y207 in Crk and CrkL,
respectively (Hrincius et al., 2014). Moreover, c-Abl could also
phosphorylate p85β (Sattler et al., 1996). While an effective
inhibition of c-Abl activity was evident by a profound suppression
of CrkL tyrosine phosphorylation, we observed no effect on NS1-
induced Akt phosphorylation (Supplementary Fig. 3), thus ruling
out a critical role for c-Abl in this regulation.
In summary, we conclude that the efﬁcient recruitment of Crk
proteins into the PI3K–NS1 complex underlies the enhanced PI3K
activation by SH3 binding competent NS1 proteins. However,
additional qualitative differences between the two alternative
Crk(L)–NS1–p85β might also exist and could favor PI3K activation
in the context of Complex 1.
Discussion
Binding to the p85β regulatory subunit of PI3K is a conserved
function of NS1 proteins of diverse IAV strains (Ehrhardt and
Ludwig, 2009; Hale and Randall, 2007). This interaction leads to
activation of PI3K/Akt signaling, which can contribute to viral
replication and disease pathogenesis (see later). The capacity of
NS1 of certain IAV strains to bind to the SH3 domains of the Crk
adapter proteins is associated with enhanced PI3K activation
(Heikkinen et al., 2008). The same SH3 domain normally couples
Crk proteins to PI3K by binding to a proline-rich target motif in
p85pre (Gelkop et al., 2001; Sattler et al., 1997).
In this study we show that SH3 binding-competent NS1
proteins can displace this natural SH3 interaction, and direct the
assembly of a novel Crk(L)–NS1–p85β complex (“Complex 1”)
where NS1 is the bridging factor. The interaction of p85β with
NS1 lacking the capacity for SH3 binding also takes place in
association with Crk(L), but involves an alternative trimeric com-
plex NS1–p85β–Crk(L) (“Complex 2”) where p85β is the bridging
factor. Because of the low cellular levels of p85β, and the relatively
modest afﬁnity of p85β for the CrkL SH3 domain, Complex 2 could
be physically observed only when p85β was overexpressed.
Indeed, our data suggest that the enhanced PI3K activation in
the context of Complex 1 is caused by a more efﬁcient tethering of
Crk(L) to NS1 and PI3K. In support of this conclusion, overexpres-
sion of CrkL could compensate for this difference, and thereby
potentiate PI3K activation by SH3 binding-deﬁcient NS1.
These results establish that enhancement of NS1-induced PI3K/
Akt signaling by Crk(L) is directly coupled to the PI3K-activating
NS1–p85β interaction, rather than acting somewhere upstream or
downstream in the PI3K/Akt signaling pathway. Previous studies
have found both Crk(L) and p85β in anti-NS1 immunocomplexes
(Heikkinen et al., 2008; Hrincius et al., 2010), but this could also be
explained by distinct dimeric NS1–p85β and NS1–Crk
(L) complexes. In contrast, the combination of our mutagenesis
and co-precipitation approaches provides a deﬁnite proof for
mutual complexes involving all three proteins, and correlates the
assembly of this trimeric complex with enhancemement of PI3K/
Akt activation.
Fig. 6. Effect of CrkL overexpression on PI3K/Akt activation induced by various NS1
proteins. (a) Wild-type Mallard NS1 (WT), NS1-AxxA (AxxA), Udorn NS1 (Udorn) or
an empty control vector (vector) were transfected into Huh7 cells with or without
an expression vector for biotinylation domain-tagged CrkL. Induced PI3K/Akt
signaling in the transfected cells was examined by probing the lysates with an
antibody speciﬁc for phospho-Akt (top panel). The presence of NS1 and CrkL
proteins in these lysates was detected with anti-Myc antibody or labeled strepta-
vidin. The uniform loading of the lysates was controlled by probing with an anti-α-
tubulin antibody (bottom panel). (b) Phospho-Akt signal intensities from (a) and
two similar experiments were quantiﬁed using the Odyssey scanning software, and
the enhanced pAkt signal intensity is shown as fold increase induced by CrkL
overexpression as indicated. Statistical signiﬁcance of the differences were deter-
mined by Student's t-test (*Po0.01).
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according to two distinct principles, depending on the SH3 binding
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ylation, whereas the weaker PI3K activation by NS1-AxxA was
signiﬁcantly potentiated by CrkL overexpression. When the natu-
rally Crk(L) binding-deﬁcient NS1 protein from the Udorn strain
was tested, a similar potentiation of PI3K activation by CrkL
overexpression could also be observed. Moreover, we also tested
the capacity of overexpressed CrkI and CrkII to potentiate PI3K/Akt
activation by Crk(L) binding-deﬁcient NS1, and obtained results
that were very similar to those seen with CrkL (data not shown).
Previously it was reported that the SH3 binding function of NS1
is involved in regulation of the c-Abl activity, a tyrosine kinase that
phosphorylates tyrosine residues Y221 and Y207 in Crk and CrkL,
respectively (Hrincius et al., 2014). Moreover, c-Abl could also
phosphorylate p85β (Sattler et al., 1996). While an effective
inhibition of c-Abl activity was evident by a profound suppression
of CrkL tyrosine phosphorylation, we observed no effect on NS1-
induced Akt phosphorylation (Supplementary Fig. 3), thus ruling
out a critical role for c-Abl in this regulation.
In summary, we conclude that the efﬁcient recruitment of Crk
proteins into the PI3K–NS1 complex underlies the enhanced PI3K
activation by SH3 binding competent NS1 proteins. However,
additional qualitative differences between the two alternative
Crk(L)–NS1–p85β might also exist and could favor PI3K activation
in the context of Complex 1.
Discussion
Binding to the p85β regulatory subunit of PI3K is a conserved
function of NS1 proteins of diverse IAV strains (Ehrhardt and
Ludwig, 2009; Hale and Randall, 2007). This interaction leads to
activation of PI3K/Akt signaling, which can contribute to viral
replication and disease pathogenesis (see later). The capacity of
NS1 of certain IAV strains to bind to the SH3 domains of the Crk
adapter proteins is associated with enhanced PI3K activation
(Heikkinen et al., 2008). The same SH3 domain normally couples
Crk proteins to PI3K by binding to a proline-rich target motif in
p85pre (Gelkop et al., 2001; Sattler et al., 1997).
In this study we show that SH3 binding-competent NS1
proteins can displace this natural SH3 interaction, and direct the
assembly of a novel Crk(L)–NS1–p85β complex (“Complex 1”)
where NS1 is the bridging factor. The interaction of p85β with
NS1 lacking the capacity for SH3 binding also takes place in
association with Crk(L), but involves an alternative trimeric com-
plex NS1–p85β–Crk(L) (“Complex 2”) where p85β is the bridging
factor. Because of the low cellular levels of p85β, and the relatively
modest afﬁnity of p85β for the CrkL SH3 domain, Complex 2 could
be physically observed only when p85β was overexpressed.
Indeed, our data suggest that the enhanced PI3K activation in
the context of Complex 1 is caused by a more efﬁcient tethering of
Crk(L) to NS1 and PI3K. In support of this conclusion, overexpres-
sion of CrkL could compensate for this difference, and thereby
potentiate PI3K activation by SH3 binding-deﬁcient NS1.
These results establish that enhancement of NS1-induced PI3K/
Akt signaling by Crk(L) is directly coupled to the PI3K-activating
NS1–p85β interaction, rather than acting somewhere upstream or
downstream in the PI3K/Akt signaling pathway. Previous studies
have found both Crk(L) and p85β in anti-NS1 immunocomplexes
(Heikkinen et al., 2008; Hrincius et al., 2010), but this could also be
explained by distinct dimeric NS1–p85β and NS1–Crk
(L) complexes. In contrast, the combination of our mutagenesis
and co-precipitation approaches provides a deﬁnite proof for
mutual complexes involving all three proteins, and correlates the
assembly of this trimeric complex with enhancemement of PI3K/
Akt activation.
Fig. 6. Effect of CrkL overexpression on PI3K/Akt activation induced by various NS1
proteins. (a) Wild-type Mallard NS1 (WT), NS1-AxxA (AxxA), Udorn NS1 (Udorn) or
an empty control vector (vector) were transfected into Huh7 cells with or without
an expression vector for biotinylation domain-tagged CrkL. Induced PI3K/Akt
signaling in the transfected cells was examined by probing the lysates with an
antibody speciﬁc for phospho-Akt (top panel). The presence of NS1 and CrkL
proteins in these lysates was detected with anti-Myc antibody or labeled strepta-
vidin. The uniform loading of the lysates was controlled by probing with an anti-α-
tubulin antibody (bottom panel). (b) Phospho-Akt signal intensities from (a) and
two similar experiments were quantiﬁed using the Odyssey scanning software, and
the enhanced pAkt signal intensity is shown as fold increase induced by CrkL
overexpression as indicated. Statistical signiﬁcance of the differences were deter-
mined by Student's t-test (*Po0.01).
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Importantly, our results also reveal a general role for Crk
proteins as host cell cofactors in NS1-mediated activation of
PI3K/Akt signaling, which is not limited to NS1 variants carrying
a functional Crk(L) SH3 binding motif. However, the latter have
clearly evolved a more efﬁcient strategy to usurp Crk proteins as
cofactors in PI3K regulation. The mechanistic role of Crk(L) in NS1-
mediated PI3K/Akt activation remains to be fully understood. It is
possible that Crk(L) or an additional Crk(L)-associated protein
would be directly involved in the process where binding of NS1
leads to dismantling of the negative regulation imposed by p85β
on the p110 subunit. Considering the role of Crk(L) as an arche-
typic cellular adapter protein, as well as the ﬂexibility of the
observed Crk(L)–NS1–p85β complex architecture, however, a
perhaps more likely scenario is that Crk(L) serves as an anchor
to localize the NS1–PI3K complex to a subcellular compartment
that is favorable for activation of the PI3K/Akt pathway by NS1.
Indeed, PI3K signaling is complex, involving several alternative
p85 and p110 isoforms that can associate in many different
combinations (Vanhaesebroeck et al., 2010). It is likely that these
different types of PI3K variants operate in overlapping but differ-
ent signaling pathways, and associate with distinct sets of partner
proteins that regulate and target their activities. Thus, it is easy to
envision how Crk(L) could be involved in guiding the NS1–PI3K
complex to a speciﬁc cellular signaling domain that optimally
supports PI3K activation as well as otherwise ensures a cellular
response that maximally beneﬁts the virus.
The NS1 gene of most seasonal IAV strains would need just a
single nucleotide change to acquire the capacity to encode a
functional Crk(L) SH3 binding motif, which therefore would be
expected happen quickly if it provided direct replicative advantage
for the virus. Thus, the reason why viruses like the 1918 pandemic
strain have incorporated this feature into their genome must
reﬂect part of a more complex strategy that they have evolved to
interact with PI3K-dependent pro- and antiviral processes in
their hosts.
Regulation of host cell PI3K activity during different steps of
the IAV life-cycle is a multifaceted process that is not limited to the
action of NS1 (see Ehrhardt and Ludwig, 2009). The role of PI3K
activation by NS1 during IAV replication in cell culture and
pathogenesis in mice has been studied using engineered viruses
with mutant NS1 proteins that cannot bind to p85β. Originally it
was reported that such mutants are attenuated, giving rise to a
smaller plaque size and lower viral titers (Hale et al., 2006; Shin et
al., 2007). More recently a profound reduction in viral replication
and pathogenesis in mouse models of IAV infection was also
reported (Ayllon et al., 2012b; Hrincius et al., 2012). However,
the study by Hale and colleagues showed that the requirement for
NS1-induced PI3K activation is strikingly virus strain dependent.
While the underlying biology remains to be clariﬁed (see Ayllon et
al., 2012a), it is evident that variation elsewhere in the viral
genome can render PI3K activation by NS1 largely or completely
dispensable for IAV replication. On the other hand, only some
(typically avian) strains of IAV encode SH3-binding competent NS1
proteins that can efﬁciently recruit Crk proteins to enhance NS1-
induced PI3K activation (Heikkinen et al., 2008). As shown in the
current study, however, Crk(L)-mediated potentiation of PI3K/Akt
signaling depends entirely on p85β-binding coordinated by the
tyrosine residue 89 of NS1. Thus, the variable capacity for Crk
(L) SH3 binding by NS1 proteins from different IAV provides
another layer of complexity to the strain-speciﬁc variation in host
cell PI3K regulation.
In summary, the data presented in this study provide a detailed
characterization of the Crk(L)–NS1–PI3K multiprotein complex,
and emphasize the role of Crk proteins as host cell cofactors of the
IAV virulence factor NS1. The fact that some IAV have incorporated
a Crk(L) SH3 binding motif in the NS1 protein to take maximal use
of the Crk proteins in order to enhance NS1-mediated PI3K
activation attests the importance of PI3K-regulated host cell
processes for IAV.
Materials and methods
Cells
Human embryonic kidney 293T (ATCC: CRL-11268) and human
hepatocellular carcinoma Huh-7 (a gift from Mark Harris, Uni-
versity of Leeds, UK) cell lines were maintained in Dulbecco's
modiﬁed Eagle's medium high glucose supplemented with 0.6 μg/
ml penicillin, 60 μg/ml streptomycin, 10% fetal bovine serum, and
2 mM glutamine.
Plasmids and recombinant proteins
Plasmid constructs for the myc-NS1 (A/Mallard/Netherlands/
12/2000/H7N3, A/Udorn/72 and A/WSN/33) proteins, GST-NS1,
MBP-NS1 and the C-terminally biotinylated Crk proteins have
been described before (Heikkinen et al., 2008; Kesti et al., 2007).
The cDNA for mouse p85β (Open Biosystems) was cloned into the
pEBB-vector (Tanaka et al., 1995) with an N-terminal HA-tag or a
biotin acceptor domain. Codon changes in NS1 and p85β genes
were generated by standard overlap PCR mutagenesis. GST-NS1
and MBP-NS1 recombinant proteins were produced as previously
described (Heikkinen et al., 2008).
Protein precipitation and detection
For immunoprecipitation and protein pull-down experiments,
293T cells were transfected by a standard calcium phosphate
precipitation method. 48 h after transfection the cells were col-
lected and lysed in 1% NP40 lysis buffer (150 mM NaCl; 50 mM
Tris–HCl, pH 7.9; 1% NP40). Cell lysates were used for immuno-
precipitation with an anti-CrkL or an anti-HA antibody coupled to
Dynabeads protein G magnetic beads (Invitrogen). Alternately
lysates were used for streptavidin pulldown with streptavidin-
coated Dynabeads (Invitrogen). To examine the phosphorylation
status of Akt, Huh7 cells in 6-well plates were transfected with
4 mg of plasmid DNA using Lipofectamine 2000 (Invitrogen)
according to manufacturer's instructions. Cells were serum-
starved for 12 h and 48 h after transfection followed by lysis in
1% NP40 buffer. In Supplementary Fig. 3 the cells were treated
with 20 μM Imatinib for 12 h. Western blots were visualized with
the Odyssey infrared imaging system (LI-COR Biosciences).
Antibodies and inhibitors
The following primary antibodies were used in this study:
mouse anti-Myc (9E10, Santa Cruz Biotechnology), mouse anti-
CrkL (clone 5–6, Millipore), mouse anti-HA (F-7, Santa Cruz
Biotechnology), rabbit anti-phospho Akt(Ser473) (D9E, Cell Signal-
ing Technology), mouse anti-Akt (40D4, Cell Signaling Technol-
ogy), mouse anti-p85β (T15, AbD Serotec), mouse anti-α-tubulin
(DM1A, Sigma-Aldrich) and guinea-pig anti-NS1 (Melen et al.,
2007). Streptavidin IRDye680CW, Streptavidin IRDye800CW,
IRDye680CW goat anti-mouse IgG, IRDye800CW goat anti-mouse
IgG, IRDye680CW goat anti-rabbit IgG, and IRDye800CW goat anti-
rabbit were from LI-COR Biotechnology. IRDye800CW rabbit anti-
guinea pig was from Rockland Immunochemicals. The c-Abl
inhibitor Imatinib was from Sigma-Aldrich.
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according to manufacturer's instructions. Cells were serum-
starved for 12 h and 48 h after transfection followed by lysis in
1% NP40 buffer. In Supplementary Fig. 3 the cells were treated
with 20 μM Imatinib for 12 h. Western blots were visualized with
the Odyssey infrared imaging system (LI-COR Biosciences).
Antibodies and inhibitors
The following primary antibodies were used in this study:
mouse anti-Myc (9E10, Santa Cruz Biotechnology), mouse anti-
CrkL (clone 5–6, Millipore), mouse anti-HA (F-7, Santa Cruz
Biotechnology), rabbit anti-phospho Akt(Ser473) (D9E, Cell Signal-
ing Technology), mouse anti-Akt (40D4, Cell Signaling Technol-
ogy), mouse anti-p85β (T15, AbD Serotec), mouse anti-α-tubulin
(DM1A, Sigma-Aldrich) and guinea-pig anti-NS1 (Melen et al.,
2007). Streptavidin IRDye680CW, Streptavidin IRDye800CW,
IRDye680CW goat anti-mouse IgG, IRDye800CW goat anti-mouse
IgG, IRDye680CW goat anti-rabbit IgG, and IRDye800CW goat anti-
rabbit were from LI-COR Biotechnology. IRDye800CW rabbit anti-
guinea pig was from Rockland Immunochemicals. The c-Abl
inhibitor Imatinib was from Sigma-Aldrich.
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 Supplementary Fig. 1. 
Competitive disruption of the CrkL/p85β-V573M complex by titration of recombinant wild-
type NS1. Increasing amounts (from 0 μg to 12 μg) of recombinant wild-type NS1 or 12 μg of NS1-
AxxA expressed as GST fusion proteins were added to lysates of cells transfected with biotinylation 
domain-tagged CrkL and HA-tagged p85β-V573M (total protein amount 200 μg). The amount of 
p85β and NS1 proteins associated with CrkL precipitated with streptavidin beads was examined by 
Western blotting. 
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 Supplementary Fig. 2. 
Complex formation with purified proteins. (a) Biotinylation domain-tagged wild-type and 
P294A/P297A mutant p85β proteins (200 ng per reaction) purified from 293 cell cultures were 
mixed as indicated with MBP-tagged wild-type or AxxA mutant NS1 proteins (500 ng per reaction) 
and/or GST-tagged SH3 domain-containg fragment of CrkL (2 μg per reaction). NS1 and CrkL 
proteins co-precipitating with p85β proteins on streptavidin-coated particles were detected with an 
anti-NS1 antibody (middle panel) and anti-GST antibody (bottom panel). Despite some unavoidable 
background binding (evident also in the absence of any NS1) of the GST-tagged CrkL fragment to 
the p85β-P294A/P297A-containing beads, the specific capacity of wild-type NS1 (but not NS1-
AxxA) to couple CrkL to p85β-P294A/P297A is clearly evident. (b) Quality and purity of the 
proteins used in (a) analyzed by SDS-PAGE and Coomassie staining. 
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 Supplementary Fig. 3.  
Effect of c-Abl inhibition on PI3K/Akt activation induced by NS1. Wild-type Mallard NS1 
(WT) or an empty control vector (vector) was transfected into Huh7 cells. The cells were serum 
starved and treated or left untreated with 20 μM Imatinib for 12 h. Induction of PI3K/Akt signaling 
was examined by probing the lysates with an anti-phospho-Akt antibody (top panel), and expression 
of NS1 detected with an anti-Myc antibody (upper middle panel). To control the effect of Imatinib 
treatment, antibody specific for phospho-CrkL (Tyr207) was used (lower middle panel). Even 
loading of the gel was confirmed with an antibody for cellular α-tubulin (bottom panel). 
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Abstract: The non-structural protein-1 (NS1) of many influenza A strains, especially those of avian
origin, contains an SH3 ligand motif, which binds tightly to the cellular adaptor proteins Crk
(Chicken tumor virus number 10 (CT10) regulator of kinase) and Crk-like adapter protein (CrkL).
This interaction has been shown to potentiate NS1-induced activation of the phosphatidylinositol
3-kinase (PI3K), but additional effects on the host cell physiology may exist. Here we show that NS1
can induce an efficient translocation of Crk proteins from the cytoplasm into the nucleus, which
results in an altered pattern of nuclear protein tyrosine phosphorylation. This was not observed
using NS1 proteins deficient in SH3 binding or engineered to be exclusively cytoplasmic, indicating a
physical role for NS1 as a carrier in the nuclear translocation of Crk. These data further emphasize
the role of Crk proteins as host cell interaction partners of NS1, and highlight the potential for host
cell manipulation gained by a viral protein simply via acquiring a short SH3 binding motif.
Keywords: NS1; influenza A virus; SH3 domain; Crk; virus-host interaction
1. Introduction
Influenza A virus (IAV) belongs to the Orthomyxoviridae family of enveloped viruses. It has a
segmented genome consisting of eight single stranded negative-sense RNA strands. The non-structural
protein 1 (NS1) of IAV is an important virulence factor, and a remarkably multifunctional protein that
acts in several different ways to facilitate IAV replication (for reviews, see [1,2]).
The dynamic localization of NS1 in the nucleus as well as in the cytoplasm of IAV-infected cells
is mediated by two nuclear localization signals (NLS) and by one nuclear export signal (NES) [3–5].
Soon after IAV infection, newly synthesized NS1 accumulates in the nucleus, but at late time points
of infection it is transported into the cytoplasm. The conserved NLS1 of NS1 protein involves the
amino acids R35, R37, R38, and K41 [3,6], while NLS2 is virus strain-specific, and it is located in the
C-terminus of the protein [3,6,7]. The NES is located between the amino acids 138–147, leucine residues
144 and 146 being critical for its function [8,9].
The NS1 protein has several reported functions both in the nucleus and in the cytoplasm.
In the nucleus, NS1 can inhibit cellular mRNA maturation and export by interacting with cleavage
and polyadenylation specificity factor (CPSF), poly(A)-binding protein II (PABPII), mRNA splicing
machinery, and nuclear export factors [10–12]. In the cytoplasm, NS1 prevents the activation of
interferon-inducing proteins by inhibiting RNA helicase retinoic acid inducible gene-I (RIG-I) through
a direct interaction [13,14], and by preventing RIG-I ubiquitination via interacting with ubiquitin E3
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Abstract: The non-structural protein-1 (NS1) of many influenza A strains, especially those of avian
origin, contains an SH3 ligand motif, which binds tightly to the cellular adaptor proteins Crk
(Chicken tumor virus number 10 (CT10) regulator of kinase) and Crk-like adapter protein (CrkL).
This interaction has been shown to potentiate NS1-induced activation of the phosphatidylinositol
3-kinase (PI3K), but additional effects on the host cell physiology may exist. Here we show that NS1
can induce an efficient translocation of Crk proteins from the cytoplasm into the nucleus, which
results in an altered pattern of nuclear protein tyrosine phosphorylation. This was not observed
using NS1 proteins deficient in SH3 binding or engineered to be exclusively cytoplasmic, indicating a
physical role for NS1 as a carrier in the nuclear translocation of Crk. These data further emphasize
the role of Crk proteins as host cell interaction partners of NS1, and highlight the potential for host
cell manipulation gained by a viral protein simply via acquiring a short SH3 binding motif.
Keywords: NS1; influenza A virus; SH3 domain; Crk; virus-host interaction
1. Introduction
Influenza A virus (IAV) belongs to the Orthomyxoviridae family of enveloped viruses. It has a
segmented genome consisting of eight single stranded negative-sense RNA strands. The non-structural
protein 1 (NS1) of IAV is an important virulence factor, and a remarkably multifunctional protein that
acts in several different ways to facilitate IAV replication (for reviews, see [1,2]).
The dynamic localization of NS1 in the nucleus as well as in the cytoplasm of IAV-infected cells
is mediated by two nuclear localization signals (NLS) and by one nuclear export signal (NES) [3–5].
Soon after IAV infection, newly synthesized NS1 accumulates in the nucleus, but at late time points
of infection it is transported into the cytoplasm. The conserved NLS1 of NS1 protein involves the
amino acids R35, R37, R38, and K41 [3,6], while NLS2 is virus strain-specific, and it is located in the
C-terminus of the protein [3,6,7]. The NES is located between the amino acids 138–147, leucine residues
144 and 146 being critical for its function [8,9].
The NS1 protein has several reported functions both in the nucleus and in the cytoplasm.
In the nucleus, NS1 can inhibit cellular mRNA maturation and export by interacting with cleavage
and polyadenylation specificity factor (CPSF), poly(A)-binding protein II (PABPII), mRNA splicing
machinery, and nuclear export factors [10–12]. In the cytoplasm, NS1 prevents the activation of
interferon-inducing proteins by inhibiting RNA helicase retinoic acid inducible gene-I (RIG-I) through
a direct interaction [13,14], and by preventing RIG-I ubiquitination via interacting with ubiquitin E3
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ligases TRIM-25 and Riplet, [15,16]. NS1 also inhibits the activity of protein kinase R (PKR) [ 17], and
21-51-oligoadenylate synthetase (OAS) [18], two important interferon-induced antiviral proteins.
In addition, NS1 can activate the host cell phosphatidylinositol 3-kinase (PI3K) cascade, a signaling
pathway intimately involved in viral replication and innate immunity, by interacting directly with
p85β, a regulatory subunit of the PI3K complex [19,20]. PI3K activation is further enhanced by NS1
proteins that contain an SH3 binding motif, which mediates a strong and selective binding to the
cellular adaptor proteins Crk (Chicken tumor virus number 10 (CT10) regulator of kinase) and Crk-like
adaptor protein (CrkL) [21]. This NS1 SH3 binding motif is commonly found in avian IAVs, but
only in some human IAV strains, including the 1918 pandemic Spanish flu virus. This potentiation
of PI3K activation involves reorganization of the cellular p85β-Crk protein complex. While SH3
binding-incompetent NS1 proteins simply bind to p85β in this complex, PI3K-superactivating NS1
proteins hijack the SH3 domain of Crk, thereby breaking the pre-existing p85β-Crk complex and
assembling an alternative trimeric complex where NS1 is a bridging factor between p85β and Crk [22].
Crk proteins consist of a family of three members: CrkI, CrkII, and CrkL. CrkII and CrkL both
contain one SH2 and two SH3 domains, while CrkI is a truncated form of CrkII that due to an alternative
mRNA splicing possess only the SH2 and the N-terminal SH3 domain [23,24]. Although Crk proteins
lack any enzymatic activity, they play a crucial role in cell biology by serving as essential adaptor
proteins linking together different signaling molecules, such as tyrosine kinases and small G proteins
through their SH2 and SH3 domains. They coordinate numerous biological processes, ranging from
cell proliferation, cell adhesion and migration, phagocytic and endocytic pathways, apoptosis, and
regulation of gene expression (for reviews, see [25,26]). The SH2 and SH3 domains of Crk proteins
are highly homologous and display similar binding preferences and they have several overlapping
roles, for example, in maintaining the cell structure and motility in mouse embryonic fibroblast (MEF)
cells [27]. Use of knockout mice has revealed also some non-overlapping roles for these proteins in
embryonic development. Knockout of CrkI/II or CrkL individually leads to different developmental
defects in mice and they die perinatally [28,29]. Most of the cellular functions described for Crk
proteins involve coordination of cytoplasmic signaling processes. However, Crk proteins have also
been reported to enter the nucleus to regulate additional signaling pathways involved in malignant
transformation and programmed cell death. The nuclear partners for Crk proteins are not well
known, but prominently include the tyrosine kinase c-Abl, whose nuclear functions are important
in cellular responses to DNA damage, cell cycle progression, and apoptosis [30]. Moreover, nuclear
translocation of CrkII and its interaction with the nuclear tyrosine kinase Wee1 has been reported to
be proapoptotic [31,32]. It has also been reported that the binding of CrkL to phosphorylated form of
signal transducer and activator of transcription (STAT5) leads to translocation of the complex into the
nucleus where it binds to the promoter region of c-Abl or Bcr-Abl genes in chronic myeloid leukemia
(CML) cells [33,34]. Regulation of the nuclear entry of Crk proteins is not well understood. CrkII and
CrkL have a nuclear export signal located in theC-terminal SH3-domain [35], but all Crk proteins
lack a canonical nuclear localization signal, and apparently they can enter the nucleus only through
interaction with other proteins that contain a functional NLS [36].
Since both NS1 and Crk have distinct nuclear and cytoplasmic functions, and since the effects
on cellular physiology described for nuclear Crk proteins appear to depend on interaction partners
that are actively transported into the nucleus, we examined how NS1 might influence the intracellular
distribution of Crk proteins. Here we report that infection of cells with IAV encoding NS1 proteins
that are competent for Crk binding, in contrast to viruses encoding NS1 lacking the SH3 ligand motif,
cause a robust translocation of Crk proteins from the cytoplasm into the nucleus, which is associated
with a noticeable change in tyrosine phosphorylation pattern of proteins in the nuclear fraction.
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Since both NS1 and Crk have distinct nuclear and cytoplasmic functions, and since the effects
on cellular physiology described for nuclear Crk proteins appear to depend on interaction partners
that are actively transported into the nucleus, we examined how NS1 might influence the intracellular
distribution of Crk proteins. Here we report that infection of cells with IAV encoding NS1 proteins
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2. Materials and Methods
2.1. Cell Culture
The human lung epithelial (A549) and the human hepatocellular carcinoma (Huh-7) cell lines
were maintained in Dulbecco1s Modified Eagle Medium (DMEM) (Sigma Aldrich, St. Louis, MO, USA)
supplemented with 4500 mg/L of glucose, 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA),
0.05 mg/mL penicillin, 0.05 mg/mL streptomycin (Sigma Aldrich), and 1 mM L-glutamine (Sigma
Aldrich) at 37 ˝C in 5% CO2.
2.2. Recombinant Influenza A Viruses
The recombinant influenza A viruses were generated by using a plasmid-based reverse genetics
as previously described [37]. A/WSN/1933 IAV was used as the background virus. The NS
segment originated from either A/WSN/1933/H1N1 or A/Mallard/Netherlands/12/2000/H7N3
virus. The codon changes to NS1 sequence (A/WSN T215P; A/Mallard K217E) were introduced using
overlapping polymerase chain reaction (PCR) mutagenesis. Influenza A/WSN/1933 recombinant
viruses were propagated in 11-day-old embryonated chicken eggs at 34 ˝C for three days.
The recombinant viruses used in this study are: A/WSN-NS1Mallard(wt), A/WSN-NS1Mallard(K217E),
A/WSN-NS1WSN(wt), and A/WSN-NS1WSN(T215P).
2.3. DNA Transfections and Plasmids
A549 and Huh-7 cells were transfected by using a Lipofectamine 2000 reagent (Invitrogen,
Waltham, Massachusetts, USA) according to manufacturer1s instructions. The vector for A/Mallard
myc-NS1 wild-type (WT) has been described before [21]. To generate fluorescent fusion proteins,
mCherry was fused to the N-terminus of A/Mallard NS1, and enhanced green fluorescent protein
(eGFP) to the N-terminus of CrkL. To generate a cytoplasmic A/Mallard NS1 (Cyto), the NES from
MAPKK1 (LQKKLEELEL) was inserted between the mCherry and NS1 coding sequences. In addition,
the NLS1 of NS1 protein was mutated (R38A, R41A) by standard overlap PCR mutagenesis. All plasmid
constructs were verified correct by DNA sequencing.
2.4. Antibodies
The following primary antibodies were used in this study: mouse monoclonal anti-CrkL (clone 5–6,
Millipore, Billerica, MA, USA), mouse monoclonal anti-Crk (clone 22, BD Transduction Laboratories,
San Jose, CA, USA), rabbit monoclonal anti-phospho Akt (Ser473) (D9E, Cell Signaling Technology,
Danver, MA, USA), mouse monoclonalanti-α-tubulin (DM1A, Sigma-Aldrich), rabbit polyclonal
anti-Histone H3 (Cell Signaling Technology), monoclonal mouse anti-phosphotyrosine (PY20, Santa
Cruz Biotechnology, Dallas, TX, USA), and guinea-pig polyclonal anti-NS1 [3]. The secondary
antibodies for Western blotting were: IRDye680CW goat anti-mouse IgG, IRDye680CW goat anti-rabbit
IgG, and IRDye800CW goat anti-rabbit, and IRDye800CW rabbit anti-guinea pig were from LI-COR
Biotechnology (Lincoln, NE, USA). Secondary antibodies for immunofluorescence staining were:
AlexaFluor 488 goat anti-guinea pig IgG (Abcam, Cambridge, UK), and AlexaFluor 546 goat anti-mouse
IgG (Molecular Probes, Eugene, OR, USA). Nuclei were stained with Hoechst.
2.5. Immunoprecipitation and Detection
For immunoprecipitation A549 cells were infected with recombinant IAVs for 24 h, and the cells
were collected and lysed in 1% NP40 lysis buffer (150 mM NaCl; 50 mM Tris–HCl, pH 7.9; 1% NP40).
Cell lysates were used for immunoprecipitation with an anti-CrkL antibody coupled to Dynabeads
protein G magnetic beads (Invitrogen). To examine the phosphorylation status of Akt, Huh7 cells
on 6-well plates were transfected with 4 µg of plasmid DNA. Transfected cells were serum-starved
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for 12 h, and 48 h after transfection the cells were lysed in 1% NP40 lysis buffer. Western blots were
visualized with the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).
2.6. Cell Fractionation
A549 cells were seeded on 10 cm diameter well plates at 3 ˆ 106 density. The next day, the cells
were mock infected or infected with recombinant IAVs at a multiplicity of infections (MOI) 2 in the
presence of 5 µg/mL of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK)-treated trypsin
(Sigma Aldrich). 24 h after infection the cells were scraped into 500 µL of ice cold Buffer A (20 mM
Tris, pH 7.5, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2) supplemented with 0.5% Triton X-100.
The cells were incubated on ice for 10 min and after that the nuclei were pelleted at 800 g for 10 min.
The cytoplasmic extract (C) was collected and centrifuged at 16,100 g for 15 min. To prepare the
nuclear extract (N), the nuclear pellet was washed once with Buffer A + 0.5% Triton X-100 and twice
with Buffer A. The nuclei were suspended in 70 µl of Buffer B (20 mM¨Tris, pH 8.0, 500 mM¨NaCl,
2 mM¨EDTA, pH 8.0, 0.1% Igepal) and sonicated for 3 s. The nuclear proteins were collected after
centrifugation at 16,100 g for 15 min.
2.7. Immunofluorescence Staining and Confocal Imaging
For immunofluorescence microscopy, A549 cells were grown on coverslips and infected at an MOI
of 0.5 in the presence of TPCK-treated trypsin (5 µg/mL). At 20 h after infection, the cells were fixed
with ice cold methanol for 10 min at ´20 ˝C, permeabilized with 0.1% Triton X-100, and incubated
with guinea-pig anti-NS1 antibody, followed by AlexaFluor 488 goat anti-guinea pig IgG. CrkL was
stained with mouse anti-CrkL antibody, followed by AlexaFluor 546 goat anti-mouse IgG. The cells
were then examined with Leica TCS SP8 confocal microscope. Channels were scanned sequentially.
The mean intensities of the CrkL fluorescence signal in the nuclei were analyzed by using the open
source software, FiJi distribution of ImageJ (Version 1.50b, NIH) [38].
3. Results
3.1. SH3 Binding-Competent NS1 Proteins Translocate Crk Proteins into the Nucleus
To study the Crk/NS1 interaction in an infectious setting, we generated a set of recombinant
viruses using a typical human IAV A/WSN/1933/H1N1 (A/WSN) as a background strain.
These recombinant viruses are isogenic with wild-type A/WSN virus, except for the segment
8 (NS segment), which encodes either the wild-type or a mutated NS1 from an avian IAV
A/Mallard/Netherlands/12/2000/H7N3 (A/Mallard) or a mutant construct of NS1 of A/WSN. To
generate an SH3 binding-incompetent mutant of the A/Mallard NS1, a K217E mutation was introduced
into its NS1 sequence. Conversely, to engineer the naturally SH3 binding-incompetent A/WSN NS1 to
become SH3 binding-competent, a T215P mutation was introduced into its NS1 sequence. Although
not directly relevant for this study, it should be noted that the T215P mutation could also alter the
phosphorylation pattern of NS1 as T215 has been reported as a functional phosphorylation site [39,40].
The mutations made in the NS1 sequence do not affect the NS2/NEP open reading frame (ORF).
The sequences of the relevant SH3-binding regions in the NS1 proteins of these viruses are shown in
Figure 1A.
To establish that the engineered mutations had the expected effects on the capacity of the
corresponding A/Mallard and A/WSN NS1 proteins to interact with Crk proteins in IAV infected
cells, we immunoprecipitated endogenous CrkL (Figure 1B,C) from mock infected or recombinant
virus-infected A549 cells and examined NS1 co-precipitation by Western blotting. As seen in Figure 1B,
while wild-type A/Mallard NS1 readily co-precipitated with CrkL, the NS1 mutant (K217E) did not
associate with CrkL at detectable levels. Conversely, no association of wild-type A/WSN NS1 with
CrkL could be detected, whereas efficient co-precipitation of the mutant NS1-T215P protein with a
restored Crk SH3-binding motif was observed (Figure 1C).
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Figure 1. A functional SH3 binding motif in the non-structural protein-1 (NS1) is required for interaction
with Crk-like adapter protein (CrkL) in influenza A virus (IAV)-infected cells. (A) The consensus
sequence of class II SH3 binding motif, and its presence (+) or absence (´) in the C-terminal region
(residues 212–217 shown) of NS1 proteins of the recombinant IAV strains used in this study. In SH3
binding consensus x indicates any residue, F a hydrophopic residue, and + a positively charged amino
acid, which for Crk-family SH3 domains is preferable a lysine residue; ( B,C) Co-immunoprecipation
of NS1 proteins with CrkL from lysates of A549 cells infected with recombinant A/WSN-based IAV
strains expressing wild-type or mutant NS1 proteins derived from A/Mallard ( B) or A/WSN (C) for
24 h at a multiplicity of infections (MOI) 2. Note that these NS1 proteins naturally differ in their
SH3 binding capacity, and the mutations introduced in them thus have opposite effects. NS1 and
nucleoprotein (NP) blots from whole cell extracts (WCE) before anti-CrkL immunoprecipitation are
shown to control equal infection of the cells by the different viruses.
Next, we analyzed the localization of NS1 and Crk proteins in the infected cells by
immunofluorescence staining and confocal imaging. A549 cells were infected with an MOI of
0.5 with A/WSN-NS1Mallard(wt) or A/WSN-NS1Mallard(K217E) recombinant viruses and the cells were
fixed 20 h later. CrkL was localized mainly in the cytoplasm in mock-infected cells, and only faint
staining was observed in the nucleus (Figure 2A, top row). In the infected cells, both the WT and
the K217E-mutant NS1 proteins were predominantly localized in the nucleus (Figure 2A, in green).
Strikingly, in cells infected with A/WSN-NS1Mallard(wt) CrkL was found to mainly co-localize with NS1
in the nucleus (Figure 2A, middle row), whereas in cells infected with A/WSN-NS1Mallard(K217E) the
distribution of CrkL was indistinguishable from its predominantly cytoplasmic localization pattern in
mock-infected cells (Figure 2A, bottom row). Very similar differential distribution was also observed
for Crk when examined by immunostaining with an antibody that detects both CrkI and CrkII (data
not shown). To more formally establish this effect, the mean intensity of CrkL-fluorescence signal
in NS1-positive nuclei was quantified from 50 individual cells infected with A/WSN-NS1Mallard(wt),
A/WSN-NS1Mallard(K217E), or mock-infected cells (Figure 2A, right panel). When the mean intensities
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strains expressing wild-type or mutant NS1 proteins derived from A/Mallard ( B) or A/WSN (C) for
24 h at a multiplicity of infections (MOI) 2. Note that these NS1 proteins naturally differ in their
SH3 binding capacity, and the mutations introduced in them thus have opposite effects. NS1 and
nucleoprotein (NP) blots from whole cell extracts (WCE) before anti-CrkL immunoprecipitation are
shown to control equal infection of the cells by the different viruses.
Next, we analyzed the localization of NS1 and Crk proteins in the infected cells by
immunofluorescence staining and confocal imaging. A549 cells were infected with an MOI of
0.5 with A/WSN-NS1Mallard(wt) or A/WSN-NS1Mallard(K217E) recombinant viruses and the cells were
fixed 20 h later. CrkL was localized mainly in the cytoplasm in mock-infected cells, and only faint
staining was observed in the nucleus (Figure 2A, top row). In the infected cells, both the WT and
the K217E-mutant NS1 proteins were predominantly localized in the nucleus (Figure 2A, in green).
Strikingly, in cells infected with A/WSN-NS1Mallard(wt) CrkL was found to mainly co-localize with NS1
in the nucleus (Figure 2A, middle row), whereas in cells infected with A/WSN-NS1Mallard(K217E) the
distribution of CrkL was indistinguishable from its predominantly cytoplasmic localization pattern in
mock-infected cells (Figure 2A, bottom row). Very similar differential distribution was also observed
for Crk when examined by immunostaining with an antibody that detects both CrkI and CrkII (data
not shown). To more formally establish this effect, the mean intensity of CrkL-fluorescence signal
in NS1-positive nuclei was quantified from 50 individual cells infected with A/WSN-NS1Mallard(wt),
A/WSN-NS1Mallard(K217E), or mock-infected cells (Figure 2A, right panel). When the mean intensities
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of CrkL immunostaining in these nuclei were normalized to the value of the mock-infected cells, a
robust and highly significant nuclear translocation of CrkL by SH3 binding-competent but not by SH3
binding-incompetent NS1 could be demonstrated.
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of CrkL immunostaining in these nuclei were normalized to the value of the mock-infected cells, a
robust and highly significant nuclear translocation of CrkL by SH3 binding-competent but not by SH3
binding-incompetent NS1 could be demonstrated.
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When the kinetics of nuclear translocation of the Crk proteins was examined in more detail,
we could observe first signs of nuclear accumulation of the Crk and CrkL at 6 h post-infection (p.i.)
coinciding with the nuclei becoming clearly positive for NS1 staining (Figure 2B). At 8 h p.i. nuclear
accumulation of Crk proteins was already prominent, and at 12 h p.i. Crk/CrL localization seemed
already complete showing a pattern that looked identical to the 20 h p.i. time point shown in Figure 2A.
To extend and support these imaging studies by using a biochemical approach, we prepared
cytoplasmic and nuclear fractions of cells infected with recombinant viruses and compared the presence
of Crk proteins and wild-type or mutant NS1 proteins in these fractions (Figure 3A,B). The quality and
purity of the nuclear and cytoplasmic protein fractions obtained from these cells were established by
Western blotting of these preparations using antibodies against anti-α-tubulin (a cytoplasmic marker)
and anti-histone H3 (a nuclear marker).
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virus at an MOI 2. In addition to antibodies against the Crk-family proteins and NS1, the blotted A549
fractions were also probed with antibodies against Histone H3 and α-tubulin to confirm successful
separation of nuclear and cytoplasmic fractions. In addition, unfractionated whole cell extracts (WCE)
of the infected cells were Western blotted with anti-NS1 and anti-NP antibodies to confirm uniform
infection of cells by the different viruses; (B) Same as (A) except that the cells were infected with
recombinant A/WSN virus carrying wild-type (WT) or the T215P mutant NS1 from A/WSN.
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When the kinetics of nuclear translocation of the Crk proteins was examined in more detail,
we could observe first signs of nuclear accumulation of the Crk and CrkL at 6 h post-infection (p.i.)
coinciding with the nuclei becoming clearly positive for NS1 staining (Figure 2B). At 8 h p.i. nuclear
accumulation of Crk proteins was already prominent, and at 12 h p.i. Crk/CrL localization seemed
already complete showing a pattern that looked identical to the 20 h p.i. time point shown in Figure 2A.
To extend and support these imaging studies by using a biochemical approach, we prepared
cytoplasmic and nuclear fractions of cells infected with recombinant viruses and compared the presence
of Crk proteins and wild-type or mutant NS1 proteins in these fractions (Figure 3A,B). The quality and
purity of the nuclear and cytoplasmic protein fractions obtained from these cells were established by
Western blotting of these preparations using antibodies against anti-α-tubulin (a cytoplasmic marker)
and anti-histone H3 (a nuclear marker).
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As expected, NS1 protein was seen mainly in the nuclear fractions regardless of the recombinant
virus that was used to infect these cells. The nuclear fractions of mock-infected cells did not contain
detectable amounts of CrkI, CrkII, or CrkL proteins (Figure 3A,B), whereas strong signals of expected
size for these proteins were observed in the cytoplasmic fractions. Nuclear vs. cytoplasmic fractionation
of Crk proteins derived from cells infected with viruses expressing an SH3 binding-incompetent version
of NS1 (A/WSN-NS1WSN(wt) and A/WSN-NS1Mallard(K217E)) was identical with that observed with
mock-infected cells (Figure 3A,B). In sharp contrast, in cells infected with viruses having an SH3
binding-competent NS1 (A/WSN-NS1WSN(T215P) and A/WSN-NS1Mallard(wt)) all Crk proteins could
be abundantly detected in the nuclear fractions, especially CrkL becoming predominantly nuclear
(Figure 3A,B).
3.2. NS1-Induced PI3K-Activation does not Depend on Crk Relocalization into the Nucleus
Our previous studies have shown that simultaneous recruitment of Crk proteins by NS1
substantially potentiates NS1-induced activation of PI3-kinase pathway [21,22]. While these signaling
interactions would be expected to take place in the cytoplasm, it is nevertheless possible that
subsequent nuclear transit of the bulk of cellular Crk proteins by NS1 could somehow contribute to
the observed PI3K superactivation.
To address this possibility we generated a mutant NS1 protein that remains predominantly in the
cytoplasm (NS1-Cyto). This was achieved by mutating the N-terminal NLS1 of A/Mallard NS1 (this
strain does not contain NLS2) at the critical basic residues (R38A,R41A) combined with the addition
of a strong heterologous nuclear export signal (NES) from mitogen-activated protein kinase kinase-1
(MAPKK1) [41].
The localization of NS1-Cyto was compared with wild-type A/Mallard NS1 by transient
transfection of red fluorescent fusion protein (mCherry) derivatives of these NS1 proteins. Similar to
the NS1 immunostaining in IAV-infected cells, in virtually all productively NS1-transfected cells (96%;
of 100 cells counted) the red fluorescence of wild-type NS1 showed a distinctly nuclear localization
pattern as illustrated in Figure 4A (upper panel). By contrast, only 1% of cells transfected with
NS1-Cyto showed such a nuclear fluorescence, and in almost all (92%) of these cells the nuclei were
devoid of NS1 signal and appeared as dark areas inside cytoplasmic red fluorescence (Figure 4A,
lower panel), thus establishing the success of our double mutation approach to generate an NS1
mutant restricted to a cytoplasmic localization. Co-transfection of a vector expressing CrkL tagged
with eGFP recapitulated our results obtained by infection with recombinant IAV variants, showing a
prominently nuclear green fluorescence that faithfully co-localized with wild-type NS1. Conversely, in
NS1-Cyto-transfected cells also CrkL fluorescence was found predominantly in the cytoplasm (see
Figure 4B for statistics of the observed NS1 and CrkL localization patterns). When eGFP-CrkL was
transfected alone (data not shown), a localization pattern similar to that observed for endogenous
CrkL by immunostaining (Figure 2A).
When the capacity of NS1-Cyto to trigger PI3K-activation in transfected cells was compared with
that of wild-type A/Mallard NS1, a similar increase in the phosphorylation of Akt, a downstream
effector of the PI3K cascade was observed (Figure 4C). Thus, while recruitment of Crk proteins by NS1
is required for the enhancement PI3K-activation [21,22], NS1-mediated nuclear translocation of Crk
is not. Likewise, it can be concluded that while the cytoplasmic interaction between NS1 and Crk is
sufficient to potentiate PI3K activation, nuclear targeting of Crk cannot be triggered by a contact with
NS1 in the cytoplasm, but indeed physically depends on the nuclear entry of Crk-NS1-complex driven
by the NLS of NS1.
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As expected, NS1 protein was seen mainly in the nuclear fractions regardless of the recombinant
virus that was used to infect these cells. The nuclear fractions of mock-infected cells did not contain
detectable amounts of CrkI, CrkII, or CrkL proteins (Figure 3A,B), whereas strong signals of expected
size for these proteins were observed in the cytoplasmic fractions. Nuclear vs. cytoplasmic fractionation
of Crk proteins derived from cells infected with viruses expressing an SH3 binding-incompetent version
of NS1 (A/WSN-NS1WSN(wt) and A/WSN-NS1Mallard(K217E)) was identical with that observed with
mock-infected cells (Figure 3A,B). In sharp contrast, in cells infected with viruses having an SH3
binding-competent NS1 (A/WSN-NS1WSN(T215P) and A/WSN-NS1Mallard(wt)) all Crk proteins could
be abundantly detected in the nuclear fractions, especially CrkL becoming predominantly nuclear
(Figure 3A,B).
3.2. NS1-Induced PI3K-Activation does not Depend on Crk Relocalization into the Nucleus
Our previous studies have shown that simultaneous recruitment of Crk proteins by NS1
substantially potentiates NS1-induced activation of PI3-kinase pathway [21,22]. While these signaling
interactions would be expected to take place in the cytoplasm, it is nevertheless possible that
subsequent nuclear transit of the bulk of cellular Crk proteins by NS1 could somehow contribute to
the observed PI3K superactivation.
To address this possibility we generated a mutant NS1 protein that remains predominantly in the
cytoplasm (NS1-Cyto). This was achieved by mutating the N-terminal NLS1 of A/Mallard NS1 (this
strain does not contain NLS2) at the critical basic residues (R38A,R41A) combined with the addition
of a strong heterologous nuclear export signal (NES) from mitogen-activated protein kinase kinase-1
(MAPKK1) [41].
The localization of NS1-Cyto was compared with wild-type A/Mallard NS1 by transient
transfection of red fluorescent fusion protein (mCherry) derivatives of these NS1 proteins. Similar to
the NS1 immunostaining in IAV-infected cells, in virtually all productively NS1-transfected cells (96%;
of 100 cells counted) the red fluorescence of wild-type NS1 showed a distinctly nuclear localization
pattern as illustrated in Figure 4A (upper panel). By contrast, only 1% of cells transfected with
NS1-Cyto showed such a nuclear fluorescence, and in almost all (92%) of these cells the nuclei were
devoid of NS1 signal and appeared as dark areas inside cytoplasmic red fluorescence (Figure 4A,
lower panel), thus establishing the success of our double mutation approach to generate an NS1
mutant restricted to a cytoplasmic localization. Co-transfection of a vector expressing CrkL tagged
with eGFP recapitulated our results obtained by infection with recombinant IAV variants, showing a
prominently nuclear green fluorescence that faithfully co-localized with wild-type NS1. Conversely, in
NS1-Cyto-transfected cells also CrkL fluorescence was found predominantly in the cytoplasm (see
Figure 4B for statistics of the observed NS1 and CrkL localization patterns). When eGFP-CrkL was
transfected alone (data not shown), a localization pattern similar to that observed for endogenous
CrkL by immunostaining (Figure 2A).
When the capacity of NS1-Cyto to trigger PI3K-activation in transfected cells was compared with
that of wild-type A/Mallard NS1, a similar increase in the phosphorylation of Akt, a downstream
effector of the PI3K cascade was observed (Figure 4C). Thus, while recruitment of Crk proteins by NS1
is required for the enhancement PI3K-activation [21,22], NS1-mediated nuclear translocation of Crk
is not. Likewise, it can be concluded that while the cytoplasmic interaction between NS1 and Crk is
sufficient to potentiate PI3K activation, nuclear targeting of Crk cannot be triggered by a contact with
NS1 in the cytoplasm, but indeed physically depends on the nuclear entry of Crk-NS1-complex driven
by the NLS of NS1.
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Figure 4. NS1-mediated Crk relocalization is independent of NS1-activated PI3K-signaling.
(A) Fluoresence microscopy imaging of Huh7 cells co-transfected with eGFP-fused CrkL (green
fluorescense) together with mCherry-fusion protein (red fluorescence) of wild-type A/Mallard NS1
(WT) or its dominantly cytoplasmic mutant NS1-Cyto; (B) Localization of NS1 and CrkL was examined
in 100 cells from (A) and the observed fluorescence patterns were scored as nuclear, intermediate,
or cytoplasmic; (C) PI3K-activation by wild-type and mutant version of NS1 revealed by Akt
phosphorylation. Huh7 cells were transiently transfected with a vector expressing the indicated
NS1 variants, and 48 h later examined by Western blotting with antibodies against phospho-Akt (pAkt),
NS1, and α-tubulin.
3.3. A Change in Nuclear Protein Tyrosine Phosphorylation after NS1-Mediated Nuclear Re-Localization of Crk
Crk proteins interact with many tyrosine phosphorylated proteins as well as tyrosine kinases [25],
and upon the original discovery of the viral Crk oncogene (v-Crk) an increase in cellular protein
tyrosine phosphorylation was described as a hallmark of Crk-mediated malignant transformation [42].
To study whether NS1-mediated nuclear translocation of Crk proteins in IAV-infected cells would lead
to any functional consequences, we compared the patterns of protein tyrosine phosphorylation in
nuclear extracts of A549 cells that were mock-infected or infected for 24 h with IAV expressing
NS1 proteins either capable (A/WSN-NS1Mallard(wt) and A/WSN-NS1WSN(T215P)) or not capable
(A/WSN-NS1WSN(wt) and A/WSN-NS1Mallard(K217E)) for binding and nuclear targeting of Crk.
To enhance the accumulation of phosphotyrosine-modified proteins, the cells were treated for 10 min
with the phosphotyrosine phosphatase-inhibitor pervanadate before they were fractionated into
nuclear and cytoplasmic extracts that were subjected to Western blotting with an anti-phosphotyrosine
(anti-pTyr) antibody (Figure 5). Successful subcellular fractionation was confirmed by probing with
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(A) Fluoresence microscopy imaging of Huh7 cells co-transfected with eGFP-fused CrkL (green
fluorescense) together with mCherry-fusion protein (red fluorescence) of wild-type A/Mallard NS1
(WT) or its dominantly cytoplasmic mutant NS1-Cyto; (B) Localization of NS1 and CrkL was examined
in 100 cells from (A) and the observed fluorescence patterns were scored as nuclear, intermediate,
or cytoplasmic; (C) PI3K-activation by wild-type and mutant version of NS1 revealed by Akt
phosphorylation. Huh7 cells were transiently transfected with a vector expressing the indicated
NS1 variants, and 48 h later examined by Western blotting with antibodies against phospho-Akt (pAkt),
NS1, and α-tubulin.
3.3. A Change in Nuclear Protein Tyrosine Phosphorylation after NS1-Mediated Nuclear Re-Localization of Crk
Crk proteins interact with many tyrosine phosphorylated proteins as well as tyrosine kinases [25],
and upon the original discovery of the viral Crk oncogene (v-Crk) an increase in cellular protein
tyrosine phosphorylation was described as a hallmark of Crk-mediated malignant transformation [42].
To study whether NS1-mediated nuclear translocation of Crk proteins in IAV-infected cells would lead
to any functional consequences, we compared the patterns of protein tyrosine phosphorylation in
nuclear extracts of A549 cells that were mock-infected or infected for 24 h with IAV expressing
NS1 proteins either capable (A/WSN-NS1Mallard(wt) and A/WSN-NS1WSN(T215P)) or not capable
(A/WSN-NS1WSN(wt) and A/WSN-NS1Mallard(K217E)) for binding and nuclear targeting of Crk.
To enhance the accumulation of phosphotyrosine-modified proteins, the cells were treated for 10 min
with the phosphotyrosine phosphatase-inhibitor pervanadate before they were fractionated into
nuclear and cytoplasmic extracts that were subjected to Western blotting with an anti-phosphotyrosine
(anti-pTyr) antibody (Figure 5). Successful subcellular fractionation was confirmed by probing with
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antibodies against prototypic nuclear and cytoplasmic proteins, and uniform infection of the cells was
demonstrated by probing unfractionated lysates of these cells with antibodies against IAV NS1 and NP.
While the nuclear extracts of cells infected with viruses expressing NS1 proteins lacking Crk binding
activity did not differ from mock-infected cells in their patterns of tyrosine phosphorylated proteins,
a prominent new phosphotyrosine-containing protein with a MW of about 135 kDa appeared in the
nuclear extracts of cells infected with A/WSN-NS1Mallard(wt) or A/WSN-NS1WSN(T215P) (Figure 5,
pointed with arrows). Thus, we conclude that Crk proteins translocated into the nucleus upon
IAV infection via their binding to NS1 can reprogram cellular signaling pathways in the nucleus as
evidenced by altered nuclear protein tyrosine phosphorylation.Viruses 2016, 8, x 10 of 14 
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4. Discussion
Acquiring a target motif for an SH3 domain-mediated interaction provides a convenient
strategy for viruses to hijack key signaling pathways that regulate the behavior of their host cells.
The high-affinity Crk SH3 binding site in the carboxyterminus of the IAV NS1 protein is an interesting
example of the ease of such virus-host interaction evolution. As highlighted by the recombinant
IAV strain A/WSN-NS1WSN(T215P) used in this study, a single nucleotide change in the segment 8 of
the viral genome to change an ACT codon into CCT is sufficient to give rise to an NS1 protein with
a capacity for fundamentally altering host cell physiology by taking the control of Crk-dependent
signaling pathways. The degree of this control can be quite remarkable as evidenced by the dramatic
relocalization of cellular Crk proteins to the nucleus described in this study.
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4. Discussion
Acquiring a target motif for an SH3 domain-mediated interaction provides a convenient
strategy for viruses to hijack key signaling pathways that regulate the behavior of their host cells.
The high-affinity Crk SH3 binding site in the carboxyterminus of the IAV NS1 protein is an interesting
example of the ease of such virus-host interaction evolution. As highlighted by the recombinant
IAV strain A/WSN-NS1WSN(T215P) used in this study, a single nucleotide change in the segment 8 of
the viral genome to change an ACT codon into CCT is sufficient to give rise to an NS1 protein with
a capacity for fundamentally altering host cell physiology by taking the control of Crk-dependent
signaling pathways. The degree of this control can be quite remarkable as evidenced by the dramatic
relocalization of cellular Crk proteins to the nucleus described in this study.
Viruses 2016, 8, 101 11 of 15
Despite our present findings as well as other effects on the host cell previously assigned to the
Crk SH3 interaction motif of NS1 [21,22,43,44], the overall role of SH3 binding capacity of NS1 in
supporting IAV replication and pathogenesis remains unclear. Should this property alone provide a
clear-cut replicative or immune evasion advantage, it would quickly become fixed in IAV evolution
also in humans, which has not happened. Mutations analogous to our A/WSN-NS1WSN(T215P) mutant
of the human IAV strains A/Udorn/72 and the 2009 Swine Flu pandemic virus (A/California/04/09)
to introduce an SH3 binding site in NS1 did not result in enhanced viral replication [40,45]. On the
other hand, another human IAV strain, A/PR8/8/34, was shown to benefit from the introduction
of an SH3 binding motif to its NS1 and was more pathogenic in mice [46]. It is tantalizing to note
that the 1918 pandemic Spanish flu virus A/Brevig Mission/1/18/H1N1 is one of the known human
IAV strains that naturally contains this sequence motif, suggesting a positive contribution to viral
fitness in this context [21]. It is likely that the utility of hijacking Crk signaling depends on a complex
combination of other functional variables of IAV that are not only determined by the sequence variation
in the multifunctional NS1 protein itself, but also encoded by other segments of its genome.
In addition to enhancing PI3K activation [21] via re-organization of the PI3K-Crk-complex [22], a
functional Crk SH3 binding site of NS1 has previously been linked to suppression of c-Jun N-terminal
kinase-activating transcriptional factor 2 (JNK-ATF2) pathway [43] and to an inhibition of the tyrosine
kinase c-Abl [44]. Our current data suggest that this list may have to be extended to include many
more of the diverse cellular functions of the Crk protein family. It should mentioned, however, that
the interferon-antagonizing effects of NS1 do not fall into this category, and have been shown to be
independent of Crk SH3 binding [21].
Nuclear relocalization of the bulk of cellular Crk proteins can be expected to affect several
cytoplasmic Crk functions. However, phosphorylation and protein interactions are probably more
relevant in regulation of these functions than the total cytoplasmic Crk concentration. This would
explain why we did not observe the PI3K-NS1-Crk complex-dependent enhancement of PI3K activity
in cells expressing an NS1 mutant that was forced to remain cytoplasmic and thus unable to move
Crk into the nucleus. Perhaps more important than the reduction in the amount of cytoplasmic Crk
may indeed be the triggering of new signaling events in the nucleus induced by NS1-mediated nuclear
transportation of Crk.
Previous studies on cancer biology have described triggering of major signaling events and
outcomes caused by nuclear transport of Crk proteins. CrkII has been reported to participate in
apoptosis by activating caspases and binding to the nuclear cell cycle regulator, Wee1 through CrkII
SH2 domain [31,32]. On the other hand, CrkL has been reported to bind via its SH2 domain to tyrosine
phosphorylated Stat5 [34,47]. The complex can translocate into the nucleus to bind Stat5-responsive
elements followed by regulation of gene expression [48,49]. It will be interesting to see how closely
NS1-mediated nuclear relocalization of Crk recapitulates these events, and to what extent the complex
with NS1 redirects Crk to alternative nuclear protein complexes and functions.
As a demonstration that NS1-mediated nuclear transport of Crk proteins can indeed
reprogram nuclear signal transduction pathways, we showed the appearance of a novel nuclear
tyrosine phosphorylated protein with an estimated molecular weight (MW) of 135 kDa (pp. 135).
However, despite the established role of Crk proteins in regulating cellular pTyr protein levels, it
should be noted that we cannot exclude the possibility that some SH3-dependent function of NS1
other than the observed robust nuclear transport of Crk could account for the associated changes in
nuclear protein tyrosine phosphorylation.
The 135 kDa size of the novel pTyr-decorated nuclear protein matches with the major cytoplasmic
tyrosine-phosphorylated protein partner of Crk proteins, the p130Cas [50,51]. However, while this
remains a possible scenario, so far we have not been able to prove that cytoplasmic p130Cas is
transported into the nucleus as a part of an NS1-Crk-p130Cas complex. Another candidate for pp. 135
that we have considered, but likewise not been able to prove is c-Abl, a partially nuclear [52] tyrosine
kinase that can be activated by Crk [ 53] and undergo autophosphorylation [ 54]. However, since Crk
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of an SH3 binding motif to its NS1 and was more pathogenic in mice [46]. It is tantalizing to note
that the 1918 pandemic Spanish flu virus A/Brevig Mission/1/18/H1N1 is one of the known human
IAV strains that naturally contains this sequence motif, suggesting a positive contribution to viral
fitness in this context [21]. It is likely that the utility of hijacking Crk signaling depends on a complex
combination of other functional variables of IAV that are not only determined by the sequence variation
in the multifunctional NS1 protein itself, but also encoded by other segments of its genome.
In addition to enhancing PI3K activation [21] via re-organization of the PI3K-Crk-complex [22], a
functional Crk SH3 binding site of NS1 has previously been linked to suppression of c-Jun N-terminal
kinase-activating transcriptional factor 2 (JNK-ATF2) pathway [43] and to an inhibition of the tyrosine
kinase c-Abl [44]. Our current data suggest that this list may have to be extended to include many
more of the diverse cellular functions of the Crk protein family. It should mentioned, however, that
the interferon-antagonizing effects of NS1 do not fall into this category, and have been shown to be
independent of Crk SH3 binding [21].
Nuclear relocalization of the bulk of cellular Crk proteins can be expected to affect several
cytoplasmic Crk functions. However, phosphorylation and protein interactions are probably more
relevant in regulation of these functions than the total cytoplasmic Crk concentration. This would
explain why we did not observe the PI3K-NS1-Crk complex-dependent enhancement of PI3K activity
in cells expressing an NS1 mutant that was forced to remain cytoplasmic and thus unable to move
Crk into the nucleus. Perhaps more important than the reduction in the amount of cytoplasmic Crk
may indeed be the triggering of new signaling events in the nucleus induced by NS1-mediated nuclear
transportation of Crk.
Previous studies on cancer biology have described triggering of major signaling events and
outcomes caused by nuclear transport of Crk proteins. CrkII has been reported to participate in
apoptosis by activating caspases and binding to the nuclear cell cycle regulator, Wee1 through CrkII
SH2 domain [31,32]. On the other hand, CrkL has been reported to bind via its SH2 domain to tyrosine
phosphorylated Stat5 [34,47]. The complex can translocate into the nucleus to bind Stat5-responsive
elements followed by regulation of gene expression [48,49]. It will be interesting to see how closely
NS1-mediated nuclear relocalization of Crk recapitulates these events, and to what extent the complex
with NS1 redirects Crk to alternative nuclear protein complexes and functions.
As a demonstration that NS1-mediated nuclear transport of Crk proteins can indeed
reprogram nuclear signal transduction pathways, we showed the appearance of a novel nuclear
tyrosine phosphorylated protein with an estimated molecular weight (MW) of 135 kDa (pp. 135).
However, despite the established role of Crk proteins in regulating cellular pTyr protein levels, it
should be noted that we cannot exclude the possibility that some SH3-dependent function of NS1
other than the observed robust nuclear transport of Crk could account for the associated changes in
nuclear protein tyrosine phosphorylation.
The 135 kDa size of the novel pTyr-decorated nuclear protein matches with the major cytoplasmic
tyrosine-phosphorylated protein partner of Crk proteins, the p130Cas [50,51]. However, while this
remains a possible scenario, so far we have not been able to prove that cytoplasmic p130Cas is
transported into the nucleus as a part of an NS1-Crk-p130Cas complex. Another candidate for pp. 135
that we have considered, but likewise not been able to prove is c-Abl, a partially nuclear [52] tyrosine
kinase that can be activated by Crk [ 53] and undergo autophosphorylation [ 54]. However, since Crk
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uses its N-terminal SH3 domain for binding to c-Abl [ 55], this interaction could take place only after
dissociation of the NS1-Crk complex following its nuclear entry. At any case, further studies on the
identity of pp135 as well as comprehensive analyses on the changes in the nuclear phosphoproteome
induced by NS1-mediated nuclear transport of Crk proteins in IAV-infected cells clearly warrants
further experimental attention in order to better characterize the functional significance of this novel
function of NS1.
IAV is an unusual RNA virus in the sense that it replicates in the nucleus of the host cell. Thus, it is
easy to understand why manipulation of the nuclear environment would be relevant for promoting the
IAV life cycle. Ludwig and colleagues have reported that activation of the apoptotic effector caspase-3
at late stages of the IAV replication cycle is required for efficient nuclear exit of viral RNP complexes [56].
Given the previous reports on the capacity of nuclear Crk protein to promote apoptosis [31,32], a role
of NS1-mediated nuclear transport of Crk in facilitating vRNP release from the nucleus poses one
potentially interesting possibility. Since lamins are important caspase substrates and key components
of the nuclear lamina, we have initiated studies on lamin cleavage and integrity of the nuclear lamina
during IAV infection. Our preliminary data suggest that viruses expressing Crk binding-competent
NS1 proteins could indeed induce lamin A/C cleavage and induce more extensive changes in the
nuclear morphology than do viruses with NS1 proteins that lack the SH3 binding motif [57].
The present results further emphasize the role of Crk proteins as host cell interaction partners
of IAV, although much work remains to be done to characterize the detailed nuclear functions of Crk
protein relocalization to the nucleus by NS1, and the significance of this reprogrammed signaling for
IAV replication and pathogenesis. Nevertheless, the remarkable potential of SH3 binding-competent
NS1 proteins to robustly relocate a key family of host cell signaling factors from the cytoplasm to the
nucleus attests to the extensive consequences that adopting a short protein interaction motif by a viral
protein can have, and suggests that the role of the NS1-Crk interaction in cell biology of IAV may be
broader than we have so far appreciated.
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induced by NS1-mediated nuclear transport of Crk proteins in IAV-infected cells clearly warrants
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